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E-NTPDase, Ecto-nucleoside triphosphate diphospho-hydrolase 
ENT, Equilibrative nucleoside transporters 
ER, Endoplasmic reticulum 
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JNK, c-Jun N-terminal kinase 
LDH, Lactate dehydrogenase 
MAPK, Mitogen-activated protein kinases 
MDLK, Madin-Darby canine kidney cells 
MFQ, Mefloquine 
MRS 2179, 2'-Deoxy-N6-methyladenosine 3',5'-bisphosphate tetrasodium salt 
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MTX, Methrotrexate 
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NLRP3, NOD-like receptor family, pyrin domain containing 3 
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NO, Nitric oxide 
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PAGE, Polyacrylamide gel electrophoresis 
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SP, Substance P 
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WB, Western blot 
  
7 
 
RESUMO 
Apesar do seu tamanho e localização ao longo de todo o corpo, o tecido 
conjuntivo não especializado tem sido geralmente ignorado ou mal interpretado, 
sendo considerado como relativamente supérfluo para além de desempenhar um 
papel de suporte dos tecidos mais especializados. Evidências recentes sugerem, 
no entanto, que o tecido conjuntivo subcutâneo pode tornar-se mais espesso e 
menos flexível em doentes com dor crónica, possivelmente como resultado de 
inflamação crónica e fibrose. Desta forma, a resposta esperada a um estiramento 
mecânico pode ser perturbada pela alteração das propriedades viscoelásticas do 
tecido conjuntivo subcutâneo, como consequência da remodelação mediada pelos 
fibroblastos e promovida por mediadores inflamatórios, como a histamina e a 
bradicinina. Considerando que o tecido conjuntivo subcutâneo é ricamente 
inervado por terminações nervosas sensoriais, as aferências de um tecido 
conjuntivo afetado podem alterar a percepção da dor.  
Estudos anteriores demonstraram que a histamina e a bradicinina podem 
induzir a libertação de ATP a partir de vários tipos de células, incluindo células 
musculares lisas, células epiteliais, células endoteliais e uroteliais, e várias linhas 
de células imortalizadas. No entanto, os mecanismos de libertação de ATP 
induzidos pela bradicinina e pela histamina são ainda mal compreendidos, 
particularmente em tecidos humanos. Além disso, células danificadas durante a 
lesão dos tecidos moles podem provocar a libertação de grandes quantidades de 
ATP para o meio extracelular. Uma vez libertado, o ATP pode actuar como um 
mediador autócrino ou parácrino em células vizinhas, através da activação de 
receptores purinérgicos. Esta via de sinalização pode ainda ser modulada por 
ectonucleotidases ligadas à membrana, que sequencialmente catabolizem 
nucleósidos 5'-trifosfatos para o respectivo 5'-di- e monofosfato. 
Considerando que [1] alterações na regulação da sinalização mediada pelo 
ATP no tecido conjuntivo pode ser importante na patogénese da dor inflamatória 
crônica e que [2] mediadores inflamatórios algogénicos, como a bradicinina e a 
histamina, podem sensibilizar as células de forma autócrina e parácrina por 
intermédio de sinais operados pelos nucleótidos de adenina extracelulares, este 
estudo pretendeu averiguar em fibroblastos isolados do tecido subcutâneo 
humano em cultura: 1) o envolvimento do ATP nas oscilações do cálcio 
intracelular produzidas pela bradicinina e pela histamina; 2) os mecanismos de 
libertação de ATP desencadeados pelos dois mediadores inflamatórios; 3) as vias 
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enzimáticas envolvidas no catabolismo extracelular do ATP e na formação de 
adenosina nestas células; e 4) a expressão dos receptores purinérgicos (P1 e P2). 
Os resultados mostraram que a incubação tanto com histamina (100 µM) 
como com bradicinina (> 1 µM) aumenta a concentração citosólica de Ca2+ ([Ca2+]i) 
nos fibroblastos subcutâneos humanos por activação de receptores H1 e B2, 
respectivamente. Ambas as respostas apresentavam características bifásicas, 
tendo-se observado um aumento inicial rápido de Ca2+ que diminuiu rapidamente 
para um patamar sustentado acima da linha de base. O aumento do [Ca2+]i 
induzido pela histamina e pela bradicinina parece depender da ativação da 
fosfolipase C (PLC) e do recrutamento de Ca2+ a partir das reservas intracelulares, 
o que é compatível com o envolvimento da via Gq → PLC → via IP3, sinalização 
essa que é característica da activação dos receptores H1 e B2. Após a subida inicial 
transitória do Ca2+ devido ao recrutamento do Ca2+ do retículo endoplasmático, a 
fase de patamar foi mantida através da entrada de Ca2+ proveniente do meio 
extracelular. Paralelamente às oscilações de [Ca2+]i observadas, estas células 
também libertaram ATP quando expostas aos dois mediadores inflamatórios, 
histamina e bradicinina. No entanto, os mecanismos envolvidos na libertação de 
ATP parecem ter características distintas. Embora os dois mediadores 
inflamatórios pareçam despoletar a abertura de hemicanais contendo panexina 1 
(Panx1), o efeito da bradicinina parece envolver também hemicanais contendo 
conexinas (como a Cx43 e outras, possivelmente). Em ambas as situações, o ATP 
libertado desempenha um efeito the amplificação da resposta de [Ca2+]i motivada 
pela activação de receptores P2. Os dados também mostraram que o patamar de 
elevação de [Ca2+]i observada em células estimuladas com bradicinina foi, pelo 
menos em parte, atribuído à activação de receptores purinérgicos P2Y12. Além 
disso, a exposição prolongada (até 28 dias) das células à histamina potenciou a 
sua proliferação, um efeito que foi parcialmente devido à activação do receptor 
P2Y1. 
Os resultados também mostram que, uma vez no meio extracelular, o ATP 
(3/30 µM) e o ADP (3/30 µM) foram metabolizados numa proporção global de 
aproximadamente 2 (ATP):1 (ADP), compatível com o envolvimento preferencial 
da E-NTPDase1 nas culturas de fibroblastos humanos de tecido subcutâneo. Este 
facto foi confirmado através de uma imunorreactividade mais evidente para a N-
NTPDase1 comparativamente à E-NTPDase2; nestas células não se observou 
maracação positiva para a E-NTPDase3. Curiosamente, o AMP foi rapidamente 
desfosforilado em adenosina independentemente do substrato nucleotídico 
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utilizado (tempo de semi-vida de 1,5-3,0 min para concentrações de substrato de 
3-30 µM, respectivamente). A existência de uma forte imunorreactividade para a 
ecto-5'nucleotidase / CD73 nestas células é compatível com os valores 
encontrados para as cinéticas enzimáticas e explica por que razão se observou 
uma acumulação negligenciável de AMP nas culturas, independentemente do 
nucleótido testado. Por outro lado, verificámos que os fibroblastos do tecido 
subcutâneo humano possuem uma fraca actividade da adenosina desaminase 
(ADA), metabolizando muito lentamente a adenosina (tempo de semi-vida de ~ 
40-160 min, quando se incubaram as células com 3-30 µM de adenosina, 
respectivamente). Resultados preliminares sugerem ainda que a adenosina e os 
seus análogos estáveis potenciam a proliferação celular e a produção de 
colagénio tipo I pelos fibroblastos humanos em cultura, um efeito que parece ser 
devido à activação do receptor A2A.  
Concluindo, os fibroblastos do tecido subcutâneo humano expressam 
receptores purinérgicos funcionais, nomeadamente receptores P2Y1, P2Y12 e A2A, 
bem como enzimas envolvidas na cascata de metabolização extracelular das 
purinas, nomeadamente as E-NTPDases1 e -2 e a CD73. Tanto a histamina como a 
bradicinina estimulam a libertação de ATP pelos fibroblastos humanos em cultura 
amplificando as suas respostas iniciais. Os mecanismos de sinalização envolvidos 
na resposta a cada mediador inflamatório parecem depender de microdomínios 
específicos nas células, nomeadamente no que respeita às vias de libertação do 
ATP (hemicanais do tipo Panx1 e Cx43, entre outras conexinas) e aos receptores 
purinérgicos (P2Y1 e P2Y12) envolvidos. Estes mecanismos podem envolver a 
mobilização dinâmica de ectonucleotidases (provavelmente a E-NTPDase2) para 
regiões específicas da membrana celular condicionando a resposta purinérgica 
mediante a acumulação (transitória) the determinada espécie nucleotídica, ATP ou 
ADP. Além disso, nestas células a adenosina tende a acumular-se no fluido 
extracelular e parece aumentar a proliferação, através da activação do receptor 
A2A. 
Assim, clarificar as vias que levam à libertação de nucleótidos e posterior 
sinalização purinérgica em fibroblastos humanos do tecido conjuntivo 
subcutâneo pode ser útil para: 1) compreender o papel deste tecido na 
patogénese de doenças músculo-esqueléticas dolorosas crónicas, 2) esclarecer os 
mecanismos que podem ser envolvidos nos efeitos analgésicos induzidos por 
manipulações de tecidos moles periféricos, tais como as técnicas de fisioterapia, 
e 3) formular estratégias terapêuticas farmacológicas inovadoras em relação à 
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modulação da comunicação entre as células inflamatórias, os fibroblastos e as 
terminações nervosas sensoriais.  
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ABSTRACT 
Despite its overwhelming size throughout the body, unspecialized 
connective tissue has been generally overlooked or misunderstood, being 
considered as relatively superfluous apart from its supporting role amongst more 
specialized tissues. Recent evidences suggest, however, that subcutaneous 
connective tissue may become thicker and less compliant in patients with chronic 
pain, possibly as a result of chronic inflammation and fibrosis. Therefore, the 
normal response to mechanical stretch may be dampened by disturbance of the 
viscoelastic properties of subcutaneous connective tissue as a consequence of 
fibroblast remodeling promoted by inflammatory mediators, like histamine and 
bradykinin. Given that subcutaneous connective tissue is richly innervated by 
sensory nerve endings, inputs arising from affected connective tissue may alter 
pain perception.  
Previous studies demonstrated that histamine and bradykinin elicit the 
release of ATP from various cell types, including smooth muscle fibers, epithelial, 
endothelial and urothelial cells, and several immortalized cell lines. Still, the 
mechanism of ATP release induced by bradykinin and histamine is poorly 
understood, particularly in human tissues. In addition, huge amounts of 
extracellular ATP may also leak from damaged cells during mild tissue injury. 
Furthermore, once released, ATP may act as an autocrine or paracrine mediator in 
neighboring cells via purinoceptors activation, a signaling pathway that may be 
modulated by membrane-bound ectonucleotidases, which sequentially catabolize 
nucleoside 5’-triphosphates to their respective 5’-di- and monophosphates.  
Therefore, taking into consideration that [1] changes in the regulation of 
connective tissue ATP signaling may be important in the pathogenesis of chronic 
inflammatory pain and that [2] algogenic inflammatory mediators, such as 
bradykinin and histamine, may sensitize cells to autocrine and paracrine signals 
operated by extracellular adenine nucleotides, we investigated: 1) the 
involvement of ATP in bradykinin- and histamine-induced Ca2+ signals in human 
subcutaneous fibroblasts; 2) the ATP-release mechanisms triggered by bradykinin 
and histamine in human subcutaneous fibroblasts; 3) the extracellular enzymatic 
pathways responsible for ATP catabolism and adenosine formation in human 
subcutaneous fibroblast cultures; and 4) the expression of purinoceptors (P1 and 
P2) in fibroblasts from the human subcutaneous connective tissue. 
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Results showed that incubation with histamine (100 µM) and bradykinin (> 
1 µM) increased cytosolic intracellular Ca2+ ([Ca2+]i) in human subcutaneous 
fibroblasts via the activation of H1 and B2 receptors, respectively. [Ca2+]i responses 
were biphasic, as we observed a fast Ca2+ rise that declined rapidly to a sustained 
plateau above baseline. Histamine- and bradykinin-induced [Ca2+]i rises depended 
on PLC activation and the recruitment of Ca2+ from intracellular stores, which is 
compatible with the involvement of the Gq → PLC → IP3 signaling pathway that is 
characteristic of H1 and B2 receptors activation. Following the initial Ca2+ transient 
due to Ca2+ recruitment from the endoplasmic reticulum, the plateau phase was 
maintained via Ca2+ entry into human subcutaneous fibroblasts from the 
extracellular milieu. In parallel to the [Ca2+]i oscillations observed, these cells also 
released ATP when exposed to histamine and bradykinin through different 
nucleotide-releasing pathways. While both histamine and bradykinin caused the 
opening of pannexin-1 (Panx1) hemichannels, connexin hemichannels (Cx43 and 
others, possibly) are only involved in bradykinin responses. For both 
inflammatory mediators, the released ATP amplified the [Ca2+]i rise due to P2 
receptors activation. Data also showed that the plateau of elevated [Ca2+]i 
observed in cells stimulated with bradykinin was, at least in part, attributed to 
P2Y12 purinoceptors activation. Moreover, prolonged exposure (until 28 days) to 
histamine potentiated the proliferation of fibroblasts, an effect that was partially 
due to the P2Y1 receptor.  
Results also demonstrated that, once in the extracellular milieu, ATP (3/30 
µM) and ADP (3/30 µM) were metabolized with a ratio of approximately 
2(ATP):1(ADP), which is compatible with E-NTPDase1 being the most effective 
isoform of E-NTPDases in these cultures. Furthermore, human subcutaneous 
fibroblasts showed a stronger immunoreactivity to E-NTPDase1 when compared 
to E-NTPDase2, and these cells presented no immunoreactivity against NTPDase3. 
Interestingly, AMP was rapidly dephosphorylated into adenosine independently of 
the nucleotide substrate used (half-life time of 1.5-3.0 min, 3-30 µM, 
respectively), and a strong immunoreactivity against ecto-5’nucleotidase/CD73 
was also found. Conversely, adenosine deamination occurs slowly (half-life time 
of ~40-160 min, 3-30 µM, respectively), allowing for adenosine accumulation. 
Preliminary results also suggest that both proliferation and type I collagen 
production of cells continuously incubated with adenosine or its analogues 
increase, an effect that seems to be via the activation of the A2A receptor.  
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Concluding, human subcutaneous fibroblasts express functional 
purinoceptors, such as P2Y1 and P2Y12, as well as the NTPDases1 and -2 and 
CD73. Both histamine and bradykinin stimulated human subcutaneous fibroblasts 
to release ATP to the extracellular milieu, which ultimately amplified the response 
induced by the primary ligand. For each mediator, the subsequent signaling 
might depend on specific microdomains of the cells, triggering a stimulus-
specific rather than only a cell-specific response, involving different nucleotide-
releasing pathways (Panx1 and Cx43 hemichannels, among other connexins) and 
purinoceptors (P2Y1 and P2Y12) activation, which might also involve the dynamic 
mobilization of ectonucleotidases (probably NTPDase2) to specific regions of the 
cell membrane. Moreover, in these cells adenosine tends to accumulate in the 
extracellular fluid leading to fibroblast cells growth and type I collagen 
production via A2A receptor activation. 
Thus, targeting the pathways leading to nucleotides release and 
subsequent purinergic signaling in human fibroblasts of subcutaneous connective 
tissue may be useful in: 1) understanding the role of this tissue in the 
pathogenesis of chronic painful musculoskeletal disorders; 2) clarifying the 
mechanisms that may be involved in the analgesic effects induced by peripheral 
soft tissue manipulations, such as physical therapy techniques; and 3) 
enlightening for novel pharmacological therapeutic strategies towards the 
modulation of the communication between inflammatory cells, fibroblasts and 
sensory nerve endings. 
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Nonspecialized connective tissue 
The human body is mainly formed by four types of biological tissues, 
namely epithelial, muscular, nervous and connective tissues. The connective 
tissue plays several essential roles in the body, both structural, given that many 
of the extracellular elements possess special mechanical properties, and 
defensive, a role which is based on specific cellular functions. Often, it also has 
important trophic and morphogenetic roles in organizing and influencing the 
growth and differentiation of surrounding tissues.  
The connective tissue can be divided in several subtypes, which can be 
generally grouped at large into specialized and nonspecialized tissues. All these 
tissues include two major components: cells and the extracellular matrix (ECM), 
which are specific according to the connective tissue subtype being considered 
(see Table 1.1). Specialized connective tissues consist of adipose tissue, cartilage, 
bone and blood. Nonspecialized connective tissues, which have long been termed 
by gross anatomists as fascia, embrace several undifferentiated mesenchymal 
tissues that wrap around what are sometimes regarded as the more ‘specialized’ 
organs and tissues of the body (1). Its major cell type, the fibroblast, regulates 
the ECM homeostasis by producing and degrading their constituents (2). In 
general, the ECM is mainly composed of glycoproteins and proteoglycans, many 
of which are able to bind to specific sites on other ECM glycoproteins so that the 
matrix becomes a highly crosslinked gel. There are approximately 100 known 
ECM components, more if one includes molecules such as growth factors that are 
not structurally part of the matrix, but which bind to it. In nonspecialized 
connective tissues, ECM is formed of ground substance, a watery gel rich in 
mucopolysaccharides or glycosaminoglycans such as hyaluronic acid, chondroitin 
sulfate, keratin sulfate, and heparin sulfate, and fibers of collagen, elastin and 
reticulin (3). Collagen, by far the most common protein in the body, that 
predominates in the fascial net is primarily of type I (4).  
 
 
18 
 
Table 1.1. Predominant structures of connective tissues. 
 
Adapted from (4). 
 
In general, fascia is considered an uninterrupted viscoelastic tissue which 
forms a functional 3-dimensional collagen matrix that surrounds and penetrates 
all structures of the body extending from head to toes, binding some structures 
together, while permitting others to slide smoothly over each other, thus making 
it difficult to isolate and develop its nomenclature. Lack of consistent terminology 
has a negative effect on communication within health professions and 
compromises the advance of research (5). For example, depending on the 
authors, the connective tissue lamina of the hypodermis is named “textus 
connectives compactus”, “fascia superficialis”, “membranous layer”, 
“subcutaneous tissue”, “subcutaneous fascia” or “tela subcutanea” (1).  
In 1983, the International Anatomical Nomenclature Committee confirmed 
the usage of previous nomenclature consensus and used the term “fascia 
superficialis” for the whole loose layer of subcutaneous tissue lying superficially to 
the denser layer of “fascia profunda”. While most health professionals in English 
speaking countries followed that terminology, other countries did not congruently 
adopt it. The subsequent international nomenclature, proposed by the Federative 
Committee on Anatomical Terminology in 1998, attempted to lead towards a 
more uniform international language and defined fascia as “…sheaths, sheets or 
other dissectible connective tissue aggregations”, including “investments of 
viscera and dissectible structures related to them”. This group suggested that 
authors should no longer use the term fascia for loose connective tissue layers 
and should apply it only to denser connective tissue aggregations (6). They gave a 
long list of terms related to their definition of fascia, and attempted to offer a 
system for grouping various fasciae based on embryological origins and modes of 
Tissue type Cells Fibers
Interfibrillar elements, ground 
substance, water-binding 
proteins
Bone Osteocyte, osteoblast, osteoclast Collagen Mineral salts, calcium carbonate, 
calcium phosphate
Cartilage Chondrocyte Collagen (and elastin) Chondroitin sulfate
Fat Adipocyte Collagen More proteoglycans
Blood Red and white blood cells Fibrinogen Plasma
Dense connective tissues 
(ligaments, tendons, aponeurosis) Fibroblast Collagen 
Minimal proteoglycans between 
fibers
Loose connective tissue Fibroblasts, white blood cells, 
adipocytes, mast Collagen and elastin Significant proteoglycans
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development. However, clear details on the groupings and justification for this 
strategy were not given, remaining difficult to organize and properly use the 
multiple fascial terms (5). They also recommended the substitution of the old 
term “superficial fascia” for “tela subcutanea” or “subcutaneous tissue”, besides 
suggesting the exclusion of the most frequently used “fasciae” names in anatomy 
from their proposed definition (5,6). This attempt, for the most part, failed; most 
English textbook authorities continued to use the term “superficial fascia” to 
describe subcutaneous loose connective tissues. In addition, an increasing 
number of non-English authors followed the British-American-trend in 
international medicine and started to adopt the same terminology as their 
American or British colleagues. In fact, according to the Gray’s Anatomy, fascia 
consists of “…masses of connective tissue large enough to be visible to the 
unaided eye”, “…fibres in fascia tend to be interwoven...” and includes “loose 
areolar connective tissue” such as the subcutaneous “superficial fascia” (6).  
Concluding, discrepancies still exist concerning the official definition, 
terminology, classification and clinical significance of fascia (5). In an attempt to 
simplify, from now on we will consider the classification of superficial, deep 
(muscular) and visceral fascia, according to their anatomical location (6), in which 
subcutaneous connective tissue is considered part of the superficial fascia.   
Despite its overwhelming relative size and relevance, superficial fascia has 
been heretofore generally overlooked or misunderstood as relatively superfluous 
by conventional dissection methods (1,7). The traditional idea of being a tissue 
for supporting specialized organs has the inherent and wrong implication that 
this tissue consists on less important supporting specialized tissues. 
Progressively, the errors of this assumption are being exposed and fascia is 
undoubtedly of considerable importance to many professionals working in health-
related professions, like surgeons, physiotherapists, and others (1). In fact, it has 
its own nervous, vascular and lymphatic endowment, its own complex, elastic and 
resilient connective tissue matrix, and abundant fatty deposition, which are 
properties of a discrete and vital organ (7). 
 
Sensory innervation of nonspecialized connective tissue 
To date, little is known about the distribution and density of sensory nerve 
fibers in nonspecialized connective tissue. In 1957, Stilwell (8) identified 
numerous free nerve endings and large Pacinian corpuscles in the human 
thoracolumbar fascia. In 1963, Hirsch and coworkers (9) spoke of complex 
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unencapsulated endings without providing any illustrations. Later, in 1992, Yahia 
and coworkers (10) demonstrated the existence of two types of 
mechanoreceptors in the human thoracolumbar fascia, namely Ruffini’s 
corpuscles (or Type I receptors) and Vater-Pacini corpuscles (or Type II receptors), 
as well as nerve bundles. Moreover, it has been reported that the thoracolumbar 
body region in rats is innervated by unmyelinated and myelinated afferents with 
conduction velocities in the range of C, Aδ and Aβ fibers and that the tissues 
supplied by these fibers are sensitive to mechanical and noxious chemical 
stimulation (11). Recently, in whole mount preparations, rat thoracolumbar fascia 
had the appearance of a densely innervated tissue exhibiting an extensive net of 
nerve fibers (11). The neuronal structures included fibers of passage and nerve 
endings characterized by chains of varicosities close to the nerve terminal. Fibers 
immunoreactive to the neuronal marker protein gene product (PGP) 9.5 were 
mainly found in the outer layer and subcutaneous tissue. A positive 
immunoreactivity against tyrosine hydroxylase (TH, characteristic of 
postganglionic sympathetic fibers), calcitonin gene-related peptide (CGRP) and 
substance P (SP), both peptides involved in nociception, was also found in the 
same regions. A quantitative evaluation of the fraction of CGRP- and SP-nerve 
fibers showed that they represent a small proportion of the total innervation 
visualized with the neuronal marker, PGP 9.5 (11). Conversely, another study 
demonstrated that, of the Fast Blue-labeled dorsal root ganglia (DRG) cells 
projecting from the nonspecialized connective tissues of the low back of rats, 60-
88% expressed positive CGRP-immunoreactivity (12). A preliminary non-
quantitative evaluation of the human thoracolumbar fascia (three patients) 
indicated that the innervation density of the human thoracolumbar fascia 
visualized by PGP 9.5 was likewise high and that the appearance of the free-nerve 
endings was similar. A high number of fibers showed TH-positive 
immunoreactivity indicating that the human fascia has a rich innervation with 
sympathetic fibers. Again, peptidergic fibers represented a small fraction of the 
total innervation. The stained neuronal structures included nerve endings 
characterized by chains of varicosities. The majority of peptidergic nerve endings 
were located in the subcutaneous tissue and in structures comparable with the 
outer and inner layer of the rat thoracolumbar fascia (11).  
Together, these findings provide evidence that there are several types of 
sensory afferents in nonspecialized connective tissues, both mechanosensory and 
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nociceptive neurons, which may contribute to nociceptive circuitries, ultimately 
being involved in pain perception. 
 
Role of nonspecialized connective tissues in musculoskeletal pain 
Recent evidence suggests that nonspecialized connective tissues might be 
potential players in the pathophysiology and treatment of chronic pain conditions 
(13,14), such as low back pain, in a not well understood mechanism that could 
involve inflammation (15,16). In these studies, disorganization of the low back 
subcutaneous tissue, like thickness and fibrosis, was detected in patients with 
chronic low back pain (13,14).  
One of the hallmarks of connective tissue is its plasticity in response to 
varying levels of mechanical stress. Both increased stress due to overuse, 
repetitive movement and/or hypermobility, and decreased stress due to 
immobilization or hypomobility, can cause changes in connective tissue, which in 
turn may have consequences in neighboring tissues. A chronic, local increase in 
stress can lead to microinjury and inflammation, and a consistent absence of 
stress, on the other hand, leads to connective tissue atrophy, architectural 
disorganization, fibrosis, adhesions and contractures. For example, during the 
early phase of immobilization, loss of muscle length is primarily due to the 
shortening of muscle-associated connective tissue (deep fascia), which is then 
followed by actual shortening of muscle fibers. Therefore, fibrosis can be the 
direct consequence of hypomobility or the indirect result of hypermobility via 
injury and inflammation (16). An altered tension due to the disorganization of 
richly innervated tissues may alter the sensory input arising from the affected 
tissues by making sensory neurons more responsive. Thus, smaller stimuli 
become capable of triggering a response. Furthermore, a sustained disorder of 
the nonspecialized connective tissue may induce a pathological neuroplastic 
rearrangement of its sensory innervation, thereby contributing to the 
development of a peripheral sensitization followed by a central sensitization.  
Although it is unclear whether myofascial trigger points are the cause or 
effect of muscle injury, they are often exhibited in patients with musculoskeletal 
pain. They represent abnormally contracted muscle fibers, which can lead to the 
accumulation of signaling molecules that are essential to the onset and 
maintenance of inflammatory reactions, like prostaglandins, bradykinin, 
histamine, ATP and serotonin, and others (17). Some of the signaling substances 
that accumulate nearby may activate nociceptors, besides the fact that myofascial 
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trigger points and muscle spasms may also contribute to connective tissue 
remodeling and fibrosis (18,19), In fact, inflammatory mediators, as well as other 
noxious chemical, mechanical and thermal stimuli, may influence nociceptors 
activity, therefore triggering nociceptive circuitries and pain (20,21). For example, 
bradykinin has been described as a potent algogenic substance by directly 
depolarizing nociceptors and by reducing their threshold (22). The role of 
histamine in nociception is not clear but it appears to cooperate with the effect of 
other endogenous mediators (23). ATP, acting on multiple purinergic receptors, 
either directly on neurons or indirectly through neural-glial cell interactions, 
seems to alter nociceptive sensitivity (24). Thus, inflammation might be directly 
involved in pain as well, due to the activation/modulation of nociceptive 
neurotransmission activity/threshold induced by inflammatory mediators. 
Furthermore, activation of nociceptors can contribute to the development 
or worsening of fibrosis and inflammation, causing even more tissue stiffness 
and, as stated earlier, more pain. In the skin, it has been demonstrated that the 
release of SP from sensory C-fibers can enhance the production of histamine and 
cytokines from mast cells, monocytes and endothelial cells. Moreover, increased 
transforming growth factor β1 (TGFβ-1) production, stimulated by tissue injury 
and histamine release, seems to be a powerful driver of fibroblast collagen 
synthesis and tissue fibrosis (16).  
Interestingly, recent evidence suggests that fibroblasts help to regulate the 
switch from acute resolving to chronic persistent inflammation (25). Until quite 
recently, fibroblasts were thought to predominantly provide physical structure to 
tissues by producing and remodeling the ECM of connective tissue. However, it 
has become increasingly clear that, in addition to their landscaping properties, 
fibroblasts play an active role in governing the persistence of inflammatory 
diseases (26) by guiding multiple cell types, such as mast cells, T cells, B cells, 
among others, through the release of signaling molecules, leading to their 
recruitment, retention, activation, and differentiation (27). However, their role in 
nonspecialized connective tissue-related musculoskeletal pain still needs 
clarification. 
Finally, given that muscle activity is highly dependent on the compliance of 
the surrounding connective tissue, an altered tension due to disorganization of 
connective tissue will probably alter movement patterns. Additionally, both pain 
and pain-induced fear might cause altered activation patterns of postural 
muscles, resulting in dysfunctional movement patterns. Recent experiments 
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suggest that, in healthy individuals, fear of pain by itself can cause altered trunk 
muscle activation patterns during limb movement. Both experimental back pain 
(painful cutaneous electrical stimulation) and anticipation of pain (without 
electrical stimulation) caused increased activity and co-contraction of superficial 
muscles along with delayed or decreased activation of deep muscles. Thus, 
patients with chronic musculoskeletal pain appear to have a constellation of 
motion-limiting muscle activation patterns that may be initiated or aggravated by 
emotional factors (16)). At the end, dysfunctional movements might not provide 
an appropriate protection of the overused structures, which become more 
susceptible to injury (followed by inflammation and pain) (28). 
 
Purinergic signaling dynamics - the “purinome”  
Purines (adenosine, ADP and ATP) are molecules that are among the oldest 
and most influential biochemical compounds in the evolutionary history. In their 
physiologic state, mammalian cells contain high concentrations of ATP (5 to 8 
mM) (29), which can be released in huge amounts by damaged cells and also 
from non-damaged cells under stressful conditions.  
Nowadays it is well accepted that ATP, best known as the universal fuel 
inside living cells, also serves as a signal molecule that affects cell behavior (30). 
This ‘purinergic signaling’ hypothesis met considerable resistance in the 
beginning, partly perhaps because ATP was recognized at that time as an 
intracellular molecule contained in all cells and of particular importance as an 
energy source, and it was considered that such a ubiquitous molecule was 
unlikely to act as a neurotransmitter, even though the presence of powerful 
ectoenzymes for the extracellular breakdown of ATP were already known (31). 
Later, studies about the role of ATP as a messenger have increased evidence 
about how ATP signals work and why they are essential to basic bodily functions 
and development (30). In addition to the well-described physiological activities, 
extracellular nucleotides have been also recognized as having increasing 
importance in pathological conditions (32). Although ATP-signaling activity was 
first detected between nerve cells and muscle tissue, it is now known to operate 
within a wide variety of cell types in the body. In fact, because ATP is so 
ubiquitous, its influences can vary from tissue to tissue, offering new insights 
into a wide range of disorders and diverse ways to treat them (30). 
In contrast to the compelling evidence for the extracellular signaling role 
of ATP, the hypothesis that UTP may also fulfill an autocrine/paracrine role has 
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only recently gained experimental support. In fact, the notion that pyrimidines 
(UDP and UTP) may function as extracellular messengers originated from the 
identification of a subset of P2Y receptors that recognize uridine nucleotides as 
their most potent and, in some cases, exclusive agonists (33). 
 
Nucleoside- and nucleotide-releasing pathways 
For many years, the source of extracellular nucleosides and nucleotides 
was considered to be damaged or dying cells, except for exocytotic vesicular 
release from excitable cells such as neurons. However, it is now known that 
several cell types release nucleosides and nucleotides constitutively and or in 
response to diverse physiological stimulation, such as shear stress (34,35). Most 
cells express transmembrane nucleoside transporters that can regulate the 
extracellular levels of these molecules, especially adenosine (35). The 
mechanisms of nucleotide transport to the extracellular media is currently being 
debated and includes the: (1) electrodiffusional movement through membrane ion 
channels, including connexin (Cx) and pannexin (Panx) hemichannels, stretch- 
and voltage-activated channels; (2) facilitated diffusion by nucleotide-specific ATP-
binding cassette (ABC) transporters, such as the cystic fibrosis transmembrane 
conductance regulator (CFTR), the multidrug resistance proteins, and the multiple 
organic anion transporters; and (3) cargo-vesicle trafficking and exocytotic 
granule secretion (34-36).  
 
Purinergic receptors 
Purinergic effects are mediated via a series of nucleotide- and nucleoside-
selective receptors, namely P2 and P1 receptors, respectively (36).  
On the basis of their pharmacological and functional characteristics, two 
major receptor subfamilies of P2 receptors, P2X and P2Y, have been described. 
The P2X receptors are ligand-gated channels that gate extracellular cations in 
response to ATP and comprise seven receptor subtypes (P2X1-7) (see Table 1.2). 
The P2Y receptors are G-protein-coupled receptors (GPCR) that are categorized 
into a subfamily of receptors that predominantly couple to: (1) the Gq protein 
(P2Y1,2,4,6,11), and therefore activate phospholipase C (PLC)-β; (2) the Gi protein 
(P2Y12,13,14), thus inhibiting adenylyl cyclase (AC) and regulating ion channels (36); 
and (3) the Gs protein (P2Y11), thus activating AC and regulating ion channels 
(P2Y11 receptor is dually coupled to PLC and AC stimulation) (32). 
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Pharmacologically, P2Y receptors can be broadly subdivided into: (1) adenine 
nucleotide-preferring receptors, mainly responding to ADP and ATP; this group 
includes P2Y1, P2Y12, P2Y13, and P2Y11; (2) uracil nucleotide-preferring receptors; 
this group includes P2Y4 and P2Y6 receptors responding to either UTP or UDP; (3) 
receptors of mixed selectivity (human and rodent P2Y2, rodent P2Y4 and, possibly, 
P2Y11); and (4) receptors responding solely to the sugar nucleotides UDP-glucose 
and UDP-galactose (P2Y14) (36,37) (see Table 1.3). 
 
Table 1.2. P2X ionotropic receptors. 
 
Adapted from (35). 
 
Receptor Endogenous ligand Transduction mechanisms Main agonists Main antagonists
P2X1 Ion channel (Ca2+ and Na+) ATP, α,β−MeATP IP5I, NF023, NF449, TNP-ATP
P2X2 Ion channel (mainly Ca2+) ATP, ATPγS isoPPADS, NF279, NF770, RB-2, suramin
P2X3 Intrinsic ion channel ATP, 2-MeSATP A317491, IP5I, NF110, 
PPADS, TNP-ATP, RO-85
P2X4 Ion channel (mainly Ca2+) ATP, α,β−MeATP Coomassie blue, TNP-ATP
P2X5 Intrinsic ion channel (Cl-) ATP, α,β−MeATP Coomassie blue, PPADS, 
suramin
P2X6 Intrinsic ion channel  -
P2X7 Intrinsic ion channel and a pore ATP, BzATP KN62, KN04, MRS2427, 
oATP
ATP
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Table 1.3. P2Y metabotropic receptors. 
 
Adapted from IUPHAR and (35). 
 
 
The P1 adenosine receptors are metabotropic receptors coupled to several 
families of Gi and Go proteins, divided into four types of adenosine receptors 
(A1,2A,2B,3) with distinct pharmacological and functional properties (see Table 1.4). 
As a rule, the A1 and A3 receptors exert an inhibitory effect on AC (mediated 
through Gi/o proteins), whereas A2A and A2B receptors activate cyclic AMP (cAMP) 
production via Gs proteins. A1 and A3 receptors also regulate PLC and thus inositol 
1,4,5-trisphosphate (IP3) synthesis; in some cells, A1 receptors were reported to 
activate K+ and/or Ca2+ channels (38). 
 
Table 1.4. P1 metabotropic receptors. 
 
Adapted from IUPHAR and (35). 
 
Receptor Endogenous ligand
Primary transduction 
mechanisms
Secondary transduction 
mechanisms Main agonists Main antagonists
P2Y1 ADP>ATP
Gq/G11 → PLC-β 
activation
Gi/Go family → Ion 
channel (K+ and Ca2+)
ADP, 2-MeSADP, ATP, 
ATPγS
2-ClATP, 2-MeSATP, 
MRS2179, MRS2279
P2Y2 UTP=ATP
Gq/G11 → PLC-β 
activation
Gi/Go family; 
G12/G13 family
ATP, Ap4A, UTP, 
UTPγS
ARC126312, suramin
P2Y4 UTP>ATP
Gq/G11 → PLC-β 
activation
PLA2 stimulation ATP, Up4U, Up4dC, UTP PPADS, RB-2, suramin
P2Y6 UDP>>UTP>ATP
Gq/G11 → PLC-β 
activation
G12/G13 → AC stimulation
MRS2693, UDP, 
UDPβS, Up3U
MRS2567, MRS2575, 
MRS2578, RB-2
P2Y11 ATP>UTP
Gq/G11 → PLC-β 
activation
Gs → AC stimulation
ARC67085, ATP, 
ATPγS, BzATP, dATP
5'AMPS, NF157, NF340, RB-
2, suramin
P2Y12 ADP>>ATP Gi/Go → AC inhibition Gi/Go → AC inhibition
ADP, ADPβS, 2-
MeSADP, 2-MeSATP
AZD6140, BX667, Cangrelor, 
Clopidogrel, INS50589, AR-
C66096
P2Y13 ADP>>ATP Gi/Go → AC inhibition
ADP, ADPβS, 2-
MeSADP, 2-MeSATP
Ap4A, Cangrelor, 2-
MeSAMP, MRS2211, 
MRS2603, RB-2
P2Y14 UDP-glucose Gi/Go → AC inhibition Gi/Go → PLC stimulation
UDP, UDP-galactose, 
UDP-glucuronate, UDP-
glucose
UDP
Receptor Endogenous ligand
Primary transduction 
mechanisms
Secondary transduction 
mechanisms Main agonists Main antagonists
A1 Gi/Go → AC inhibition
Gs → AC stimulation;        
Gi/Go → PLC stimulation
Adenosine, CCPA, R-
PIA, NECA
DPCPX, CGS15943, CPT, 
FR194921, WRC-0571, XAC
A2A Gs → AC stimulation
Gq/G11 → AC stimulation 
and PLC activation
Adenosine, ATL146e, 
CGS21680, CV-1808, 
IAB-MECA, NECA
CGS15943, MRS1093, 
SCH58261, ZM241385
A2B Gs → AC stimulation Gq/G11 → PLC activation Adenosine, NECA
AS99, AS101, MRE2029F20, 
MRS1754, OSIP339391, XAC
A3 Gi/Go → AC inhibition Gi/Go → PLC stimulation
Adenosine, I-ABA, IAB-
MECA, IB-MECA, 
NECA
MRS1177, MRS1220, 
MRE3010F20, VUF8504
Adenosine
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Extracellular nucleoside and nucleotide metabolic pathways 
Signal transduction mechanisms initiated by nucleotides are directly 
dependent on the extracellular levels of these messengers which, in turn, are 
modulated by the biochemical activity of ectonucleotidases (see Table 1.5). 
Ectonucleotidases are divided into two major categories: the nucleotide-degrading 
ectophosphohydrolases/esterases and the nucleotide-generating 
ectokinases/phosphotransferases (35).  
Several ectonucleotidases have been described, including the ecto-
nucleoside triphosphate diphosphohydrolase (E-NTPDase) family, the ecto-
nucleotide pyrophosphatase/phosphodiesterase (E-NPP) family, acid (ACPs) and 
alkaline (ALPs) phosphatases, and ecto-5'-nucleotidase (CD73) (35,36). Of the 8 
members of the NTPDase family (NTPDase1 to -8), only four are extracellular (E-
NTPDase1-3 and -8). All E-NTPDases specifically hydrolyse tri- and 
diphosphonucleosides, albeit with different affinities (35), exclusively in the 
presence of divalent cations (Ca2+ or Mg2+). E-NTPDase1 (also named CD39, 
ATPDase, ectoapyrase, ecto-ADPase) equally hydrolyzes ATP and ADP (ATP:ADP 
ratios of ≈1-2:1), E-NTPDase2 (ecto-ATPase, CD39Ll) is a preferential 
triphosphonucleosidase (ATP:ADP ratios of ≈10-40:1), and E-NTPDase3 (CD39L3, 
HB6) and E-NTPDase8 are functional intermediates between NTPDases 1 and 2 
(ATP:ADP ratios of ≈3-4:1 and ≈2:1, respectively) (39). The E-NPP family comprises 
7 ectoenzymes (NPP1 to -7) that possess the ability to hydrolyse a broad range of 
substrates present in the extracellular medium, including nucleoside tri- and 
diphosphates and their derivatives and/or lysophospholipids. NPP1 to -3 are the 
only members that can hydrolyse nucleotides such as ATP and ADP (35,40). The 
ACPs and ALPs families consist of several ectoenzymes that display broad 
substrate specificity towards different phosphomonoesters and other phosphated 
compounds, such as nucleotides (35,36). Of the 7 members of the 5’-
nucleotidase family, only one is extracellular (ecto-5’-nucleotidase/CD73). CD73 
catalyses the conversion of monophosphonucleosides to nucleosides and 
inorganic phosphate representing the main source of extracellular adenosine 
(35). 
Once formed, adenosine and other nucleosides can be inactivated by ecto-
adenosine deaminase (ecto-ADA) and/or by the cytosolic purine nucleoside 
phosphorylase (PNP) (36). Of the 3 members of the ADA family, only one is 
extracellular (ecto-ADA), which catalyses the irreversible deamination of 
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adenosine to inosine in the extracellular medium. Interestingly, analysis of the 
amino acid sequence of ecto-ADA shows no membrane-spanning domain nor 
membrane localization signal, suggesting that ecto-ADA is likely to be anchored 
to unidentified membrane proteins (35).  
The nucleotide-generating ectokinases/phosphotransferases comprise the 
ecto-adenylate kinase (ecto-AK, also known as AK1β) and the ecto-nucleoside 
diphosphokinases (ecto-NDP kinases). Of the 8 members of the AK, only two are 
extracellular (ecto-AK). Ecto-AK catalyses the transfer of a phosphate group from 
triphosphonucleosides to nucleoside monophosphates, thus yielding two 
diphosphonucleosides in a reversible manner. The NDP kinase family is a group 
of 10 proteins (NM23-H1 to -H10), of which only two are membrane-bound 
(NM23-H1 and -H2). These enzymes transfer the phosphate groups from ATP to 
nucleoside diphosphates, thus generating ADP and triphosphonucleosides (35).    
To support nucleotides-dependent signaling pathways, most cells need to 
recycle their building blocks (i.e. nucleobases or nucleosides) in a constant 
manner. To ensure that, two classes of membrane proteins, known as 
equilibrative nucleoside transporters (ENTs) and concentrative nucleoside 
transporters (CNTs), mediate their reuptake. ENTs are passive low-affinity 
facilitative transporters which allow nucleosides and, to a lesser extent, 
nucleobases, to diffuse across the plasma membrane according to their 
concentration gradient. In constrast, CNTs are high-affinity cation-dependent 
unidirectional symporters that use the potential energy built in the 
transmembrane Na+ gradient to transfer extracellular nucleosides into the 
cytoplasm  (35).  
Often these ectonucleotidases work in concert or consecutively. ATP/UTP, 
for instance, can be hydrolyzed in one step to either ADP/UDP or AMP/UMP by E-
NTPDase or NPP isoenzymes. ADP/UDP can be further hydrolyzed to AMP/UMP by 
E-NTPDases and NPPs, and AMP/UMP is converted to adenosine/uridine by 
alkaline phosphatases or the CD73. This sequential catabolism pathway not only 
terminates the triphosphonucleosides signaling but also generates intermediates 
with distinct signaling properties. Thus, diphosphonucleosides selectively interact 
with specific P2 receptor subtypes, while adenosine, acting through P1 receptors, 
plays its role as well. The relative contribution of the distinct ectonucleotidase 
species to the modulation of purinergic signaling may depend on differential 
tissue and cell distribution, regulation of expression, targeting to specific 
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membrane domains, but also on substrate availability and substrate preference 
(40). 
 
Table 1.1. Potential ectoenzymes involved in the modulation of P2 and P1 purinoceptors signaling 
 
Adapted from (39). 
 
The purinome complex 
As previously mentioned, it is now well described the existence of 
numerous different purinergic receptors sensitive to different endogenous 
ligands (ATP, UTP, ADP, UDP and adenosine), which couple to similar or quite 
different transduction pathways. On a first analysis, we might expect that 
Family Ectoenzyme Enzymatic reaction Substrates Functions or potential functions
NTPDase1 (CD39, 
apyrase, ATPDase) NTP ≈ NDP
Prevent P2Y1 and P2X1 receptors 
desensitization; Terminate P2 receptors signaling 
(P2Y2, P2Y6, P2X7, etc.); Favor adenosine 
generation
NTPDase2 (CD39L1, 
ecto-ATPase) NTP>>NDP
Termination of P2 receptors signaling; Switch of 
P2 receptors activation
NTPDase3 (CD39L3, 
HB6) NTP> NDP
Termination of P2 receptors signaling; Transient 
switch of P2 receptors activation
NTPDase8 (Hepatic 
ATPDase) NTP> NDP
Termination of P2 receptors signaling; Transient 
switch of P2 receptors activation
NPP1 (CD203a, PC-1) ATP, Npn N, pNP-TMP, 
NAD+
NPP2 (autotaxin) ATP, Npn N, pNP-TMP, 
LPC, SPC
NPP3 (CD203c, 
GP130RB13-6, B10) ATP, Npn N, pNP-TMP
PAP (ACP3) NMP → nucleoside + Pi NMP, pNP-P, various phosphorylated molecules Activation of P1 receptors
OcAP/TrAP
NTP → NDP + Pi                         
NDP → NMP + Pi                    
NMP → nucleoside + Pi                          
Molecule-P → molecule + Pi
NTP, NDP, NMP, pNP-
P, various phosphorylated 
molecules
Termination of P2 receptors signaling; 
Activation of P1 receptors
Phosphatases (ALP) TNAP (akp-2)
NTP → NDP + Pi                         
NDP → NMP + Pi                    
NMP → nucleoside + Pi                          
Molecule-P → molecule + Pi
NTP, NDP, NMP, pNP-
P, cAMP, various 
phosphorylated molecules
Termination of P2 receptors signaling; 
Activation of P1 receptors
Ecto-5'-nucleotidase Ecto-5'-nucleotidase (CD73) NMP → nucleoside + Pi NMP Activation of P1 receptors
NDPK NTP + N'DP ↔ NDP + N'TP NTP, NDP Swith of P2 receptors activation
AK 2ADP ↔ AMP + ATP ADP Favor ADP-sensitive receptors (P2Y1,12,13); 
Swith of P2 receptors activation
Ecto-ADA Ecto-ADA (adenosine 
aminohydrolase)
Adenosine + H2O → inosine + 
NH4+
Adenosine Terminate/reduce P1 receptors signaling; Favor 
nucleobase uptake
NTP → NDP + Pi                    
NDP → NMP + Pi
Termination of P2 receptors signaling; Favor P2 
receptors activation (from dinucleotides' 
hydrolysis); Favor adenosine formation
NTP → NMP + PPi                
NDP → NMP + Pi             
Npn N → NMP + Np(n-1)           
NAD+ → AMP + nicotinamide 
ribosyl-P 3'-5'-                           
NMPc → NMP
NTPDases
NPPs
Phosphatases (ACP)
Ectokinases 
30 
 
receptors that couple to the same intracellular signal transduction pathway would 
induce analogous cellular responses. However, the expression of similar or 
distinct membrane bound receptors and/or triggering of similar or distinct 
intracellular signal transduction pathways must not be considered as the unique 
criteria to explain what contributes to determine each specific cellular response 
to extracellular nucleotides (32). Recent evidence suggests that receptors, G 
proteins and effectors are specifically 3-dimensionally organized rather than 
freely diffused in the cell system, and that the specificity of signaling in intact 
cells appears to be significantly greater than in reconstituted systems (41). That 
indicates that nature is likely to be much more complex. From such a vast 
biological scenario and molecular complexity and diversity among purinergic 
receptors subunits, it clearly emerges that: (1) any purinergic receptors must be 
associated to a dynamic process; (2) multiple purinergic receptors are required 
for gaining biological functions; and (3) purinergic-related proteins are more than 
the sum of their single entities (32).  
Increasing evidence demonstrates that the inner organization of the 
membrane of living cells plays a significant role in many biological processes and 
includes complex and distinctive biomolecular associative networks, able to 
ensure correct intracellular trafficking and fast communication among ligands, 
receptors, reuptake systems, degrading enzymes and signaling proteins (42,43). 
Therefore, biological compartments and submembrane microdomains at the 
plasmalemma level (lipid rafts, lipid rafts-like structures and caveolae) become 
critical elements in the coordination of receptor processes (42). Membrane rafts 
are defined as small (10-200 nm), heterogeneous, highly dynamic, cholesterol 
and sphingolipids containing microdomains that compartmentalize cellular 
processes. Under stimulating conditions, these smaller microdomains display a 
striking ability to coalesce and give rise to larger and stable membrane domains. 
Unlike planner membrane rafts, caveolae are a subset of raft characterized by 50-
100 nm of flask-/omega-shaped membrane invaginations. Such invaginations 
have the advantage of being able to facilitate interactions between proteins that 
are localized in separate organelles (e.g. endoplasmic reticulum (ER) and 
mitochondria), thereby mediating a communication between separate membrane 
compartments (e.g. plasmatic membrane with ER) which would, otherwise, be 
several microns apart (43). These compartments set not only the biochemical 
entity and mechanisms of receptor cooperativity and functioning, but also the 
magnitude and direction (horizontal at the plasma membrane, vertical towards 
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the extra- and/or intracellular side of the cell) of the signals propagated by each 
ligand-activated receptor, and of the signals terminated by enzymatic degradation 
or reuptake systems. This large-scale synchrony/synergism of different molecular 
units, defined as the “receptosome”, is then mechanistically ruled by specific 
receptor combinations activated within each cell phenotype, with the final aim of 
integrating the receptor assortment, to optimize the fulfillment of heterogeneous 
functions (42). 
As an example of receptosome, the term “purinome” was coined to 
describe the molecular complex responsible for the biological effects of 
extracellular purine and pyrimidine ligands (42). In addition to a vast 
heterogeneity of purinergic ligands, the purinome thus consists of 
ectonucleotide-metabolizing enzymes hydrolysing nucleoside phosphates, P1 and 
P2 purinergic receptors, nucleoside transporters with both equilibrative and 
concentrative properties, and finally, nucleotide channels and transporters. 
Notably, these purinergic elements are not independent neither exists any 
recognized dominance subsisting among these proteins. Rather, all these 
proteins seem to play tightly concerted actions under physiological conditions. As 
a whole and not singularly, they trigger, maintain and terminate the purinergic 
signaling. This signifies that the purinome is not a new, mere definition of 
juxtaposed purinergic units, but rather the experimental evidence of complex and 
dynamic molecular cross-talk and cooperation networks. The alteration of their 
global and dynamic equilibrium might even be responsible for the appearance/ 
propagation of pathological states (42). 
 
Purinergic signaling in inflammation and pain  
Extracellular nucleotides and nucleosides, such as ATP and adenosine, 
have been identified as important signaling molecules that are involved in both 
inflammation (44) and pain (45) mechanisms.  
During inflammatory conditions that occur in vascular thrombosis, 
hypoxia, ischemia, inflammatory bowel disease and acute lung injury, multiple 
cell types release nucleotides to the extracellular space, typically in the form of 
ATP and ADP. An additional source of extracellular nucleotides in such 
inflammatory conditions is provided by activated platelets, which release ATP and 
ADP through the release of granules and exocytosis. Once in the extracellular 
space, these nucleotides can exert their functions as signaling molecules. It 
seems that extracellular ATP has chemotactic effects on inflammatory cells and 
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activates the NLRP3 inflamassome. Examples of nucleotide-receptor signaling in 
inflammatory conditions include P2Y6 or P2X7 receptors, which mediate vascular 
inflammation, P2Y1, P2X1, and P2Y12 receptors, which mediate platelet activation, 
and P2Y2 and P2X7 receptors, which promote lung inflammation in chronic lung 
diseases such as asthma (29). There is, however, an often antagonistic and 
sometimes synergistic action between ATP and adenosine, which provides a 
mechanism for sophisticated cellular interactions. Therefore, ATP signaling 
should be considered together with adenosine signaling (46). In contrast to the 
ATP-induced pro-inflammatory effects, extracellular adenosine has been referred 
to as a “safety signal” that dampens inflammation. Experimental studies have 
shown that pharmacologic strategies that increase the breakdown of ATP to 
adenosine are effective in attenuating tissue injury and inflammation. For 
example in acute lung injury, it seems that enhanced inflammation that results 
from the activation of P2Y6 and P2X7 receptors might be reverted by the 
activation of adenosine-sensitive receptors, possibly A2A and A2B receptors. Thus, 
shifting the balance between purinergic P2 and P1 signaling is an emerging 
therapeutic concept in efforts to dampen pathologic inflammation and promote 
healing (29).  
Purinergic signaling seems to be an important regulatory mechanism in 
pain conditions as well. In 1996, Burnstock put forward a unifying purinergic 
hypothesis for the initiation of pain by ATP acting via P2X3 and P2X2/3 receptors. 
This hypothesis was first associated with causalgia, reflex sympathetic dystrophy, 
angina, migraine, and pelvic and cancer pain, but further research expanded this 
concept for acute, inflammatory, neuropathic, and visceral pain (45). Likewise, 
other purinergic receptors seem to be involved in nociceptive responses as well. 
The P2Y1 receptor, which has been identified in a subpopulation of sensory 
neurons that also express the P2X3 receptor, is up-regulated in DRG neurons 
after transection of sciatic nerves, suggesting its involvement in nociception. 
Moreover, interactions between vanilloid and metabotropic P2Y receptors are 
being explored in terms of treatments for chronic pain and thermal 
hypersensitivity. Analgesic effects with intrathecal administration of the P2Y 
receptor agonists UTP and UDP in normal and the neuropathic pain rat model 
have also been reported, suggesting that P2Y2 (and/or P2Y4) and P2Y6 receptors 
produce inhibitory effects in spinal pain transmission. Furthermore, P2X4 
receptors expressed in spinal microglia appear to gate tactile allodynia after 
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nerve injury, and disruption of the P2X7 receptor gene abolishes chronic 
inflammatory and neuropathic pain (45).  
In summary, there is increasing evidence demonstrating the expression of 
several P1, P2Y and P2X purinergic receptors in neurons, satellite glial cells, 
astrocytes, microglia and immune system cells, all of which, together with 
possible few more cell types, are involved in nociception (47). Altogether, these 
findings indicate that several purinergic receptors might evoke and/or modulate 
nociceptive mechanisms, both centrally and peripherally (46).  
 
Purinergic signaling in specialized connective tissues 
Bone  
Bone development and remodeling comprise a complex purinergic 
signaling involving both P1 and P2 (P2X and P2Y) receptors, which are present in 
osteoclasts and osteoblasts (45). ATP and ADP, acting through P2X2 and P2Y1 
receptors, respectively, seem to turn on the activity of osteoclasts. On the other 
hand, ATP acting via the P2X5 receptor, has been reported to stimulate 
proliferation of osteoblasts, whilst activation of the P2Y1 receptor is thought to 
modulate the response of osteoblasts to systemic factors, such as the parathyroid 
hormone. Though P2X7 receptor activation seems to reduce bone resorption by 
inducing apoptosis of osteoclasts, it has been also suggested that P2X7 receptor 
caused enhanced osteoblasts apoptosis. In contrast, P2X7 receptor stimulation in 
osteoblasts was associated to increased membrane blebbing and bone formation 
(48).  Uracil nucleotides are also important regulators by mediating osteogenic 
cells differentiation, mainly through the activation of the UDP-sensitive P2Y6 
receptor. The endogenous actions of uracil nucleotides may be balanced through 
specific E-NTPDases, determining whether osteoblast progenitors are driven into 
proliferation or differentiation (49). Moreover, P2Y2 receptor activation by ATP or 
UTP also seems to prevent mineralization by osteoblasts (48). Furthermore, 
adenosine is considered an important regulator of bone remodeling as well. A2B 
receptor activation seems to have a consistent role in the differentiation of 
primary bone marrow stromal cells, which may be balanced through the relative 
strengths of A1 or A2A receptors determining whether osteoblasts are driven into 
proliferation or differentiation (50). Therefore, purinergic signaling might be an 
important therapeutic target in bone diseases, such as osteoporosis.  
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Cartilage 
Similarly to the bone, purines play an important role in cartilage 
physiology. Mechanical stimulation, which influences the rate of nucleotides 
release and metabolism, is critical for the maintenance of healthy articular 
cartilage (45). However, evidence about purinergic signaling on cartilage seems to 
be controversial. Though it has been suggested that extracellular nucleotides, like 
ATP, negatively regulate cartilage metabolism due to the inhibition of cartilage 
formation, proteoglycan breakdown potentiation and increased production of 
inflammatory mediators, it has also been reported that ATP increases 
proteoglycan synthesis, collagen accumulation and suppression of the production 
of inflammatory mediators. In addition, ATP signaling, via P2X4 receptor 
activation, is thought to mediate the rise of intracellular Ca2+ required for 
chondrocyte differentiation (48). Moreover, it seems that nucleotide metabolism 
is tightly controlled by the cartilage extracellular matrix. Apart from modulating 
the activation of purinergic receptors, ectoenzymes regulate the levels of 
extracellular phosphate and pyrophosphate, which are the components involved 
in crystal deposition (45).  
Furthermore, a purinergic signaling also seems to be involved in the 
pathophysiology of rheumatic diseases. For example, the articular fluid removed 
from arthritic joints contains increased levels of ATP, suggesting that ATP might 
potentiate the underlying inflammation levels of cartilage (45). In addition, 
methotrexate (MTX), which remains the most widely used agent for the treatment 
of rheumatoid arthritis and other chronic inflammatory diseases, exerts at least 
part of its anti-inflammatory effects via adenosine, possibly by altering the 
expression and function of adenosine receptors on inflammatory cells (51,52). 
Moreover, in MTX-resistant rheumatoid arthritis patients, blockage of the A2B 
receptor has been shown an effective therapy and with minimal side effects in 
comparison to the anti-TNFα therapy, which is successful but accompanied by 
severe side effects (53). These findings are in agreement that, similarly to bone 
diseases, purinergic signaling might be an important therapeutic target in 
cartilage disorders. 
 
Adipose tissue 
There is evidence that nucleosides and nucleotides are important 
physiological regulators of adipose tissue function as well, whose dysfunction 
might ultimately contribute to obesity. Endogenous adenosine seems to promote 
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lipolysis (reviewed by (54)) and has been shown to increase the production of 
leptin in isolated white adipocytes through the A1 receptor activation (reviewed by 
(55)). Though the mediating P2 purinergic receptors are still unidentified, as well 
as their functional significance, ATP and UTP were found to increase cytoplasmic 
calcium in white and brown adipocytes. In rat adipocytes, P2Y receptors were 
associated with lipogenesis and ATP was also found to decrease the release of 
leptin, possibly due to the P2Y11 receptor activation (reviewed by (55)). On the 
other hand, P2Y1 receptors can support leptin secretion in adipocytes and 
possibly affect the circulating levels of leptin in lean animals (55). 
 
Blood 
In the blood, extracellular nucleotides, such as ATP, ADP, UTP and UDP, are 
important signaling mediators that are strongly released by leucocytes, 
lymphocytes, endothelium, and platelets. Once released, these mediators bind to 
multiple P2Y and P2X receptors on platelets, endothelium, vascular smooth 
muscle cells, leucocytes and immunocytes, triggering short- and long-term 
processes affecting cellular metabolism, nitric oxide (NO) release, adhesion, 
activation and migration. As an example, the platelet activation and integrin 
binding necessary to platelet-aggregation seems to depend on the activation of 
P2Y1, P2Y12 and P2X1 receptors (56).  
 
Purinergic signaling in nonspecialized connective tissues  
Purinergic signaling in nonspecialized connective tissues is a ground to 
explore given that evidence is missing. This finding is not surprising due to the 
fact that nonspecialized connective tissues were considered less important, thus 
discarded until quite recently. The role of fibroblasts, its major cell type, has, 
however, been investigated in several organs, like lungs, intestine, liver and the 
heart (57-68).  
In the intestine, fibroblasts seem to act as mechano-sensors, releasing ATP 
in response to mechanical stimulation, further eliciting a Ca2+-wave propagation 
through the fibroblasts’ network via P2Y1 activation. The released ATP also seems 
to activate P2X receptors expressed in neighboring sensory neurons, regulating 
peristaltic motility (57).  
Literature about cardiac fibroblasts as important myocardial remodeling 
key players after ischemic heart disease is also emerging and recent studies 
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suggest that purines and pyrimidines might be involved in this process. There is, 
however, some controversy. Although both ATP and UTP seem to induce a 
profibrotic response in mouse and rat cardiac fibroblasts by activating the P2Y2 
receptor (58,59), in rat in vivo models it has been described that UTP, via P2Y2 
receptor activation, induces cardioprotection by decreasing infarct size and 
restoring cardiac function following myocardial infarction (60,61). Furthermore, 
P2Y2 receptor mRNA is up-regulated in patients with congestive heart failure, 
suggesting a pathophysiological role for this receptor in disease development 
(62). This controversy might be explained by the non-isolated cell-preparations, 
with which becomes unclear if results are attributable to cardiac fibroblasts, 
cardiomyocytes or endothelial cells. The expression of several other purinergic 
receptors in cardiac fibroblasts has also been reported, such as the P2Y1, P2Y4 and 
P2Y6 receptors, however their functional role remains to be clarified. In addition 
to the P2 receptors, P1 receptors also seem to play an important role in cardiac 
remodeling. Adenosine, via A2B receptor activation, inhibits collagen production 
by cardiac fibroblasts (63,64), which might be considered a protective property 
for fibrosis development (63). Moreover, the downregulation of A2B receptors 
seems to contribute to a disorganized collagen deposition and hypertrophy of 
cardiac fibroblasts following cardiac ischemia and reperfusion (65).   
Conversely to what has been described in the heart, the activation of the 
A2B receptor in the lungs seems to play a role in the pathogenesis of chronic 
obstructive pulmonary disease and interstitial fibrosis. Similarly, in the skin and 
in the liver, A2A receptor activation seems to mediate and increase fibrosis due to 
an increase of collagen production, an effect that is prevented by the non-
selective antagonist of P1 receptors, caffeine (66). 
In pulmonary fibroblasts, little is known about the nature and the 
underlying mechanisms of purinergic responses in pulmonary fibroblasts, 
particularly in human, nor about their functional consequences. Recent data are 
consistent with extracellular nucleotides acting upon human pulmonary 
fibroblasts via the P2Y4, P2Y6 and/or P2Y11 subtypes, rather than by P2Y1 nor P2Y2 
subtypes, liberating internally sequestered Ca2+ leading to a Ca2+-wave which 
courses throughout the cell and excites the nucleus, resulting in increased gene 
transcription of various proteins that are important for tissue repair and fibrosis 
(68). 
Overall, these findings suggest that, according to their origin, differences 
in purinergic signaling cascades might occur in fibroblasts (see Table 1.6). This 
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finding is not unexpected. Differences in fibroblasts morphology have been 
mentioned for a long time, as well as in the proliferation potential between 
fibroblasts derived from specific regions (69)). Nevertheless, we are not aware of 
any studies which have characterized purinergic receptors and ectonucleotidases 
in human subcutaneous fibroblasts. Recently, it was demonstrated that rat 
subcutaneous fibroblast’s cytoskeletal remodeling induced by tissue stretch 
involves ATP signaling (70), possibly due to the activation of P2Y1, P2Y2, P2Y4 
and/or P2X7 receptors (71). However, this is an open field still to be explored, 
especially when purinergic signaling may potentially play a role in connective 
tissue remodeling and, thereby, in the pathogenesis of connective tissue-related 
disorders.  
 
Clinical relevance of this study  
As previously mentioned, literature points out that subcutaneous 
connective tissue receives both proprioceptive and nociceptive innervation 
(10,12). Though the specific role of the identified nerve fibers remains unclear to 
consider this unspecialized connective tissue a sensory organ, such innervation 
supports recent studies that suggest the involvement of subcutaneous tissue in 
the pathophysiology of pain states, like back pain (13,14,16). This could occur 
either through direct activation or modulation of nociceptors activity or by its 
influence on muscle activity, therefore, in movement patterns (16). 
 
Table 1.6. P2 purinergic receptors expressed in fibroblasts from different origins. 
  Origin Species Positive expression Negative expression Reference   
  Lung Human P2Y4, P2Y6, P2Y11 P2Y1, P2Y2, P2X1, P2X3, P2X4, P2X6 (68)   
  Heart Human P2X4, P2X7, P2Y2 P2X1, P2X2, P2X3, P2X5, P2X6, P2Y1 (72)   
  Heart Rat P2Y2   (59)   
  Heart Rat P2Y2>>P2Y6>>P2Y1>P2Y4 P2Y6 (58)   
  Skin Human P2X7   (73)   
  Lung Mouse P2Y2   (67)   
  Intestine Rat P2Y1 P2Y6, P2Y12, P2X2, P2X7; P2Y4 ? (57)   
  Synovial tissue Human 
P2X1, P2X3, P2X7; lower 
expression of P2X2, P2X4, 
P2X5, P2X6  
  (74)   
  
Subcutaneous 
tissue Human P2Y1, P2Y2, P2Y4, P2X7 P2X1, P2X4 (71)   
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  Interestingly, although the origins of astrocytes and fibroblasts are 
different (ectoderm and mesenchyme, respectively), both cells have very similar 
physiological characteristics and similar shape conversion mechanisms (75). 
Astrocytes, also classically considered as supportive cells, in this case for 
neurons, and without a direct role in brain information processing, are emerging 
as relevant elements in brain physiology through their ability to regulate neuronal 
activity and synaptic transmission and plasticity. In relation to the key role of 
astrocyte-neuron interactions in synaptic physiology, accumulating evidence 
suggests that dysfunctions of astrocyte-neuron signaling may be linked to the 
pathology of various neurological and neurodegenerative diseases (76). These 
findings support the idea that fibroblasts might also mediate and modify 
intercellular signal transductions among neighboring cells, like smooth muscles 
and neurons (75). 
Increasing evidence suggests that purinergic signaling may potentially play 
a role in the function of fibroblasts and subsequent connective tissue remodeling, 
which could be the basis of the long-term pain-relieving benefits of acupuncture 
or physical therapy techniques involving mechanical manipulation of connective 
tissue (71). Thus, unveiling the purinergic mechanisms that underlie connective 
tissue remodeling might help to clarify their involvement in the pathogenesis of 
pain conditions, as well as to determine potential therapeutic targets for clinical 
use.  
Taking into consideration that [1] changes in the regulation of connective 
tissue ATP signaling may be important in the pathogenesis of chronic 
inflammatory pain (44) and that [2] algogenic inflammatory mediators, such as 
bradykinin and histamine, may sensitize cells to autocrine and paracrine signals 
operated by extracellular adenine nucleotides (77), we investigated in this study: 
- the involvement of ATP in bradykinin- and histamine-induced Ca2+ signals 
in human subcutaneous fibroblasts; 
- the ATP-release mechanisms triggered by bradykinin and histamine in 
human subcutaneous fibroblasts; 
- the extracellular enzymatic pathways responsible for ATP catabolism and 
adenosine formation in human subcutaneous fibroblast cultures; 
- and the expression of purinoceptors (P1 and P2) in fibroblasts from 
human subcutaneous connective tissue. 
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ABSTRACT 
Changes in the regulation of connective tissue ATP-mediated mechano-
transduction and remodeling may be an important link to the pathogenesis of 
chronic pain. It has been demonstrated that mast cell-derived histamine plays an 
important role in painful fibrosing diseases. Here we analyzed the involvement of 
ATP in the response of human subcutaneous fibroblasts to histamine. Acute 
histamine application caused a rise in intracellular Ca2+ ([Ca2+]i) and ATP release 
from human subcutaneous fibroblasts via H1 receptor activation. Histamine-
induced [Ca2+]i rise was partially attenuated by apyrase, an enzyme that inactivates 
extracellular ATP, and by blocking P2 purinoceptors with 4-((4-formyl-5-hydroxyl-
6-methyl-3-((phosphonooxy)-methyl)-2-pyridinyl)azo)-1,3-benzenedisulfonic acid 
tetrasodium salt and reactive blue 2. [Ca2+]i accumulation caused by histamine 
was also reduced upon blocking pannexin-1 hemichannels with 10Panx, 
probenecid or carbenoxolone, but not when connexin hemichannels were 
inhibited with mefloquine or 2-octanol. Brefeldin A, an inhibitor of vesicular 
exocytosis, also did not block histamine-induced [Ca2+]i mobilization. Prolonged 
exposure of human subcutaneous fibroblast cultures to histamine favored cell 
growth and type I collagen synthesis via the activation of H1 receptor. This effect 
was mimicked by ATP and its metabolite, ADP, whereas the selective P2Y1 
receptor antagonist, 2’-deoxy-N6-methyladenosine 3’,5’-bisphosphate tetrasodium 
salt, partially attenuated histamine-induced cell growth and type I collagen 
production. Expression of pannexin-1 and ADP-sensitive P2Y1 receptor on human 
subcutaneous fibroblasts was confirmed by immunofluorescence confocal 
microscopy and Western blot analysis. In conclusion, histamine induces ATP 
release from human subcutaneous fibroblasts via pannexin-1 hemichannels 
leading to [Ca2+]i mobilization and cell growth through the cooperation of H1 and 
P2 (probably P2Y1) receptors. 
 
Keywords: human subcutaneous fibroblasts, ATP release, pannexin 1, P2 
purinoceptors, histamine 
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INTRODUCTION 
Unspecialized connective tissue forms an anatomical mesh throughout the 
body, which acts as a body-wide mechanosensitive signaling network (7,78). 
Despite its overwhelming size, the relative importance of unspecialized 
connective tissue has been generally overlooked or misunderstood; it was 
considered as relatively superfluous apart from its supporting role amongst more 
specialized tissues (7). Nowadays, evidence suggests that increased connective 
tissue disorganization may be an important link in the pathogenesis of chronic 
musculoskeletal pain, such as low back pain (14,16), and we hypothesized that 
this might also occur in fibromyalgia.  
Like the skin, the underlying subcutaneous connective tissue is richly 
innervated by sensory nerve endings, including mechanoceptors, nociceptors and 
thermoceptors (12,79). Therefore, sensory inputs arising from affected 
connective tissue may alter the activity of nociceptors. Conversely, activation of 
nociceptors causes the release of substance P from sensory C-fibers, which 
triggers the production of inflammatory mediators, like histamine and several 
cytokines, from neighboring cells (80). It was demonstrated that substance P and 
histamine augment cytokine-induced proliferation of dermal fibroblasts, thus 
indicating that mast cell-derived histamine may be a key player in the induction of 
tissue fibrosis in painful fibrosing diseases (81). In view of this, nociceptor 
activation may, by itself, contribute to prolong inflammation and to exaggerate 
tissue fibrosis.  
Inflammatory mediators, such as cytokines and histamine, are essential to 
the onset and maintenance of inflammatory reactions (82). In addition, adenine 
and uracil nucleotides have also been related to the pathophysiology of chronic 
inflammation (44). Besides their acute actions, nucleotides exert autocrine and/or 
paracrine activities regulating cellular processes, like proliferation and 
differentiation of human cells (49). Interestingly, it has been described that 
smooth muscle and epithelial cells release ATP in response to histamine (83), but 
this was never demonstrated in fibroblasts. Therefore, we postulated that 
inflammatory mediators, like histamine, could influence connective tissue 
plasticity through the release of ATP from fibroblasts, the predominant cell type 
of this tissue, leading to signal amplification via P2 purinoceptors located in 
neighboring cells. 
Nucleotides reach the external milieu via both lytic and non-lytic 
mechanisms from various cell types upon mechanical or chemical stimulation. 
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Nucleotide-releasing pathways include [1] electrodiffusional movement through 
membrane ion channels, including pannexin and connexin hemichannels; [2] 
facilitated diffusion by nucleotide-specific ATP-binding cassete (ABC) transporters; 
and [3] cargo-vesicle trafficking and exocytotic granule secretion (36). The extent 
of the paracrine activity mediated by ATP and/or related released nucleotides may 
be limited by the presence of membrane-bound nucleotide metabolizing 
enzymes. Ectonucleotidases sequentially catabolize nucleoside 5’-triphosphates 
to their respective nucleoside 5’-di- and monophosphates, nucleosides and free 
phosphates or pyrophosphate, which can all appear in the extracellular fluid at 
the same time (36). Although a comprehensive study on the kinetics of 
extracellular catabolism of adenine nucleotides and adenosine formation in the 
human musculoskeletal system is still lacking, the coexistence of various 
metabolic pathways for the nucleotide extracellular hydrolysis represents an 
opportunity for regulating cell-specific responses to surrounding adenine 
nucleotides and for terminating purinergic actions. 
Therefore, this study was designed to investigate if the response of human 
subcutaneous fibroblasts to histamine involves a purinergic loop consisting in the 
release of ATP, formation of its biological active metabolites (namely ADP) and 
subsequent P2 purinoceptors activation. Understanding the mechanisms 
underlying the purinergic amplification loop regulating cell signaling and 
subcutaneous tissue remodeling triggered by inflammatory mediators may 
highlight new therapeutic strategies for chronic painful conditions. 
 
EXPERIMENTAL PROCEDURES 
Cell cultures 
Human fibroblasts were isolated from the subcutaneous tissue of organ 
donors (52 ± 5 years old (mean ± S.E. of the mean), n = 16) with no clinical 
history of connective tissue disorders. The protocol was approved by the Ethics 
Committee of Hospital Geral de Santo António SA (University Hospital) and of 
Instituto de Ciências Biomédicas de Abel Salazar (Medical School) of University of 
Porto. The investigation conforms to the principles outlined in the Declaration of 
Helsinki. Subcutaneous tissues were maintained at 4-6ºC in M-400 transplantation 
solution (4.190 g/100 mL mannitol, 0.205 g/100 mL KH2PO4, 0.970 g/100 mL 
K2HPO4·3H2O, 0.112 g/100 mL KCl, and 0.084 g/100 mL NaHCO3, pH 7.4) until 
used, which was between 2 and 16 hours after being harvested (84). Cells were 
then obtained by the explant technique and cultured in DMEM medium 
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supplemented with 10% fetal bovine serum (FBS), 2.5 µg/mL of amphotericin B 
and 100 U/mL of penicillin/streptomycin, at 37ºC in a humidified atmosphere of 
95% air and 5% CO2. Medium was replaced twice a week. Primary cultures were 
maintained until near confluence (~3 – 4 weeks), then adherent cells were 
enzymatically released with 0.04% trypsin-EDTA solution plus 0.025% type I 
collagenase in phosphate-buffered saline (PBS). The resultant cell suspension was 
cultured and maintained in the same conditions mentioned above. All the 
experiments were performed in the first subculture.  
 
Extracellular ATP quantification by bioluminescence  
Extracellular ATP was quantified by the luciferin-luciferase ATP 
bioluminescence assay kit HS II (Roche Applied Science) using a multi detection 
microplate reader (Synergy HT, BioTek Instruments). Briefly, cells were seeded in 
flat bottom 96 well plates at a density of 3x104 cells/mL for 21 days. At the 
beginning of the experiment, cells were washed twice with Tyrode’s solution (137 
mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 0.4 mM NaH2PO4, 11.9 mM 
NaHCO3, and 11.2 mM glucose, pH 7.4) at 37ºC and let rest during 30 minutes 
(basal), after which samples were collected (75 µL).  Subsequently, histamine (100 
µM) was added. Samples were collected at five different incubation times (0 – 240 
seconds) and immediately stored at -20ºC. Luciferin-luciferase experiments were 
performed at room temperature and light emission acquisition was performed 20 
seconds after addition of luciferin-luciferase to the collected sample. 
 
Measurement of [Ca2+]i  
Changes in [Ca2+]i were measured with the calcium sensitive dye Fluo-4 NW 
using the multi detection microplate reader referred above (85). Human 
fibroblasts were seeded in flat bottom 96 well plates at a density of 3x104 
cells/mL. Cells were cultured for 5 – 15 days in supplemented DMEM as described 
before. On the day of the experiment, cells were washed twice with Tyrode’s 
solution and incubated at 37ºC for 45 minutes with the cell-permeant fluorescent 
Ca2+ indicator, Fluo-4 NW (2.5 µM). After removal of the fluorophore loading 
solution, cells were washed again twice and 150/300 µL of Tyrode’s solution was 
added per culture well/dish, respectively. For the recordings, temperature was 
maintained at 32ºC and readings were made with 5 seconds of interval, during 
approximately 30 minutes, using a tungsten halogen lamp. Fluorescence was 
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excited at 485/20 nm and emission was measured at 528/20 nm. Calcium 
measurements were calibrated to the maximal calcium load produced by 
ionomycin (5 µM, 100% response) (86,87). 
 
Single-cell [Ca2+]i imaging and To-Pro3 dye uptake detection by 
confocal microscopy  
In some of the experiments, we monitored single-cell [Ca2+]i oscillations 
and To-Pro3 dye uptake from the same cells by confocal microscopy (FV1000, 
Olympus, Japan) (49). Due to their high molecular mass, carbocyanine monomer 
nucleic acid fluorescent dyes, like To-Pro3 (671 Da), are membrane impermeable 
and generally excluded from viable cells unless large diameter pores open. Thus, 
increases in fluorescence intensity can be taken as measure of To-Pro3 dye 
uptake into viable cells, which may occur through connexin and pannexin-1 
hemichannels that conduct molecules up to 1 kDa in size across the plasma 
membrane (ATP has 507 Da). Human subcutaneous fibroblasts were seeded onto 
35 mm glass bottom dishes at a density of 2x104cells/mL and allowed to grow for 
5 – 15 days in supplemented DMEM, as described before. On the day of the 
experiment, cells were first loaded with the fluorescent Ca2+ indicator, Fluo-4 NW 
(2.5 µM, see above). Culture dishes were mounted on a thermostatic (32ºC) 
perfusion chamber at the stage of an inverted laser-scanning confocal microscope 
equipped with a 20x magnification objective lens (LUCPLFLN 20x PH; NA: 0.45). 
The chamber was continuously superfused (1 mL/min) with gassed (95% O2, 5% 
CO2, pH 7.4) Tyrode’s solution. To monitor histamine-induced hemichannels 
opening in parallel to [Ca2+]i oscillations, To-Pro3 iodide (1 μM) was added to the 
superfusion solution 6 minutes before histamine application and was kept up to 
the end of the experiment. Fluo-4 NW was excited with the 488 nm Multi-line Ar 
laser and the emitted fluorescence was detected at 510-560 nm; TO-PRO-3 was 
excited with the 633 nm Red He-Ne laser and the emitted fluorescence was 
detected at 661 nm. Time-lapse sequences were recorded at scanning rates with 
20 seconds of interval for approximately 30 minutes, digitized, and processed 
off-line. Regions of interest were defined manually. 
 
Cell viability/proliferation  
Viability /proliferation studies included the MTT assay as previously 
described (50). Human fibroblasts were seeded in flat bottom 96 well plates at a 
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density of 3x104 cells/mL and cultured in supplemented DMEM as described 
before. Cell cultures were routinely monitored by phase contrast microscopy and 
characterized at days 1, 7, 14, 21 and 28. The MTT assay consists on the 
reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
to a purple formazan reaction product by viable cells. In the last 4 h of each test 
period, cells were incubated with 0.5 mg/mL of MTT for 4 h in the conditions 
referred above. The medium was carefully removed, decanted and the stained 
product dissolved with DMSO before absorbance (A) determination at 600 nm 
using a microplate reader spectrometer. Results were expressed as A/well. 
 
Total type I collagen determination  
Type I collagen determination was performed using the Sirius Red staining 
assay. Human fibroblasts were cultured as described for the viability/proliferation 
studies. The staining protocol was adapted from Tullberg-Reinert & Jundt (1999) 
(88). Cell layers were washed twice in PBS before fixation with Bouin’s fluid for 1 
h. The fixation fluid was removed by suction and the culture plates were washed 
by immersion in running tap water for 15 minutes. Culture dishes were allowed to 
air dry before adding the Sirius Red dye (Direct Red 80). Cells were stained for 1 h 
under mild shaking on a microplate shaker. To remove non-bound dye, stained 
cells were washed with 0.01 N hydrochloric acid and then dissolved in 0.1 N 
sodium hydroxide for 30 minutes at room temperature using a microplate shaker. 
Optical density was measured at 550 nm against 0.1 N sodium hydroxide as 
blank (88). Results were expressed as A/well. 
 
Enzymatic kinetic experiments and HPLC analysis  
After a 30-min equilibration period at 37ºC, culture day 11 cells were 
incubated with 30 μM ATP, ADP or AMP, which were added to the culture medium 
at zero time. Samples (75 μL) were collected from each well at different times up 
to 30 minutes for high-performance liquid chromatography (HPLC, LaChrome 
Elite, Merck) analysis of the variation of substrate disappearance and product 
formation (49,89). ATP and ADP catabolism analysis was performed by ion-pair 
reverse-phase HPLC (90), whereas for AMP catabolism analysis was used a linear 
gradient (100% of 100 mM KH2PO4, pH = 7, to 100% of 100 mM KH2PO4, pH = 7, - 
30% of methanol) during 10 minutes with a constant rate flow of 1.25 ml/min. 
Under these conditions, the retention times of metabolites was as follows: AMP 
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(2.17 min), hypoxantine (3.07 min), inosine (5.09 min) and adenosine (7.51 min). 
Concentrations of the substrate and products were plotted as a function of time 
(progress curves). The following parameters were analyzed for each progress 
curve: half-life time (t1/2) of the initial substrate, time of appearance of the 
different concentrations of the products, concentration of the substrate or any 
product remaining at the end of the experiment. 
The spontaneous degradation of adenine nucleotides and nucleosides at 
37ºC in the absence of the cells was negligible (0 – 3%) over 30 minutes. At the 
end of the experiments, the remaining incubation medium was collected and 
used to quantify the lactate dehydrogenase (LDH, EC 1.1.1.27) activity. The 
negligible activity of LDH in the samples collected at the end of the experiments 
is an indication of the integrity of the cells during the experimental period. 
 
Antibody production  
The development and specificity of anti-human NTPDase2 and NTPDase3 
has been reported previously (91,92). Hartley guinea pigs and New Zealand 
rabbits were obtained from Charles River Laboratories (Quebec City, Canada). 
Genetic immunization protocol was carried out with plasmids (pcDNA3 for human 
NTPDase1 and pcDNA3.1 for human CD73) encoding each protein using New 
Zealand rabbits for antibodies against human NTPDase1 and Hartley guinea pigs 
for human CD73 antibodies. 
 
Immunocytochemistry  
Human fibroblasts were seeded in chamber slides at a density of 2.5x104 
cells/mL and allowed to grow for 5 – 15 days. Cultured cells were fixed in 4% 
paraformaldehyde (PFA) in PBS for 10 minutes, washed 3 times in PBS (10 minutes 
each) and, subsequently, incubated with blocking buffer I (10% FBS, 1% bovine 
serum albumin (BSA), 0.1% Triton X, 0.05% NaN3) for 1 h. Primary antibodies, 
diluted in blocking buffer II (5% FBS, 1% BSA, 0.1% Triton X, 0.05% NaN3), were 
applied [mouse anti-porcine vimentin 1:75 (DAKO); rabbit anti-human collagen I 
1:50 (AbDSerotec); rabbit anti-human P2Y1 1:50, rabbit anti-human P2Y12 1:100 
and rabbit anti-human P2Y13 1:25 (Alomone); rabbit anti-human Cx43 1:600 and 
rabbit anti-human Panx1 1:1000 (Abcam); rabbit anti-human NTPDase1 1:100, 
rabbit anti-human NTPDase2 1:200, mouse anti-human NTPDase3 1:200 and 
guinea-pig anti-human CD73 1:300 (University of Laval, Québec, QC, Canada; see 
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the Centre de Recherche du CHUL Web site for further details) and the slides 
incubated overnight at 4ºC. After incubation, cells were washed 3 times in PBS 1X 
(10 minutes each). The donkey anti-rabbit IgG Alexa Fluor 488, donkey anti-
mouse IgG Alexa Fluor 488, donkey anti-mouse IgG Alexa Fluor 568 and donkey 
anti-guinea pig IgG Alexa Fluor 568 secondary antibodies (Invitrogen) were 
diluted in blocking buffer II (5% FBS, 1% BSA, 0.1% Triton X) and applied for 1h at 
dark. A last wash was performed with PBS 1X and glass slides were mounted with 
VectaShield medium and stored at 4ºC. Observations were performed and 
analyzed with an Olympus FV1000 confocal microscope (49,93). 
 
SDS–PAGE and Western blotting  
Fibroblasts were homogenized in a lysis buffer with the following 
composition: 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% sodium deoxycholate, 
1% Triton-X-100, 0.1% SDS and a protease inhibitor cocktail. Protein content of 
the samples was evaluated using the BCA protein assay kit according to the 
manufacturer’s instructions (Pierce). Samples were solubilized in SDS reducing 
buffer (0.125 mM Tris-HCl, 4% SDS, 0.004% bromphenol blue, 20% glycerol, and 
10% 2-mercaptoethanol, pH 6.8 at 70ºC for 10 minutes), subjected to 
electrophoresis in 10% SDS-polyacrylamide gels and electrotransferred onto PVDF 
membranes (MilliPore). Protein loads were 60 µg for P2Y1, P2Y12 and P2Y13, 25 µg 
for Panx1 and 15 µg for Cx43. The membranes were blocked for 1 h in Tris-
buffered saline (TBS: 10 mM Tris-HCl, pH 7.5, 150 mM NaCl) containing 0.05% 
Tween 20 + 5% BSA. Membranes were subsequently incubated with goat anti-
human P2Y1 1:200 (Santa Cruz), rabbit anti-human P2Y12 1:200 (Alomone), rabbit 
anti-human P2Y13 1:200 (Alomone), rabbit anti-human Panx1 1:250 (Novex, Life 
Technologies) and rabbit anti-human Cx43 1:6000 (Abcam) in the above blocking 
buffer overnight at 4ºC. Membranes were washed three times for 10 minutes in 
0.1% Tween 20 in TBS and then incubated with donkey anti-rabbit IgG (HRP) 
1:30000 (Abcam) and donkey anti-goat IgG (HRP) 1:25000 (Abcam) secondary 
antibodies, for 60 minutes at room temperature. For comparison purpose, the 
membranes were also incubated with rabbit anti-human β-tubulin 1:2500 (Abcam) 
antibody following the procedures described above. Membranes were washed 
three times for 10 minutes and antigen-antibody complexes were visualized by 
chemiluminescence with an ECL reagent using the ChemiDoc MP imaging system 
(Bio-Rad Laboratories). 
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Materials and reagents  
1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan  (thiazolyl blue formazan 
– MTT), 2-mercaptoethanol, 2-octanol, 4-[[4-formyl-5-hydroxyl-6-methyl-3-
[(phosphonooxy)methyl]-2-pyridinyl]azo]-1,3-benzenedisulfonic acid tetrasodium 
salt (PPADS), adenosine (ADO), adenosine 5’-diphosphate sodium salt (ADP), 
adenosine 5′-monophosphate sodium salt (AMP), adenosine 5’-triphosphate 
disodium salt (ATP), adenosine 5′-[γ-thio]triphosphate tetralithium salt (ATPγS), 
apyrase, bovine serum albumin (BSA), brefeldin A (BFA), bromphenol blue, 
carbenoxolone (CBX), Direct Red 80, ethylenediaminetetraacetic acid (EDTA), 
ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), glycerol, 
histamine (Hist), mefloquine (MFQ), phosphate buffered saline system (PBS), picric 
acid, probenecid, protease inhibitor cocktail, quinacrine dihydrochloride, reactive 
blue 2 (RB-2), sodium deoxycholate, sodium dodecyl sulfate (SDS), trypsin, Tween 
20, type I collagenase, and cell culture reagents were purchased from Sigma-
Aldrich. 1-[6-[[(17β)-3-Methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-
2,5-dione (U73122), [2-[4-[(4-Chlorophenyl)phenylmethyl]-1-
piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine), 2-
(propylthio)adenosine-5'-O-(β,γ-difluoro methylene) triphosphate tetrasodium salt 
(AR-C 66096), 2',3'-O-(2,4,6-trinitrophenyl)adenosine-5'-triphosphate 
tetra(triethylammonium) salt (TNP-ATP), 2-[(2-chloro-5-nitrophenyl)azo]-5-
hydroxy-6-methyl-3-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde disodium 
salt (MRS 2211), 2'-deoxy-N6-methyladenosine 3',5'-bisphosphate tetrasodium 
salt (MRS 2179), (S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-hexahydro-
1H-1,4-diazepine dihydrochloride (H1152), 10Panx and thapsigargin were obtained 
from Tocris Cookson Inc.. Dimethylsulphoxide (DMSO), glacial acetic acid and 
Triton X-100 were obtained from Merck and Bouin’s solution was acquired from 
Panreac. BFA, H1152, MFQ, thapsigargin and U73122 were prepared in 
dimethylsulphoxide (DMSO). The other drugs were prepared in distilled water. 
DMSO (%v/v < 0.05%) did not affect the parameters under study. All stock 
solutions were stored as frozen aliquots at -20ºC.  
ATP bioluminescence assay kit HS II was from Roche Applied Science. 
Bicinchoninic acid (BCA) Protein Assay Kit was from Pierce. Fluo-4 NW dye was 
supplied by Molecular Probes (Invitrogen). 
Tissue culture plates: 96-well plates were purchased from Corning; 
FluoroDish plates for confocal microscopy were from World Precision Instruments; 
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chamber slides were from Nunc. Polyvinyl difluoride (PVDF) membranes were 
obtained from Millipore.  
 
Presentation of data and statistical analysis  
Data are expressed as mean ± S.E.M. from an n number of 
experiments/cells/individuals. Data from different individuals were evaluated 
one-way analysis of variance (ANOVA). Statistical differences found between 
control and drug-treated cultures were determined by the Bonferroni’s method. p 
values < 0.05 were considered to represent significant differences.  
 
RESULTS 
Fibroblasts characterization  
Cultured cells are elongated and showed a spindle-shape morphology that 
is characteristic of fibroblasts (94,95). Their fibroblastic nature was confirmed by 
immunocytochemistry. All cells exhibited a positive immunoreactivity against 
vimentin, the intermediate protein filament considered a reliable fibroblast-cell 
marker (Fig. 2.1.1A) (96). Cells also stained positive for type I collagen (Fig. 
2.1.1B), which is highly produced by fibroblasts (96).  
 
 
 
Figure 2.1.1. Immunocytochemical staining of fibroblasts isolated from the human subcutaneous 
tissue. Cells exhibited positive immunoreactivity against vimentin, which has been described as a 
reliable fibroblast marker (red, A). Most of the cells also stained positive to type I collagen (green, 
B), which is highly produced by activated fibroblasts. Panel C shows merge of vimentin and type I 
collagen staining. Scale bar 60 µm. 
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Histamine recruits Ca2+ from intracellular stores via the activation of 
H1 receptors coupled to phospholipase C  
Incubation of human subcutaneous fibroblasts with histamine (100 µM, n = 
34) caused a fast (within seconds) rise in [Ca2+]i, which attained 35 ± 2% of the 
maximal calcium load produced by ionomycin (5 µM, 100% response) (Fig. 
2.1.2B). Although the kinetics of [Ca2+]i rise induced by histamine differed slightly 
among cells (see Fig. 2.1.2Biv), the initial fast phase was always followed by a 
slow decay lasting about 2 min; beyond that point, [Ca2+]i levels remained fairly 
constant until drug washout (Fig. 2.1.2Biii).  
Histamine-induced [Ca2+]i oscillations were significantly (p < 0.05) 
attenuated by selective blockade of H1 receptors with cetirizine, applied in a 
concentration (1 µM, n = 6) that on its own did not change baseline (Fig. 2.1.2C). 
Phospholipase C (PLC) involvement on histamine-induced [Ca2+]i response was 
confirmed using the PLC inhibitor, U73122 (3 µM, n = 6) (Fig. 2.1.2D). [Ca2+]i 
oscillations produced by histamine (100 µM, n = 10) were also prevented (p < 
0.05) by the selective inhibitor of endoplasmic reticulum Ca2+-ATPase, 
thapsigargin (2 µM, n = 4), which is known to deplete intracellular Ca2+ stores 
following a transient (< 2 min) rise of [Ca2+]i levels (97) (Fig. 2.1.2E). Removal of 
external Ca2+ (Ca2+-free medium plus EGTA, 100 µM, n = 4) depressed (p < 0.05) 
only the late component of histamine (100 µM, n = 13) response, keeping 
constant the initial fast rise (Fig. 2.1.2F).  
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Figure 2.1.2. Histamine recruits Ca2+ from intracellular stores via the activation of H1 receptors. 
Panels A and B represent fluorescence [Ca2+]i oscillations in human subcutaneous fibroblasts in 
culture in the absence (A) and in the presence (B) of histamine (Hist, 100 μM). Cells were pre-
incubated with the fluorescent calcium indicator, Fluo-4 NW; changes in fluorescence were detected 
in the time-lapse mode using a confocal microscope (Ai-Aii and Bi-Bii) or a microplate reader (Aiii 
and Biii) (see Experimental Procedures). Note that the kinetics of [Ca2+]i signals produced by 
histamine differed slightly among cells (Biv). [Ca2+]i transients were calibrated to the maximal 
calcium load produced by ionomycin (5 μM, 100% response). Shown are also [Ca2+]i oscillations 
produced by Hist (100 µM) applied in the presence of the selective H1 receptor antagonist, cetirizine 
(1 µM, C), the phospholipase C inhibitor, U73122 (3 µM, D), the selective endoplasmic reticulum 
Ca2+-ATPase inhibitor, thapsigargin (2 µM, E), and after removal of extracellular Ca2+ (Ca2+-free 
medium plus EGTA, 100 µM, F). Black arrows indicate the time of drugs application. Each point 
represents pooled data from an n number of experiments. The vertical bars represent S.E.M. and are 
shown when they exceed the symbols in size. Image scale bars: 20 μm. *p < 0.05 represent 
significant differences from Hist (100 µM) alone. 
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Histamine-induced [Ca2+]i accumulation is partially dependent on ATP 
release leading to P2 purinoceptors activation  
Using the luciferin-luciferase bioluminescence assay, results show that 
histamine (100 µM) significantly (p < 0.05) increase ATP release from human 
subcutaneous fibroblasts as compared to the control situation where the cells 
were exposed to Tyrode’s solution (Fig. 2.1.3A). 
Extracellular ATP inactivation with apyrase (2 U/mL, n = 9) reduced 
significantly (p < 0.05) the late component of histamine (100 µM, n = 26) 
response, while keeping fairly conserved the magnitude of the initial [Ca2+]i rise 
(Fig. 2.1.3Bi). A similar pattern was observed when human subcutaneous 
fibroblasts were pre-incubated with non-selective P2 antagonists, RB-2 (100 µM, n 
= 7) and PPADS (100 µM, n = 6) (Fig. 2.1.3Bii and 2.1.3Biii, respectively). 
Attenuation of histamine-induced [Ca2+]i oscillations by PPADS and RB-2 (p < 0.05) 
contrasts with the absence of effect obtained with the preferential P2X receptor 
antagonist, TNP-ATP (10 µM, n = 2) (data not shown).  
In line with these observations, exogenous application of ATP and ADP 
(0.1-1 mM) concentration-dependently increased [Ca2+]i; when applied at 1 mM 
concentration, ATP and ADP transiently increased [Ca2+]i reaching respectively 43 
± 4% (n = 26) and 25 ± 8% (n = 3) of the maximal calcium load caused by 
ionomycin within 20 s from drug application. ATP-induced [Ca2+]i transients were 
prevented (p < 0.05) by pre-incubation of human subcutaneous fibroblasts with 
PPADS (300 µM) (Fig. 2.1.3Biv).        
 
Histamine-induced [Ca2+]i mobilization depends on pannexin-1 
hemichannels activity  
Given that histamine-induced [Ca2+]i oscillations in human subcutaneous 
fibroblasts depend, at least partially, on the release of ATP and subsequent P2 
purinoceptors activation, we tested the action of selective inhibitors of nucleotide 
releasing pathways on histamine [Ca2+]i responses. 
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Figure 2.1.3. Histamine-induced [Ca2+]i mobilization in cultured human subcutaneous fibroblasts is 
partially dependent on ATP release and P2 purinoceptors activation. Panel A illustrates the ATP (nM) 
content of samples from the incubation medium in the presence of histamine (Hist, 100 µM) as 
compared to the control condition where only Tyrode’s solution was applied (luciferin-luciferase ATP 
bioluminescence assay). Each bar represents pooled data from 2-3 replicates of one individual. The 
vertical bars represent S.E.M.. Panel B shows the effect of histamine (Hist, 100 μM) after 
pretreatment of the cells with apyrase (2 U/mL, Bi), which catabolizes ATP and ADP into AMP, and 
two P2 receptor antagonists, RB-2 (100 µM, Bii) and PPADS (100 µM, Biii). For comparison purposes, 
we also tested the effect of ATP (1 mM, Biv) on [Ca2+]i oscillations in the absence and in the presence 
of PPADS (300 µM). Cells were pre-incubated with the fluorescent calcium indicator Fluo-4 NW (see 
Experimental Procedures); [Ca2+]i transients were calibrated to the maximal calcium load produced 
by ionomycin (5 μM, 100% response). Black arrows indicate the time of drugs application. No 
changes in baseline fluorescence were observed after application of apyrase and the two P2 
purinoceptors antagonists. Each point represents pooled data from an n number of experiments. 
The vertical bars represent S.E.M. and are shown when they exceed the symbols in size. *p < 0.05 
represent significant differences from Hist (100 µM) or ATP (1 mM) alone. 
 
Cx43 expression is characteristic of fibroblasts from other tissue origins 
(78,98) and connexin-containing hemichannels are putative mediators of ATP 
translocation into the extracellular milieu. Inhibition of connexin hemichannels, 
either with mefloquine (MFQ, 3 µM, n = 4), which has been described to 
completely block Cx36- and Cx50-containing hemichannels (99,100), or with 2-
octanol (1 mM, n = 7), which blocks Cx43, Cx46 and Cx50 hemichannels 
(100,101), failed to modify (p > 0.05) histamine-induced [Ca2+]i signals (Fig. 
2.1.4Ai and 2.1.4Aii, respectively). Despite the fact that 2-octanol (1 mM, n = 7) 
failed to modify [Ca2+]i rises caused by histamine (100 µM), we re-evaluated the 
effect of MFQ increasing its concentration to 30 µM, which is high enough to 
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completely block Cx43-contaning hemichannels (100). Unfortunately, on its own 
MFQ (30 µM, n = 3) produced a yet unexplained rise (p < 0.05) in [Ca2+]i, thus 
precluding further studies to test the histamine response (data not shown).  
Carbenoxolone (CBX, 300 µM, n = 5), a non-selective inhibitor of connexins 
Cx26, Cx30, Cx32, Cx43 and Cx46, which also blocks pannexin 1 (Panx1)-
containing hemichannels (101), significantly (p < 0.05) attenuated histamine-
induced [Ca2+]i response (Fig. 2.1.4Aiii). The inhibitory effect of CBX (300 µM) was 
reproduced by the selective Panx1 mimetic inhibitory peptide, 10Panx (100 µM, n 
= 6) (102) (Fig. 4Aiv), as well as by probenecid (150 µM, n = 4) (103), a powerful 
inhibitor of Panx1 hemichannels without any action on connexin-containing 
channels (Fig. 2.1.4Av). Compounds that affect hemichannels pore permeability, 
like the Rho kinase inhibitor, H1152 (3 µM, n = 6), also significantly (p < 0.05) 
decreased histamine-induced [Ca2+]i rise (Fig. 2.1.4Avi).  
Using immunofluorescence confocal microscopy and Western blot analysis, 
we confirmed that fibroblasts of the human subcutaneous tissue in culture 
express both Cx43 and Panx1 (Fig. 2.1.4B). In spite of this, data suggest that ATP 
release via Panx1 hemichannels play a more relevant role on histamine-evoked 
[Ca2+]i mobilization under the present experimental conditions. The uptake of 
high molecular mass membrane-impermeable fluorescent dyes, such To-Pro3, has 
been used to investigate hemichannels opening (leading to the release of ATP) in 
viable cells by time-lapse fluorescence microscopy (104). Data presented in Fig. 
2.1.5 show that perfusion of cultured fibroblasts from the human subcutaneous 
tissue with histamine (100 µM) caused a sustained rise of To-Pro3 dye uptake 
(Fig. 2.1.5Ai), which reached a maximum 30-40 s after the initial [Ca2+]i peak (Fig. 
2.1.5Aii). Compounds that block Panx1-containing channels, like CBX (300 µM, n 
= 7), or that affect hemichannels pore permeability, like H1152 (3 µM, n = 20), 
significantly (p < 0.05) decreased histamine-induced [Ca2+]i rise and To-Pro3 dye 
uptake by human subcutaneous fibroblasts (Fig. 2.1.5B). 
The involvement of nucleotide-release by exocytosis was assessed using 
the vesicular transport inhibitor, brefeldin A (BFA, 20 µM). No statistical 
significant (p > 0.05) differences were found in [Ca2+]i oscillations produced by 
histamine (100 µM) in the absence and in the presence of BFA (20 µM, n = 7, Fig. 
2.1.4C).  
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Figure 2.1.4. Histamine-induced [Ca2+]i mobilization depends on pannexin-1 hemichannels activity in 
cultured human subcutaneous fibroblasts. The effect of histamine (Hist, 100 μM) was tested in the 
presence of inhibitors of connexin- and/or pannexin-containing hemichannels, namely mefloquine 
(MFQ, 3 µM, Ai), 2-octanol (1 mM, Aii), carbenoxolone (CBX 300 µM, Aiii), 10Panx (100 µM, Aiv), 
probenecid (150 µM, Av), and H1152 (3 µM, Avi) as well as upon blocking vesicle exocytosis with 
brefeldin A (BFA, 20 µM, C). Cells were pre-incubated with the fluorescent calcium indicator Fluo-4 
NW (see Experimental Procedures); [Ca2+]i transients were calibrated to the maximal calcium load 
produced by ionomycin (5 μM, 100% response). Black arrows indicate the time of drugs application. 
None of the inhibitors significantly changed baseline fluorescence when applied alone. Each point 
represents pooled data from an n number of experiments. The vertical bars represent S.E.M. and are 
shown when they exceed the symbols in size. *p < 0.05 represent significant differences from Hist 
(100 µM) alone. Panel B shows representative confocal micrographs and blots of Cx43 and Panx1 
hemichannels immunoreactivity in cultured human subcutaneous fibroblasts from several distinct 
individuals (a-g). β-tubulin was used as a reference protein. Image scale bars: 60 μm. 
 
 
Histamine promotes the growth of human subcutaneous fibroblasts via 
H1 receptors activation  
Previous reports from the literature demonstrate that histamine promotes 
fibrosis in a number of different tissues (e.g. lung, skin) by increasing the 
proliferation of fibroblasts (105,106), yet the role played by histamine-induced 
ATP release and subsequent P2 purinoceptors activation in the growth of human 
subcutaneous fibroblasts has not been investigated so far. Figure 2.1.6Ai shows 
that cultures grown for 28 days in control conditions exhibited a gradual rise in 
cell viability/proliferation throughout the test period. Results concerning type I 
collagen production followed a similar pattern to that obtained in the MTT assay 
(Fig. 2.1.6Bi), indicating that under the present experimental conditions the 
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amount of extracellular matrix being produced depend directly on the number of 
viable cells in the culture.   
Continuous application of histamine (10-100 µM) to the culture medium 
concentration-dependently increased (p < 0.05) human subcutaneous fibroblasts 
proliferation from the first week onwards. At days 21 and 28, the MTT reduction 
values increased (p < 0.05) 16 ± 4% and 27 ± 5%, respectively, in the presence of 
100 µM histamine (n = 6), when compared to control values (Fig. 2.1.6Aii). 
Histamine (100 µM)-induced cells growth was significantly (p < 0.05) attenuated 
in the presence of the selective H1 receptor antagonist, cetirizine (1 µM, n = 3, 
Fig. 2.1.6Aii). Cetirizine (1 µM) per se was devoid of a significant (p > 0.05) effect 
(data not shown).  
The results concerning type I collagen production are shown in Figure 
2.1.6Bii. Continuous treatment of the cells with histamine (10-100 µM) 
progressively increased (p < 0.05) type I collagen production from the second 
week onwards, in a concentration-dependent manner. A maximal increase (24 ± 
4%) of type I collagen production was obtained on day 28 when the cells were 
incubated with 100 µM histamine (n = 6) (Fig. 2.1.6Bii). Selective blockade of the 
H1 receptor with cetirizine (1 µM, n = 3) significantly (p < 0.05) attenuated the 
increase of type I collagen production caused by histamine (100 µM, Fig. 2.1.6Bii). 
Because the amount of type I collagen produced depends on the number of 
viable cells in the culture (see above), we normalized Sirius Red absorbance 
values by the corresponding MTT values. This normalization eliminated the 
differences (p > 0.05) from the control situation detected on type I collagen 
production in the presence of histamine (100 µM) (Table 2.1.1).  
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Figure 2.1.5. Histamine-induced single-cell [Ca2+]i oscillations and To-Pro3 dye uptake by cultured 
fibroblasts of the human subcutaneous tissue evaluated by time-lapse fluorescence confocal 
microscopy. A, fluorescence variation in cells preloaded with the fluorescent calcium indicator Fluo-
4NW (see “Experimental Procedures”); To-Pro3 was added to the superfusion fluid 6 min before Hist 
(100 µM) (dashed vertical line). Results are expressed in arbitrary units (a.u.) of fluorescence; 
individual [Ca2+]i transients were calibrated to the corresponding maximal calcium load produced by 
ionomycin (5 µM; 100% response) in the same cell. B, bars represent the effect of Hist (100 µM) in 
the absence and in the presence of pannexin-1 hemichannel permeability blockers, CBX (300 µM) 
and H1152 (3 µM). Vertical bars represent S.E.M. from n experiments. *p < 0.05, significant 
differences from control values obtained in the absence of tested drugs; **p < 0.05, significant 
differences compared with the effect of Hist (100 µM) alone. 
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Histamine-induced human fibroblasts growth is partially dependent on 
P2Y1 purinoceptor activation  
Given that histamine promotes ATP release, we hypothesized that adenine 
nucleotides could be involved in the proliferative response of human fibroblasts 
to histamine. Continuous application of ATP (100 µM, n = 4) and ADP (100 µM, n 
= 4) to the culture medium increased (p < 0.05) cell growth (MTT assay, Fig. 
2.1.6Aiii) and type I collagen production (Sirius Red assay, Fig. 2.1.6Biii) by 
human subcutaneous fibroblasts from the second week onwards. The pattern of 
nucleotides responses was similar to that obtained with histamine (100 µM) (Fig. 
2.1.6Aii and 2.1.6Bii, respectively). Normalization of type I collagen production by 
the content of viable cells also eliminated the differences (p > 0.05) from the 
control situation (Table 1), indicating that (like histamine) adenine nucleotides 
have a net proliferative effect on human fibroblasts thereby increasing type I 
collagen content of the cultures. Interestingly, the enzymatically stable ATP 
analogue, ATPγS (100 µM, n = 3), failed to reproduce the proliferative effect of 
ATP (100 µM) (Fig. 2.1.6Aiii and 2.1.6Biii), thus suggesting that ATP has to be 
catabolized into ADP in order to promote growth of human subcutaneous 
fibroblasts. 
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Figure 2.1.6. Proliferation/viability and type I collagen production by human subcutaneous fibroblasts grown 
for 28 days in culture: role of histamine and adenine nucleotides, ATP, ADP and ATPγS. Panel Ai represent 
viability/proliferation of cells measured by the MTT assay; results are expressed as absorbance determination at 
600 nm per well at certain time points. Panel Bi represent total type I collagen production assessed by Sirius Red 
staining; results are expressed as absorbance determination at 550 nm per well at certain time points. 
Histamine (Hist, 100 μM) with or without cetirizine (selective H1 receptor antagonist, 1 µM), ATP (100 μM), ADP 
(100 μM) and ATPγS (100 μM), were all applied continuously to the culture media. The ordinates represent 
changes in cell growth (MTT values, Aii and Aiii) and type I collagen production (Sirius Red values, Bii and Biii) 
as compared to controls in the absence of test drugs at the same time points (see Panels Ai and Bi). Zero 
represents similarity between the two values (drug vs control); positive and negative values represent facilitation 
or inhibition of either cell growth or type I collagen production relative to control data obtained at the same time 
points. Cetirizine (1 µM) per se was devoid of effect. Each column represents pooled data from 3 to 6 
individuals; 4-8 replicas were performed for each individual experiment. The vertical bars represent S.E.M.. *p < 
0.05 represent significant differences from control values obtained in the absence of tested drugs; #p < 0.05 
represent significant differences compared with the effect of Hist (100 µM) alone. 
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Table 2.1.1 Normalization of type I collagen production values to cell growth (MTT assay values) in 
human subcutaneous fibroblasts grown in culture during 28 days.  
 
Histamine (Hist, 100 µM), ATP (100 µM) and ADP (100 µM) were added continuously to the culture media of human 
subcutaneous fibroblasts. Because the amount of type I collagen produced depends on the number of viable cells in 
culture, we normalized Sirius Red absorbance values by the corresponding MTT values. Values are means ± SEM from 4 
to 6 individuals; 4-8 replicas were performed for each individual experiment. *p < 0.05 represent significant differences 
from control values obtained in the absence of tested drugs (n.s. = no significance). 
 
To investigate the contribution of ADP-sensitive P2Y purinoceptors 
activation to histamine-induced growth of human subcutaneous fibroblasts, we 
tested its effect in the presence of selective P2Y1, P2Y12 and P2Y13 receptors 
antagonists (Fig. 2.1.7A). Selective blockade of the P2Y1 receptor with MRS 2179 
(0.3 µM) significantly (p < 0.05) attenuated the proliferative action of histamine 
(100 µM), but no significant differences (p > 0.05) were observed in the presence 
of AR-C 66096 (0.1 µM) and MRS 2211 (10 µM) which selectively antagonize P2Y12 
and P2Y13 receptors, respectively (Fig. 2.1.7A). None of these antagonists 
modified per se human fibroblasts proliferation (data not shown).  
The presence of ADP-sensitive P2Y purinoceptors in cultured human 
subcutaneous fibroblasts was confirmed by immunocytochemistry (Fig. 2.1.7B) 
and Western blot (Fig. 2.1.7C) analysis. Fluorescence immunoreactivity showed a 
cytoplasmic / membrane-staining pattern. The P2Y1 receptor immunoreactivity 
was the most intense, followed by P2Y12 and P2Y13 purinoceptors, which exhibited 
less significant labeling intensity (Fig. 2.1.7B). As illustrated by the Western blots 
shown in Fig. 2.1.7Ci, the expected protein bands of human P2Y1 (63 kDa), P2Y12 
(50 kDa) and P2Y13 (41 kDa) receptors were detected in homogenates from 
cultured subcutaneous fibroblasts obtained from all tested individuals (a, b and 
c). The labeling density of ADP-sensitive P2Y receptors normalized to β-tubulin 
bands indicates that the P2Y1 is the most expressed receptor in cultured human 
subcutaneous fibroblasts (Fig. 2.1.7Cii).   
Control Hist (100 µM) Control Hist (100 µM)
0.28 ± 0.02 0.35 ± 0.02 (*) 0.21 ± 0.01 0.21 ± 0.01 (n.s.)
Control ATP (100 µM) Control ATP (100 µM)
0.26 ± 0.02 0.34 ± 0.03 (*) 0.22 ± 0.02 0.22 ± 0.01 (n.s.)
Control ADP (100 µM) Control ADP (100 µM)
0.26 ± 0.02 0.31 ± 0.01 (*) 0.22 ± 0.02 0.21 ± 0.01 (n.s.)
Type I collagen (λ = 550 nm) Type I collagen (λ = 550 nm) / MTT values (λ = 600 nm)
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Pattern of the extracellular catabolism of adenine nucleotides in 
human subcutaneous fibroblast cultures  
Figure 2.1.8 illustrates the time course of the extracellular catabolism of 
adenine nucleotides, ATP, ADP and AMP, in the first subculture of fibroblasts 
isolated from the human subcutaneous tissue. ATP (30 µM) was metabolized with 
a half-life time of 21.7 ± 1.4 min (n = 4 observations from two individuals). The 
ATP metabolites detected in the bath were ADP, adenosine (ADO) and inosine 
(INO), whose concentrations increased progressively with time reaching maximal 
values of 3.7 ± 0.7 µM, 11.1 ± 0.8 µM and 6.3 ± 0.5 µM, respectively, 30 min after 
ATP (30 µM) application (Fig. 2.1.8Ai). The extracellular catabolism of ADP (30 
µM) was significantly (p < 0.05) slower (half-life time of 36.8 ± 3.2 min, n = 4 
observations from two individuals) than that of ATP (30 µM). ADP was 
metabolized into ADO and INO, whose concentrations increase with time reaching 
maximal values of 6.6 ± 1.7 µM and 6.4 ± 2.3 µM, respectively, 30 min after ADP 
(30 µM) application (Fig. 2.1.8Aii). Interestingly, AMP (30 µM) was almost 
completely dephosphorylated into ADO and INO with a half-life time of 2.9 ± 0.7 
min (n = 4 observations from two individuals), which might explain why the 
accumulation of AMP was almost negligible (less than 1 µM) when ATP (30 µM) 
and ADP (30 µM) were used as substrates (Fig. 2.1.8Aiii).  
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Figure 2.1.7. Histamine-induced human fibroblasts growth is partially dependent on P2Y1 purinoceptor 
activation. Panel A shows the variation of cell growth caused by continuous application of histamine (Hist, 100 
μM) to the culture medium in the absence and in the presence of selective P2Y1, P2Y12 and P2Y13 receptor 
antagonists, MRS 2179 (0.3 µM), AR-C 66096 (0.1 µM) and MRS 2211 (10 µM), respectively. The ordinates 
represent changes in MTT values compared to control cultures grown in the absence of test drugs at the same 
time points (see Fig. 4). Each column represents pooled data from two individuals; 4 replicates were performed 
for each individual experiment. The vertical bars represent S.E.M.. *p < 0.05 represent significant differences 
compared with the effect of Hist (100 µM) alone. Panel B shows immunoreactivity of human subcutaneous 
fibroblasts against P2Y1, P2Y12 and P2Y13 receptors at culture day 7. Images obtained under confocal microscope; 
representative of three independent experiments; scale bar is 20 µm. Panel Ci shows representative 
immunoblots of P2Y1, P2Y12 and P2Y13 receptors expression from three distinct individuals (a, b and c). Panel Cii 
shows the quantification of P2Y1, P2Y12 and P2Y13 receptor levels using β-tubulin as a reference protein of 
experiments shown in Ci. 
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Given the linearity of the semi-logarithmic representation of progress 
curves obtained by polynomial fitting of the catabolism of ATP (y = -0.0134x + 
1.3631, R² = 0.9334),  ADP (y = -0.0078x + 1.4118, R² = 0.8850) and AMP (y = -
0.0610x + 1.2594, R² = 0.9096), the analysis of the corresponding half-life time 
values clearly indicates that the extracellular catabolism of ATP/ADP into AMP 
through E-NTPDases is the rate-limiting step to generate ADO from exogenously 
added adenine nucleotides, as we previously observed in human bone marrow 
stromal cells (49,50).  
The expression of E-NTPDase family members -1, -2 and -3 and of E-5’-
nucleotidase (also called CD73, EC 3.1.3.5) was assessed by immunofluorescence 
confocal microscopy (Fig. 2.1.8B). Human subcutaneous fibroblasts exhibited a 
strong immunoreactivity against E-5’-nucleotidase (Fig 2.1.8Biv), thus supporting 
the high AMP dephosphorylation rate detected in the enzymatic kinetic studies 
(Fig. 2.1.8Aiii). These cells also stained positively for E-NTPDase1 (also called 
CD39 or apyrase, EC 3.6.1.5) (Fig. 2.1.8Bi), as well as for E-NTPDase2 (CD39L1, 
EC 3.6.1.3) (Fig. 2.1.8Bii), thought for the latter the immunoreactivity was less 
intense. No immunoreactivity against E-NTPDase3 (CD39L3 or HB6) was detected 
in these cells (Fig. 2.1.8Biii).  
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Figure 2.1.8. Time course of the extracellular catabolism of adenine nucleotides and 
immunocytochemical detection of E-NTPDases in human subcutaneous fibroblast cultures at day 11. 
ATP (Ai), ADP (Aii) and AMP (Aiii) were added at a concentration of 30 μM to the culture medium at 
time zero. Samples (75 μL) were collected from each well at indicated times in the abscissa. Each 
collected sample was analyzed by HPLC to separate and quantify ATP (filled circles), ADP (open 
circles), AMP (filled squares), adenosine (ADO, open squares), inosine (INO, filled triangles) or 
hypoxanthine (HX, open triangles). Each point represents pooled data from two individuals; 2 
replicas were performed in each individual experiment. Vertical bars represent S.E.M. and are shown 
when they exceed the symbols in size. The calculated half-life time (t1/2, min) for each initial 
substrate is shown for comparison. Panel B shows immunoreactivity of human subcutaneous 
fibroblasts against E-NTPDase1, E-NTPDase2, E-NTPDase3 and E-5’-nucleotidase (CD73). Cells grown 
in eight-well chamber slides were processed for immunocytochemistry in parallel and were 
visualized keeping unaltered the settings of the confocal microscope throughout the procedure. 
Scale bar is 20 µm. 
 
 
DISCUSSION 
Histamine belongs to a group of endogenous chemical substances that are 
released upon cell damage or during inflammatory insults (107-109). The role of 
histamine in nociception is not clear but it appears to cooperate with the effect of 
other endogenous mediators (23). It has been shown that histamine, together 
with substance P, is capable of inducing ATP release from smooth muscle cells of 
the guinea-pig vas deferens (83). To the best of our knowledge, this is the first 
study demonstrating that human fibroblasts isolated from subcutaneous 
connective tissue respond to histamine by releasing ATP into the extracellular 
media through the activation of H1 receptors.   
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Results also showed that histamine triggers intracellular Ca2+ mobilization 
via the activation of Gq protein-coupled H1 receptors, given that inhibition of PLC 
with U73122 and depletion of intracellular Ca2+-stores caused by thapsigargin 
attenuated its response. Moreover, extracellular Ca2+ might also play some role to 
sustain the late component of histamine-induced [Ca2+]i rise, since its removal 
from the incubation medium attenuated significantly histamine response. A 
similar response to histamine has been reported in epithelial cells (110). Our 
findings could be explained by a possible involvement of store-operated calcium 
channels in order to compensate the fall of the [Ca2+]i  content (111) and/or 
through a concurrent activation of other membrane receptors, namely P2 
purinoceptors. Attenuation of histamine-induced [Ca2+]i response by apyrase 
suggests the cooperation with a nucleotide mediator, such as ATP and/or ADP. 
Since blockade of P2 purinoceptors mimicked the attenuating effect of apyrase, 
our data provide the first evidence that histamine-induced [Ca2+]i accumulation by 
fibroblasts of human subcutaneous tissue is partially mediated by the release of 
ATP and subsequent activation of P2 purinoceptors. Recently, it was 
demonstrated that stretch-induced ATP release in rat subcutaneous fibroblasts 
influence cytoskeletal remodeling of the cells in part by the subsequent activation 
of P2 purinoceptors (70).  
Depending on the cell type, there are multiple nucleotide-releasing 
pathways, which represent a critical component for the initiation of the purinergic 
signaling cascade (36). Considering that Ca2+ signaling induced by histamine 
seems to partially involve P2 purinoceptors activation subsequent to the release 
of ATP from fibroblasts of the human subcutaneous tissue, we assessed the 
contribution of several nucleotide-releasing mechanisms by measuring [Ca2+]i 
oscillations. Histamine-induced [Ca2+]i oscillations were not affected upon 
inhibition of the vesicular transport with BFA, thus suggesting that exocytosis 
might not represent an important pathway for releasing ATP in these cells. 
Further studies designed to investigate unloading of vesicular ATP stores stained 
with quinacrine are required to exclude this possibility in human fibroblasts 
(112). Here, we proved that human subcutaneous fibroblasts express Cx43 and 
Panx1 hemichannels. Although both channels have been committed to 
translocation of nucleotides to the extracellular milieu in numerous cell types, 
functional data using non-selective connexin inhibitors, such as 2-octanol and 
MFQ, failed to modify histamine-induced [Ca2+]i oscillations in fibroblasts of the 
human subcutaneous tissue. Conversely, blockade of Panx1-containing 
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hemichannels with CBX (101), 10Panx (102) and probenecid (103) significantly 
attenuated the histamine-induced [Ca2+]i response. Given that probenecid is a 
powerful Panx1 inhibitor with no effect on connexin channels, our findings 
suggest that Panx1-containing hemichannels might have a predominant role on 
histamine-induced [Ca2+]i responses operated by ATP released from human 
subcutaneous fibroblasts. The reason for the disparity between protein 
expression and function may be because Cx43, unlike Panx1, hemichannels close 
at normal milimolar Ca2+ (e.g. 1.8 mM CaCl2 in Tyrode’s solution) and open upon 
external Ca2+ depletion (113).       
The involvement of ATP releasing hemichannels was further confirmed by 
time-lapse fluorescence microscopy focusing on the uptake of To-Pro3 by 
cultured human fibroblasts. Following the initial [Ca2+]i peak, histamine caused a 
sustained increase in To-Pro3 dye uptake by the cells, which paralleled the second 
component of [Ca2+]i rise. Sustained effects of histamine on both [Ca2+]i  and To-
Pro3 dye uptake were significantly attenuated upon blocking pannexin-1 
hemichannels permeability with CBX and H1152, thus implicating the opening of 
large membrane pores that facilitate translocation of high molecular mass 
molecules (like ATP) between intra- and extracellular compartments.  
The molecular mechanism(s) by which histamine releases ATP through the 
opening of Panx1 hemichannels in human subcutaneous fibroblasts deserves 
further investigations. Nevertheless, disregarding whether channel mediated 
efflux or vesicle exocytosis comprises the predominant ATP release mechanism, 
most studies have identified elevation of cytosolic Ca2+ as an important regulator 
of ATP release in different cell models. Generation of inositol trisphosphate by 
phospholipase C may be the process underlying elevation of cytosolic Ca2+ 
(114,115). Histamine H1 receptor, like other Gq-coupled receptors, may 
additionally stimulate Rho-GTPase (via G12/13) acting to strongly potentiate the Ca2+-
activated ATP release pathway (116,117). Rho activation and Ca2+ mobilization 
must be temporally coordinated to promote ATP release. Interestingly, Seminario-
Vidal and col. (2009) (117) demonstrated that Ca2+- and RhoA/Rho kinase-
dependent ATP release from thrombin-stimulated A549 lung epithelial cells 
occurs via connexin or pannexin hemichannels, but this pathway might not be 
competent for ATP release in human astrocytoma cells (116). Given the actions 
exerted by Rho/Rho kinase on scaffold proteins and cytoskeleton components 
(e.g. regulating myosin-light chain phosphorylation and actin polymerization), 
authors speculate that Rho-promoted membrane-cytoskeleton rearrangements 
70 
 
facilitate the insertion of hemichannel subunits within the plasma membrane. 
Blockade of one of these multiple mechanisms might explain the attenuating 
effect of the Rho kinase inhibitor, H1152, on histamine-induced [Ca2+]i rise 
observed in this study. These findings suggest that RhoA/Rho kinase activation is 
a step upstream of Panx1-mediated ATP release triggered by histamine in human 
subcutaneous fibroblasts.    
Our data also demonstrate that fibroblasts of human subcutaneous 
connective tissue respond to histamine by increasing cell growth and subsequent 
type I collagen production through the activation of H1 receptors. Normalization 
of type I collagen production by the number of viable cells indicates that 
histamine exerts a preferential effect on cell proliferation rather than in 
extracellular matrix remodeling. In lungs and skin, histamine exerts a pro-fibrotic 
action by increasing cells growth (105,106) and collagen deposition (106,118) via 
H2 receptors activation. Despite the close anatomical proximity between skin and 
subcutaneous connective tissue, functional differences between fibroblasts from 
different tissue origins have been described (119,120). Thus, differences between 
our findings and previous reports regarding the receptor subtype involved in the 
action of histamine may be explained by differences in tissue and species origin. 
On the other hand, distinct methodological approaches have been used. Previous 
studies (105,106,118) exposed cells to histamine from several hours to a few 
days (7 days), whereas we monitored histamine-induced effects in cells kept in 
culture for 28 days. Moreover, in contrast to previous studies, we found 
significant differences in cells growth and type I collagen production induced by 
histamine (10-100 µM) exposure from the second week onwards. Actually, we did 
not monitor acute (for hours to few days) changes operated by histamine in our 
cultures. These findings strengthen the idea that, although fibroblasts are 
ubiquitous mesenchymal cells, they might function differently depending on their 
location. 
Given that histamine triggered the release of ATP from human 
subcutaneous fibroblasts in culture, we postulated that adenine nucleotides could 
be involved in the proliferative response of histamine in these cells. Continuous 
application of ATP and ADP to the culture medium mimicked the proliferative 
effect of histamine, indicating that adenine nucleotides promote human 
fibroblasts growth and subsequent type I collagen production. Surprisingly, no 
such effect was found with the enzymatically stable ATP analogue, ATPγS, Thus, it 
seems that cells exposed to histamine release ATP into the extracellular milieu, 
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which, upon conversion into ADP, indirectly promotes growth of human 
subcutaneous fibroblasts. In fact, selective blockade of ADP-sensitive P2Y1 
receptors attenuated histamine-induced cells proliferation, but no changes were 
detected in the presence of the selective P2Y12 and P2Y13 antagonists. The 
presence of P2Y1 receptors in fibroblasts of the human subcutaneous tissue was 
confirmed by immunofluorescence confocal microscopy and Western blot 
analysis. Data show that immunoreactivity against the P2Y1 receptor was much 
more intense as compared to that of P2Y12 and P2Y13 receptors. Functional data 
and immunolabeling experiments are consistent with ADP-sensitive P2Y1 being 
the receptor subtype mediating the purinergic loop leading to cell growth in 
response to histamine. This outcome is particularly interesting considering that 
the P2Y1 receptor, along with P2Y2 and P2X7 subtypes, have been implicated in 
chronic inflammation (44). These authors used disks made of non-cytotoxic 
degradable dermal sheep collagen implanted subcutaneously in rats to monitor 
the foreign body inflammatory reaction during 21 days. They found that P2Y1, 
P2Y2 and P2X7 receptors were upregulated, in parallel to vascular activation and 
increased number of macrophages and giant cells. Although fibroblasts were 
shown to encapsulate the disks and to promote deposition of extracellular matrix 
components (44), these cells were not further evaluated. Given that inflammatory 
reactions involve the recruitment of mast cells, which release huge amounts of 
histamine to the extracellular milieu, we speculate that activated fibroblasts 
would proliferate, thus contributing to the global increase in P2Y1 receptors 
expression.  
The activity of ecto-nucleotidases is critical to define the inactivation rate 
of adenine nucleotides within close proximity of the release sites in tissue 
microenvironments. In this study we analyzed the role of three members of the 
ecto-nucleoside triphosphate diphospho- hydrolase (E-NTPDase), namely E-
NTPDase1, E-NTPDase2, and E-NTPDase3 (121). These enzymes have distinct 
biochemical properties. E-NTPDase1 hydrolyzes ATP and ADP equally well, E-
NTPDase2 preferentially hydrolyzes triphosphonucleosides, and E-NTPDase3 has 
an intermediate hydrolysis profile (39). The hydrolysis of tri- and 
diphosphonucleosides by E-NTPDases yields AMP as the final product which can 
be fully dephosphorylated to adenosine by E-5’-nucleotidase/CD73 (122). Our 
results showed that human subcutaneous fibroblasts exhibit a strong 
immunoreactivity against E-5’-nucleotidase/CD73, which is in keeping with a 
faster conversion of AMP into adenosine. A high E-5’-nucleotidase/CD73 activity 
72 
 
might also explain why the concentration of AMP was kept at low level when ATP 
and/or ADP were used as substrates (123).  
Luttikhuizen and col. (2004) (44) reported the overexpression of 
subcutaneous E-NTPDase1 in a model of chronic inflammation. Interestingly, we 
showed here that human subcutaneous fibroblasts express E-NTPDase1 
immunoreactivity under resting conditions. This member of the NTPDase family 
seems to be the most expressed ATP and/or ADP metabolizing enzyme in these 
cells, as predicted from lesser immunofluorescence signals obtained for other E-
NTPDases. These cells exhibit weak immunoreactivity against E-NTPDase2, and no 
signal was detected for E-NTPDase3, suggesting that E-NTPDase2 may participate 
together with E-NTPDase1 in the extracellular catabolism of adenine nucleotides 
in fibroblasts of the human subcutaneous tissue. E-NTPDase1, E-NTPDase2, and E-
NTPDase3 hydrolyze extracellular tri- and diphosphonucleotides with ATP:ADP 
ratios of ~1-2:1, ~10-40:1, and ~3-4:1, respectively (39). The kinetic analysis of 
the extracellular catabolism of ATP and ADP in human subcutaneous fibroblast 
cultures indicates that adenine nucleotides are metabolized with a ratio of 
approximately 1.5(ATP):1(ADP), which is compatible with E-NTPDase1 being the 
most effective isoform in these cultures. In line with this hypothesis, one would 
expect that the formation of adenosine should be prevented if NTPDase2 acted 
alone or it could be delayed if NTPDases3 was the main enzyme involved in the 
catabolism of adenine nucleotides, given that it is well known that  E-5’-
nucleotidase/CD73 is inhibited by ADP (39,123). Our results proved exactly the 
opposite showing that AMP was rapidly dephosphorylated into adenosine 
independently of the nucleotide substrate used. On the other hand, involvement 
of E-NTPDase1 is expected to terminate the effects exerted by either ATP or ADP 
sensitive receptors. Nevertheless, data indicate that responses of human 
subcutaneous fibroblasts to histamine depend on the activation of ADP-sensitive 
P2Y1 receptors. This situation can occur, because E-NTPDase2 concurs with E-
NTPDase1 to release enough ADP required to activate P2Y1 receptors in human 
subcutaneous fibroblasts, as the former enzyme preferentially hydrolyzes 
triphosphonucleosides.  
In conclusion, our findings showed for the first time that histamine 
promotes the release of ATP from human subcutaneous fibroblasts via Panx1 
hemichannels leading to [Ca2+]i mobilization from internal stores and cell growth 
through the cooperation of H1 and P2Y receptors (most probably of the P2Y1 
subtype) activation. Targeting the pathways leading to nucleotides release and 
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the purinergic cascade, consisting in metabolizing E-NTPDases and P2 
purinoceptors activation, may be useful in designing novel therapies towards the 
modulation of cell signals between fibroblasts, nociceptors and inflammatory 
cells, which underlie the pathogenesis of painful musculoskeletal diseases with 
widespread involvement of the subcutaneous connective tissue, such as 
fibromyalgia.   
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ABSTRACT 
Background – Chronic musculoskeletal pain involves connective tissue 
remodeling triggered by inflammatory mediators, such as bradykinin. Fibroblast 
cells signaling involve changes in intracellular Ca2+ ([Ca2+]i). ATP has been related 
to connective tissue mechanotransduction, remodeling and chronic inflammatory 
pain, via P2 purinoceptors activation. Here, we investigated the involvement of 
ATP in bradykinin-induced Ca2+ signals in human subcutaneous fibroblasts. 
Results – Bradykinin, via B2 receptors, caused an abrupt rise in [Ca2+]i to a peak 
that declined to a plateau, which concentration remained constant until washout. 
The plateau phase was absent in Ca2+-free medium; [Ca2+]i signal was substantially 
reduced after depleting intracellular Ca2+ stores with thapsigargin. Extracellular 
ATP inactivation with apyrase decreased the [Ca2+]i plateau. Human subcutaneous 
fibroblasts respond to bradykinin by releasing ATP via connexin and pannexin 
hemichannels, since blockade of connexins, with 2-octanol or carbenoxolone, and 
pannexin-1, with 10Panx, attenuated bradykinin-induced [Ca2+]i plateau, whereas 
inhibitors of vesicular exocytosis, such as brefeldin A and bafilomycin A1, were 
inactive. The kinetics of extracellular ATP catabolism favors ADP accumulation in 
human fibroblast cultures. Inhibition of ectonucleotidase activity and, thus, ADP 
formation from released ATP with POM-1 or by Mg2+ removal from media reduced 
bradykinin-induced [Ca2+]i plateau. Selective blockade of the ADP-sensitive P2Y12 
receptor with AR-C66096 attenuated bradykinin [Ca2+]i plateau, whereas the P2Y1 
and P2Y13 receptor antagonists, respectively MRS 2179 and MRS 2211, were 
inactive. Human fibroblasts exhibited immunoreactivity against connexin-43, 
pannexin-1 and P2Y12 receptor. 
Conclusions – Bradykinin induces ATP release from human subcutaneous 
fibroblasts via connexin and pannexin-1-containing hemichannels leading to 
[Ca2+]i mobilization through the cooperation of B2 and P2Y12 receptors. 
 
Keywords – ADP, ATP release, bradykinin, Cx43, hemichannels, human 
subcutaneous fibroblasts, Panx1, P2 purinoceptors 
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INTRODUCTION 
Despite its overwhelming size throughout the body, the connective tissue 
has been generally overlooked or misunderstood. It has been considered as 
relatively superfluous apart from its supporting role amongst more specialized 
tissues (1). It has long been known that scar tissue is a common cause of chronic 
musculoskeletal pain. Evidences have been produced suggesting that connective 
tissue may become thicker and less compliant in patients with chronic pain, 
possible as a result of chronic inflammation and fibrosis (12-14,16). Therefore, 
the normal response to mechanical stretch may be dampened by disturbance of 
the viscoelastic properties of the subcutaneous connective tissue as a 
consequence of fibroblast remodeling promoted by inflammatory mediators, like 
neurotrophins, cytokines, peptides, protons, free radicals, histamine, bradykinin, 
serotonin, and prostanoids (82). Since the subcutaneous connective tissue is 
richly innervated by sensory nerve endings, inputs arising from affected 
connective tissue may alter pain perception. 
Bradykinin is one of the most potent algogenic compounds that is 
synthesized from inactive precursors, the kininogens, following tissue injury 
(124) and by contracting skeletal muscles (reviewed in (125)). Bradykinin has been 
strongly implicated in tissue inflammation (124) and it is also known to be 
mitogenic in fibroblasts from the human foreskin and lung (126,127). Bradykinin 
preferentially induces its physiological effects by binding to the B2 receptor 
subtype. In intact cells, bradykinin was shown to induce the activation of 
phospholipases A2, C and D; the release of prostaglandins, the accumulation of 
cyclic AMP and of cyclic GMP, and the mobilization of Ca2+ were demonstrated 
(128). Bradykinin causes a rapid (within 30 s) translocation of protein kinase C 
isoforms of all groups (classical Ca2+-dependent isoform α, new Ca2+-independent 
isoform ε, and atypical isoform ζ) from the cytosol to the plasma membrane (128). 
Bradykinin-induced translocation of protein kinase C to the plasma membrane 
may favor enzyme coupling to coexistent extracellular signaling molecules under 
pathological conditions, thus significantly potentiating their effects. 
The way bradykinin is involved in pain perception might involve direct 
excitation of primary nociceptive afferents and/or the indirect reduction of 
nociceptors threshold by favoring the release of excitatory signaling mediators 
(22). It has been showed that acute bradykinin exposure potentiates algogenic 
P2X3 purinoceptor-mediated calcium responses from neurons, followed by their 
down-regulation upon chronic (24 h) exposure. On the other hand, P2Y receptors 
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responses in satellite neuroglia may be upregulated, suggesting a complex 
interplay between bradykinin and P2 purinoceptors activation in pain 
pathophysiology (129). Previous studies demonstrated that bradykinin elicits the 
release of ATP from various cell types, including smooth muscle fibers, epithelial 
cells and cardiac endothelial cells from guinea pigs (83), urothelial cells from both 
human and rats (130,131), and several immortalized cell lines (e.g. MDCK, COS-7, 
HEK-293) (reviewed in (132)). The mechanism of ATP release induced by 
bradykinin is, however, poorly understood, particularly in human tissues. 
Nucleotides-releasing pathways in intact cells include [1] electrodiffusional 
translocation via connexin- and pannexin-containing hemichannels and voltage-
dependent anion channels, [2] facilitated diffusion by nucleotide-specific ATP-
binding cassette (ABC) transporters, and [3] vesicle exocytosis (36). In parallel to 
bradykinin, huge amounts of extracellular ATP may leak from damaged cells 
during mild tissue injury. Once released, ATP may act as an autocrine or paracrine 
mediator in neighboring cells via ionotropic P2X and metabotropic P2Y 
purinoceptors activation. ATP signaling may, however, be limited by membrane-
bound ectonucleotidases, which sequentially catabolize nucleoside 5’-
triphosphates to their respective 5’-di- and monophosphates and adenosine (36). 
As a consequence, appearance of ATP and active metabolites, like ADP and 
adenosine, in the extracellular fluid form concentration gradients enabling 
differential targeting of subtype-specific purinoceptors and, thus, cell 
communication and signaling. 
Thus, taking into consideration that [1] changes in the regulation of 
connective tissue ATP signaling may be important in the pathogenesis of chronic 
inflammatory pain (44) and that [2] algogenic inflammatory mediators, such as 
bradykinin, may sensitize cells to autocrine and paracrine signals operated by 
extracellular adenine nucleotides (77), we investigated the involvement of ATP in 
bradykinin-induced Ca2+ signals in human subcutaneous fibroblasts. 
Understanding the mechanisms underlying purinergic cell signaling and its 
interplay with inflammatory mediators in the human subcutaneous connective 
tissue may highlight new strategies for the treatment of chronic musculoskeletal 
painful diseases (e.g. drug-resistant fibromyalgia). 
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EXPERIMENTAL PROCEDURES 
Cell cultures  
Human fibroblasts were isolated from the subcutaneous tissue of organ 
donors (51 ± 6 years old (mean ± S.E.M.), n = 13) with no clinical history of 
connective tissue disorders. The protocol was approved by the Ethics Committee 
of Centro Hospitalar do Porto (University Hospital) and of Instituto de Ciências 
Biomédicas de Abel Salazar (Medical School) of University of Porto (approval No. 
11-CES-05). The investigation conforms to the principles outlined in the 
Declaration of Helsinki. Subcutaneous tissues were maintained at 4-6ºC in M-400 
transplantation solution (4.190 g/100 mL mannitol, 0.205 g/100 mL KH2PO4, 
0.970 g/100 mL K2HPO4 · 3H2O, 0.112 g/100 mL KCl, and 0.084 g/100 mL 
NaHCO3, pH 7.4) until used, which was between 2 and 16 hours after being 
harvested (84). Cells were then obtained by the explant technique and cultured in 
DMEM medium supplemented with 10% fetal bovine serum (FBS), 2.5 μg/mL of 
amphotericin B and 100 U/mL of penicillin/streptomycin, at 37ºC in a humidified 
atmosphere of 95% air and 5% CO2. Medium was replaced twice a week. Primary 
cultures were maintained for 3-4 weeks, until near confluence, when adherent 
cells were enzymatically released with 0.04% trypsin-EDTA solution plus 0.025% 
type I collagenase in phosphate-buffered saline (PBS), at pH 7.4 during 15-20 
minutes. The resultant cell suspension was cultured and maintained in the same 
conditions mentioned above. All the experiments were performed in the first 
subculture.  
 
Intracellular ATP imaging by quinacrine staining  
Quinacrine is a weak-base acridine derivative that binds ATP with high 
affinity and specificity. When excited by light at 476 nm it emits fluorescence in 
the 500-540 nm range and it has been widely used to visualize ATP-containing 
sub-cellular compartments in living cells (133,134). Human fibroblasts were 
seeded on 35 mm glass bottom dishes (FluoroDish®, World Precision 
Instruments), at a density of 2x104 cells/mL, and maintained in culture for 5-15 
days. To visualize ATP-filled vesicles, dishes were washed twice with Tyrode’s 
solution (137 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 0.4 mM 
NaH2PO4, 11.9 mM NaHCO3, and 11.2 mM glucose, pH 7.4) before incubation with 
30 μM quinacrine for 1 h (134); cells were washed again twice and mounted onto 
a thermostatic (32ºC) perfusion chamber at the stage of an inverted laser-
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scanning confocal microscope (Olympus FluoViewTM FV1000) equipped with a 40x 
magnification oil immersion objective lens (UPLAPO 40x OI; NA: 1.00). The 
chamber was continuously superfused (1 mL/min) with gassed (95% O2 + 5% CO2, 
pH 7.4) Tyrode’s solution and the cells were immediately observed. Changes in 
quinacrine fluorescence were detected in the time-lapse mode with FluoView 
Advanced Software (Olympus). Quinacrine was excited with a 488 nm Multi-line Ar 
laser and the emitted fluorescence was detected at 500-550 nm, using the 
scanner of the confocal microscope. Drugs were delivered using a multichannel 
perfusion system (ValveLink 8.2, Digitimer). Time-lapse sequences were recorded 
at scanning rates of 3 seconds per image, every 5 seconds, for about 30 minutes, 
digitized, and processed off-line by the computer. Regions of interest were 
defined as bright areas with as little background as possible. 
 
Extracellular ATP quantification by bioluminescence  
Extracellular ATP was detected with the luciferin-luciferase ATP 
bioluminescence assay kit HS II (Roche Applied Science) using a Turner 
BioSystems (TD 20/20n) luminometer that accommodates 35-mm culture dishes, 
as described elsewhere (135). Briefly, cells were seeded on 35 mm glass bottom 
dishes, at a density of 2x104 cells/mL, for 5-15 days. At the beginning of the 
experiment, cells were washed twice with Tyrode’s solution at room temperature, 
before placing the dish in the luminometer reaction chamber. Bradykinin (30 μM) 
was added manually to the incubation fluid when bioluminescence baseline values 
reached stability after application of the luciferin/luciferase reagent. Experiments 
were performed at room temperature. ATP-dependent changes in extracellular 
luciferase activity were measured as relative luminescence unit (RLU) values 
integrated over 10 seconds photon counting periods. 
 
Measurement of intracellular Ca2+  
Changes in the intracellular Ca2+ concentration ([Ca2+]i) were measured with 
the calcium sensitive dye Fluo-4 NW (Fluo-4 NW calcium assay kit, Molecular 
Probes, Invitrogen) in a multi detection microplate reader (Synergy™ HT Multi-
Mode Microplate Reader, BioTek Instruments) (85). In some of the experiments, 
single-cell [Ca2+]i imaging was obtained using a laser scanning confocal 
microscope (49). Briefly, human fibroblasts were seeded in flat bottom 96 well 
plates (Costar®, Corning® Inc.) at a density of 3x104 cells/mL for the experiments 
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using the microplate reader, and into 35 mm glass bottom dishes at a density of 
2x104 cells/mL for single-cell [Ca2+]i imaging. Cells were cultured for 5-15 days in 
supplemented DMEM as described before. On the day of the experiment, cells 
were washed twice with Tyrode’s solution and incubated at 37ºC for 45 minutes 
with the cell-permeant fluorescent Ca2+ indicator, Fluo-4 NW (2.5 μM), in 1X HBSS, 
20 mM HEPES and 2.5 mM probenecid. After removal of the fluorophore loading 
solution, cells were washed again twice and 150/300 μL of Tyrode’s solution was 
added per culture well/dish, respectively. The 96-well cell plates were then loaded 
into the microplate reader. Reader control was performed using the BioTek’s 
Gen5™ Data Analysis Software. For the recordings, temperature was maintained at 
32ºC and readings were made with 5 seconds of interval, during approximately 
30 minutes, using a tungsten halogen lamp. Fluorescence was excited at 485/20 
nm and emission was measured at 528/20 nm. For the single-cell imaging, 
culture dishes were mounted on a thermostatic (32ºC) perfusion chamber at the 
stage of an inverted laser-scanning confocal microscope equipped with a 20x 
magnification objective lens (LUCPLFLN 20x PH; NA: 0.45). The chamber was 
continuously superfused (1 mL/min) with gassed (95% O2, 5% CO2, pH 7.4) 
Tyrode’s solution and drugs were delivered using a multichannel valve controlled 
perfusion system. Changes in fluorescence of the Fluo-4 NW dye were detected in 
a time-lapse mode. Fluo-4 NW was excited with a 488 nm Multi-line Ar laser and 
the emitted fluorescence was detected at 510-560 nm, using the scanner of the 
confocal microscope. Time-lapse sequences were recorded at scanning rates with 
20 seconds of interval for approximately 30 minutes, digitized, and processed 
off-line by the computer. Regions of interest were defined as bright areas with as 
little background as possible. For both methods, calcium measurements were 
calibrated to the maximal calcium load produced by ionomycin (5 μM, 100% 
response). In some experiments, we used rat subcutaneous fibroblasts obtained 
using the method described before to monitor single-cell [Ca2+]i oscillations (see 
above) in parallel with the incorporation of FM4-64 (Molecular Probes, Invitrogen), 
which is a membrane-selective fluorescent dye used to evaluate vesicle 
endocytosis and exocytosis in living cells (136,137). FM4-64 was excited with a 
488 nm Multi-line Ar laser and fluorescence emission was detected at 665-765 
nm, using the scanner of the confocal microscope. Drug application and time-
lapse sequences were performed as above. 
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Enzymatic kinetic experiments and HPLC analysis  
The kinetics of ATP, ADP and AMP hydrolysis in human fibroblast cell 
cultures was evaluated at day 11, at 37ºC. After a 30 minutes equilibration 
period, cells were incubated with 3 μM ATP, ADP or AMP, which were added to the 
culture medium at zero time. Samples (75 μL) were collected from each well at 
different times up to 30 minutes for high-performance liquid chromatography 
(HPLC, LaChrome Elite, Merck) analysis of the variation of substrate disappearance 
and product formation (49,84). Concentrations of the substrate and products 
were plotted as a function of time (progress curves). The following parameters 
were analyzed for each progress curve: half-life time (t1/2) of the initial substrate, 
time of appearance of the different concentrations of the products, concentration 
of the substrate or any product remaining at the end of the experiment. 
 
Immunocytochemistry  
Human subcutaneous fibroblasts were seeded in chamber slides at a 
density of 2.5x104 cells/mL and allowed to grow for 5-15 days. Cultured cells 
were fixed in 4% paraformaldehyde (PFA) in PBS for 10 minutes, washed 3 times in 
PBS (10 minutes each) and, subsequently, incubated with blocking buffer I (10% 
FBS, 1% bovine serum albumin (BSA), 0.1% Triton-X, 0.05% NaN3) for 1 h. Primary 
antibodies, diluted in blocking buffer II (5% FBS, 1% BSA, 0.1% Triton-X, 0.05% 
NaN3), were applied [mouse anti-porcine vimentin 1:75 (DAKO); rabbit anti-human 
collagen I 1:50 (AbDSerotec); mouse anti-human α-smooth muscle actin-FITC 
1:250 (Sigma-Aldrich); rabbit anti-human P2Y12 1:100 (Alomone); rabbit anti-
human Cx43 1:600 and rabbit anti-human Panx1 1:1000 (Abcam)] and the slides 
incubated overnight at 4ºC. After incubation, cells were washed 3 times in PBS 1X 
(10 minutes each). The Alexa Fluor 488 1:1500 (anti-rabbit) and Alexa Fluor 568 
1:1500 (anti-mouse) secondary antibodies (Molecular Probes, Invitrogen) were 
diluted in blocking buffer II (5% FBS, 1% BSA, 0.1% Triton-X) and applied for 1 h 
protected from light. A last wash was performed with PBS 1X and glass slides 
were mounted with VectaShield medium and stored at 4ºC. For negative controls, 
the secondary antibodies were applied without pre-incubation with primary 
antibodies. A positive control for α-smooth muscle actin (SMA) was performed 
with cardiac myofibroblasts isolated from Wistar rats (Charles River, Barcelona) 
using a similar procedure as previously described for human subcutaneous 
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fibroblasts. Observations were performed and analyzed with a laser-scanning 
confocal microscope (49). 
 
SDS–PAGE and Western blotting  
Fibroblasts were homogenized in a lysis buffer with the following 
composition: 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% sodium deoxycholate, 
1% Triton-X-100, 0.1% SDS and a protease inhibitor cocktail. Protein content of the 
samples was evaluated using the BCA protein assay kit according to the 
manufacturer’s instructions (Pierce). Samples were solubilized in SDS reducing 
buffer (0.125 mM Tris-HCl, 4% SDS, 0.004% bromphenol blue, 20% glycerol, and 
10% 2-mercaptoethanol, pH 6.8 at 70ºC for 10 minutes), subjected to 
electrophoresis in 10% SDS-polyacrylamide gels and electrotransferred onto PVDF 
membranes (MilliPore). Protein loads were 25 μg for Panx1 and 15 μg for Cx43. 
The membranes were blocked for 1 h in Tris-buffered saline (TBS: 10 mM Tris-
HCl, pH 7.5, 150 mM NaCl) containing 0.05% Tween 20 + 5% BSA. Membranes 
were subsequently incubated with rabbit anti-human Panx1 1:250 (Novex, Life 
Technologies) and rabbit anti-human Cx43 1:6000 (Abcam) in the above blocking 
buffer overnight at 4ºC. Membranes were washed three times for 10 minutes in 
0.1% Tween 20 in TBS and then incubated with donkey anti-rabbit IgG (HRP) 
1:30000 (Abcam) secondary antibody, for 60 minutes at room temperature. For 
comparison purpose, the membranes were also incubated with rabbit anti-human 
β-tubulin 1:2500 (Abcam) antibody following the procedures described above. 
Membranes were washed three times for 10 minutes and antigen-antibody 
complexes were visualized by chemiluminescence with an ECL reagent using the 
ChemiDoc MP imaging system (Bio-Rad Laboratories). 
 
Reagents and materials  
2-Mercaptoethanol, 2-octanol, 8-phenyltheophylline (8-PT), adenosine 5′-
diphosphate sodium salt (ADP), adenosine 5′-monophosphate sodium salt (AMP), 
adenosine 5′-triphosphate sodium salt (ATP), amphotericin B, apyrase, bovine 
serum albumin (BSA), bradykinin (BK), brefeldin A (BFA), bromphenol blue, 
carbenoxolone (CBX), Dulbecco’s Modified Eagle’s Medium (DMEM), ethylene 
diaminetetraacetic acid (EDTA), ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-
tetraacetic acid (EGTA), fetal bovine serum (FBS), glycerol, mefloquine (MFQ), 5′-
(N-ethylcarboxamide)adenosine (NECA), penicillin/streptomycin, phosphate 
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buffered saline system (PBS), protease inhibitor cocktail, quinacrine 
dihydrochloride, sodium deoxycholate, sodium dodecyl sulfate (SDS), trypsin, 
Tween 20, and type I collagenase were purchased from Sigma-Aldrich. 10Panx, 2-
(propylthio)adenosine-5'-O-(β,γ-difluoro methylene) triphosphate tetrasodium salt 
(AR-C 66096), 2-[(2-chloro-5-nitrophenyl)azo]-5-hydroxy-6-methyl-3-
[(phosphonooxy)methyl]-4-pyridine carboxaldehyde disodium salt (MRS 2211), 2′-
deoxy-N6-methyladenosine 3′,5′-bisphosphate tetrasodium salt (MRS 2179), 
icatibant (HOE-140), R715, sodium metatungstate (POM-1) and thapsigargin were 
obtained from Tocris Cookson Inc.. Bafilomycin A1 was from WAKO Chemicals 
and Triton™ X-100 was obtained from Merck. BFA, MFQ, NECA and thapsigargin 
were prepared in dimethyl sulfoxide (DMSO). All other drugs were prepared in 
distilled water. All stock solutions were stored as frozen aliquots at -20ºC. 
Dilutions of these stock solutions were made daily and appropriate solvent 
controls were done. No statistically significant differences between control 
experiments, made in the absence or in the presence of DMSO at the maximal 
concentration used (0.05% v/v), were observed. The pH of the solutions did not 
change by the addition of the drugs in the maximum concentrations applied to 
the preparations. 
 
Presentation of data and statistical analysis  
Data are expressed as mean ± S.E.M. from an n number of experiments / 
cells / individuals. Data from different individuals were evaluated by one-way 
analysis of variance (ANOVA) and no significant differences on the pattern of cell 
behavior were found. Statistical differences found between control and drug-
treated cultures were determined by the Bonferroni’s method. p values < 0.05 
were considered to represent significant differences. 
 
RESULTS 
Characterization of human fibroblast cells in culture  
Cultured cells obtained from human subcutaneous connective tissue 
through the explant technique are elongated and exhibited a spindle-shape 
morphology, which is characteristic of fibroblasts (94). At the time that functional 
experiments were conducted, all cells exhibited positive immunoreactivity against 
fibroblast-cell markers, vimentin (Figure 2.2.1Ai, red) and type I collagen (Figure 
2.2.1Ai, green) (96), and no specific staining was developed against stress fibers 
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containing α-smooth muscle actin (SMA-FITC, Figure 2.2.1Aii). Negative controls, 
in which cells were incubated only with the secondary antibodies Alexa Fluor 488 
(green) and Alexa Fluor 568 (red), are shown in Figure 2.2.1Aiii. For comparison 
purposes, Figure 2.2.1Aiv illustrates a positive control of SMA-FITC obtained in rat 
cardiac myofibroblasts where SMA-immunoreactivity exhibits a clear filamentary 
pattern (Figure 2.2.1Aiv), which was not observed in human subcutaneous 
fibroblasts (Figure 2.2.1Aii). 
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Figure 2.2.1. Bradykinin stimulates the release of intracellular Ca2+ stores and Ca2+ influx from 
the extracellular space. Panel A shows immunoreactivity of cells cultured from explants of human 
subcutaneous tissue against fibroblast-cell markers, vimentin (red, Ai) and type I collagen (green, 
Ai), and α-smooth muscle actin (SMA-FITC, green, Aii). Negative controls, in which cells were 
incubated only with secondary antibodies, Alexa Fluor 488 (green) and Alexa Fluor 568 (red), are 
shown for comparison purposes (Aiii); a positive control of SMA-FITC immunoreactivity in rat 
cardiac myofibroblasts is also shown (green, Aiv). Cell nuclei are stained with DAPI (blue); scale bar 
60 μm. Panel B illustrates intracellular Ca2+ ([Ca2+]i) oscillations in cultured human subcutaneous 
fibroblasts loaded with the fluorescent calcium indicator, Fluo-4 NW (2.5 μM, see Experimental 
procedures) obtained in the absence and in the presence of bradykinin (BK, 30 μM). Changes in 
fluorescence were detected in the time-lapse mode with a confocal microscope. Calibration to the 
maximal calcium load produced by ionomycin (5 μM, 100% response) is also shown for comparison. 
Image scale bars: 30 μm. Panel C shows that the kinetics of BK-induced [Ca2+]i signals differed 
slightly between cells of a given population. Panel D depicts the concentration-response curve of 
[Ca2+]i oscillations produced by BK (0.003-100 μM). Panels E, F and G, represent [Ca2+]i oscillations 
produced by BK (30 μM) applied in the absence (E) and in the presence of the selective endoplasmic 
reticulum Ca2+-ATPase inhibitor, thapsigargin (2 μM, F), and after removal of extracellular Ca2+ (Ca2+-
free medium plus EGTA, 100 μM, G). Black arrows indicate the time of drugs application. Each point 
represents pooled data from an n number of experiments. The vertical bars represent S.E.M.. *p < 
0.05 represent significant differences from BK (30 μM) alone. 
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Bradykinin, via B2 receptors, stimulates the release of intracellular Ca2+ 
stores and Ca2+ influx from the extracellular space  
Bradykinin (0.001-100 μM) caused prominent intracellular Ca2+ ([Ca2+]i) rises 
in human subcutaneous fibroblasts (Figure 2.2.1). Global changes in [Ca2+]i were 
monitored with a multidetection microplate reader after pre-incubation of the 
cells with the calcium sensitive dye, Fluo-4 NW; in some instances, single-cell 
[Ca2+]i imaging was also performed using a laser scanning confocal microscope in 
the time-lapse mode (Figure 2.2.1B and 2.2.1C). The effect of bradykinin (0.001-
100 μM) was dependent on the concentration (Figure 2.2.1D); significant (p < 
0.05) [Ca2+]i rises were observed at concentrations higher than 1 μM. Bradykinin 
typically produced a biphasic response (Figure 2.2.1C); at 30 μM concentration, 
[Ca2+]i raised abruptly to a peak that attained 44 ± 2% of the maximal calcium load 
produced by ionomycin (5 μM, 100% response), then declined to a plateau of 
elevated [Ca2+]i which remained fairly constant until drug washout (Figure 2.2.1E). 
Bradykinin (30 μM) produced negligible changes in [Ca2+]i in the presence of the 
selective inhibitor of endoplasmic reticulum Ca2+-ATPase, thapsigargin (2 μM, n = 
5), which is known to deplete intracellular Ca2+ stores following a transient (< 2 
min) rise of [Ca2+]i levels (97) (Figure 2.2.1F). Removal of external Ca2+ (plus EGTA, 
100 μM, n = 6) significantly (p < 0.05) attenuated the plateau phase, but the 
magnitude of the peak was kept almost unchanged (Figure 2.2.1G). It, thus, 
appears that in human subcutaneous fibroblasts the initial transient component 
must be caused by intracellular Ca2+ release from internal stores. The sustained 
plateau of elevated [Ca2+]i results from Ca2+ entry through the plasma membrane 
in response to depletion of Ca2+ stores and/or through the concurrent activation 
of other membrane-bound receptors, namely P2 purinoceptors. This pattern is 
consistent with previous findings in the literature regarding bradykinin-induced 
[Ca2+]i responses in several cell types (138,139), including human fibroblasts of 
the foreskin (140). 
Bradykinin-induced [Ca2+]i rise in human subcutaneous fibroblasts was 
concentration-dependently attenuated by the selective B2 receptor antagonist, 
HOE-140 (1 and 10 μM, n = 7) (Figure 2.2.2B and 2.2.2C), whereas selective 
blockade of the B1 receptor with R715 (1 μM, n = 4) was without effect (Figure 
2.2.2A). At the highest concentration (10 μM), HOE-140 significantly (p < 0.05) 
decreased, but did not completely block, the late phase of bradykinin-induced 
[Ca2+]i response given that the peptide was used in a concentration (30 μM) near 
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that necessary for saturation of B2 receptors in these cells (see Figure 2.2.1D). On 
their own, the two antagonists were devoid of any significant effect. 
 
 
Figure 2.2.2. Bradykinin-induced [Ca2+]i rise in human subcutaneous fibroblasts depend on B2 
receptor activation. Calcium oscillations in human fibroblasts of the subcutaneous tissue 
stimulated with bradykinin (BK, 30 μM) were tested after pretreatment of the cells with selective B1 
and B2 receptor antagonists, respectively R715 (1 μM, A) and HOE-140 (1 μM, B; 10 μM, C). Cells 
were pre-incubated with the cell-permeant fluorescent calcium indicator, Fluo-4 NW (2.5 μM, see 
Experimental procedures). Changes in fluorescence were detected using a microplate reader. 
Intracellular Ca2+ transients were calibrated to the maximal calcium load produced by ionomycin (5 
μM, 100% response). Black arrows indicate the time of drugs application. No changes in baseline 
fluorescence were observed after application of the antagonists. Each point represents pooled data 
from an n number of experiments. The vertical bars represent S.E.M.. *p < 0.05 represent significant 
differences from BK (30 μM) alone. 
 
Bradykinin induces ATP release from human subcutaneous fibroblasts: 
involvement of intracellular Ca2+ stores  
The release of ATP from human subcutaneous fibroblasts in culture was 
inferred from destaining of cells loaded with quinacrine, an ATP-binding 
intracellular fluorescent dye, by confocal microscopy in the time-lapse mode. 
Bradykinin (30 μM, n = 35) increased (p < 0.05) fluorescence intensity decay of 
cells loaded with quinacrine as compared to the control situation in which the 
cells were challenged with the Tyrode’s solution (Figure 2.2.3A and 2.2.3B). 
Quinacrine destaining of cells exposed to bradykinin was more evident at the 
periphery than near the nucleus (Figure 2.2.3A). Confirmation that human 
subcutaneous fibroblasts release ATP in response to bradykinin (30 μM, n = 4) 
was obtained by measuring the luminescence of the medium before and after 
bradykinin application to cells incubated with luciferin-luciferase (Figure 2.2.3C). 
Results demonstrate that ATP release peaked at 30 s after bradykinin (30 μM) 
application and was kept fairly constant during the 4-min drug application. 
Pretreatment with thapsigargin (2 μM, n = 6) significantly (p < 0.05) 
attenuated bradykinin-induced quinacrine destaining (Figure 2.2.3Di). In contrast, 
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removal of extracellular Ca2+ (plus EGTA, 100 μM, n = 8) from the incubation 
medium did not affect significantly (p > 0.05) the fluorescence intensity decay of 
quinacrine stained ATP granules (Figure 2.2.3Dii). These observations indicate 
that Ca2+ recruitment from thapsigargin-sensitive internal stores is required for 
the release of ATP induced by bradykinin. 
 
 
Figure 2.2.3. Bradykinin elicits ATP release from human fibroblasts by a mechanism depending 
on intracellular Ca2+ mobilization. Panels A, B and D represent cells loaded with quinacrine (30 μM, 
a fluorescent dye that specifically binds ATP), for 60 min at 37ºC. ATP release was detected by 
single-cell confocal microscopy in the time-lapse mode measuring the fluorescence intensity decay 4 
min after bradykinin (BK, 30 μM, A and B) application as compared to the control situation, in which 
only Tyrode’s solution was applied (A). Panel D, shows the effect of BK (30 μM) after pretreatment of 
the cells with the selective endoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin (2 μM, Di), and 
after removal of extracellular Ca2+ (Ca2+-free medium plus EGTA, 100 μM, Dii); the effect of BK (30 
μM) in the presence of the selective Panx1 inhibitor, 10Panx (100 μM, Diii), is also shown. Image 
scale bars: 30 μm. Graphs show quinacrine fluorescence decay (arbitrary units, a.u.) plotted versus 
time in the presence of Tyrode’s solution (B), thapsigargin (2 μM, Di), Ca2+-free medium (Dii) and 
10Panx (100 μM, Diii). Black arrows indicate the time of drugs application. Each point represents 
pooled data from an n number of cells. The vertical bars represent S.E.M.. Panel C, shows the ATP 
content in human subcutaneous fibroblast cultures at given time intervals (0-240 seconds) in the 
presence of BK (30 μM, open bars) as compared to the control condition where only Tyrode’s 
solution was applied (closed bars). Relative luminescence units (RLUs) were calibrated using a 4 nM 
ATP standard (left hand-side black vertical bar). Each bar represents pooled data from an n number 
of experiments. The vertical bars represent S.E.M.. *p < 0.05 represent significant differences from 
BK (30 μM) alone. 
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ATP release via connexin and pannexin-1 hemichannels contributes to 
bradykinin-induced [Ca2+]i mobilization  
Among other mechanisms, hemichannels containing connexins (Cx) and 
pannexin-1 (Panx1) are now widely accepted as putative mediators of ATP 
translocation to the extracellular milieu in non-excitable cells. The expression of 
Cx43 is characteristic of fibroblasts from multiple tissue origins (78,98). Using 
immunofluorescence confocal microscopy (Figure 2.2.4Ai) and Western blot 
analysis (Figure 2.2.4Aii), we demonstrated that fibroblasts of the human 
subcutaneous tissue in culture express anti-Panx1 (~50 kDa) immunoreactivity in 
addition to the expected Cx43 (43 kDa). Panx1 and Cx43 are both expressed in 
relatively high density as compared to β-tubulin standard protein levels (Figure 
2.2.4Aiii). 
These findings prompted us to test whether bradykinin-induced [Ca2+]i 
oscillations in human subcutaneous fibroblasts depend on the release of ATP via 
hemichannels using subtype selective connexin and pannexin-1 inhibitors. 
Inhibition of Cx36- and Cx50-containing hemichannels with mefloquine (99,100) 
(MFQ, 3 μM, n = 8) was devoid of effect on bradykinin-induced [Ca2+]i rise (Figure 
2.2.4Bi). On the other hand, 2-octanol (1 mM, n = 6), which blocks Cx43, Cx46 
and Cx50 hemichannels (100,101) (Figure 2.2.4Bii), and carbenoxolone (CBX, 300 
μM, n = 5), a non-selective inhibitor of connexins Cx26, Cx30, Cx32, Cx43 and 
Cx46, which also blocks Panx1-containing hemichannels (101) (Figure 2.2.4Biii), 
significantly (p < 0.05) attenuated the [Ca2+]i response induced by bradykinin (30 
μM). Interestingly, the selective Panx1 mimetic inhibitory peptide, 10Panx (102) 
(100 μM, n = 6), also decreased the bradykinin-induced [Ca2+]i response (Figure 
2.2.4Biv). CBX (300 μM) was the most effective of the three inhibitors, probably 
because it has a broad inhibitory spectrum blocking equally well connexin and 
Panx1 containing hemichannels. Coincidently or not, 2-octanol (1 mM), CBX (300 
μM) and 10Panx (100 μM), were more effective in depressing the plateau phase of 
bradykinin (30 μM) response (Figures 2.2.4Bii-4Biv), although 2-octanol (1 mM) 
and CBX (300 μM) also inhibited (p < 0.05) the fast [Ca2+]i rise induced by the 
peptide. Confocal microscopy studies demonstrated that 10Panx (100 μM) also 
attenuated (p < 0.05) bradykinin (30 μM)-induced ATP release from human 
fibroblasts loaded with quinacrine (see Figure 2.2.3Diii). 
In order to test if bradykinin-induced [Ca2+]i oscillations involved nucleotides-
release by exocytosis we used the vesicular transport inhibitor, brefeldin A (BFA, 
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Figure 2.2.4Bv), and the specific inhibitor of H+-ATPases of the vacuolar type, 
bafilomycin A1 (Baf A1, Figure 2.2.4Bvi). No statistical significant (p > 0.05) 
differences were found in [Ca2+]i oscillations produced by bradykinin (30 μM) in 
the absence and in the presence of BFA (20 μM, n = 4) and Baf A1 (3 μM, n = 7). 
Confocal microscopy experiments with primary cultures of rat subcutaneous 
fibroblasts loaded with the calcium sensitive dye, Fluo-4 NW, and then incubated 
with FM4-64, a membrane-selective fluorescent dye, were used to evaluate vesicle 
endocytosis and exocytosis in the time lapse mode (136,137). Results depicted in 
Figure 2.2.4Ci, show that bradykinin (30 μM)-induced [Ca2+]i oscillations were not 
accompanied by measurable changes in FM4-64 fluorescence signals in the same 
cells (Figure 2.2.4Cii). Ionomycin (5 μM) increased moderately FM4-64 
fluorescence labeling because plasma membrane modifications (e.g. membrane 
protrusions, microvesiculation, blebbing) are likely to occur in the presence of the 
Ca2+ ionophore. Overall, our findings suggest that ATP release via connexins 
(most probable Cx43) and Panx1 hemichannels, rather than by vesicle exocytosis, 
may contribute importantly to the plateau phase of bradykinin-induced [Ca2+]i 
response in fibroblasts cultured from the human subcutaneous connective tissue. 
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Figure 2.2.4. Bradykinin-induced [Ca2+]i signals in human subcutaneous fibroblasts 
involve connexin and pannexin-1 containing hemichannels opening. Panel A shows 
representative confocal micrographs (Ai) and blots (Aii) of Cx43 and Panx1 hemichannels 
immunoreactivity in cultured human subcutaneous fibroblasts from 3-4 individuals. Image scale 
bars: 60 μm. β-tubulin was used as a reference protein to determine the relative density of Cx43 and 
Panx1 immunoblots (Aiii). Panel B shows the effect of bradykinin (BK, 30 μM) tested in the presence 
of inhibitors of connexin and/or Panx1 hemichannels, namely mefloquine (MFQ, 3 μM, Bi), 2-octanol 
(1 mM, Bii), carbenoxolone (CBX, 300 μM, Biii) and 10Panx (100 μM, Biv). The effects of the vesicular 
transport inhibitor, brefeldin A (BFA, 20 μM, Bv), and of the specific inhibitor of vacuolar H+-ATPases, 
bafilomycin A1 (Baf A1, 3 μM, Bvi), are also shown for comparison. Cells were pre-incubated with 
the cell-permeant fluorescent calcium indicator, Fluo-4 NW (2.5 μM, see Experimental procedures). 
Changes in fluorescence were detected using a microplate reader. [Ca2+]i transients were calibrated 
to the maximal calcium load produced by ionomycin (5 μM, 100% response). Black arrows indicate 
the time of drugs application. None of the inhibitors significantly change baseline fluorescence 
when applied alone. Each point represents pooled data from an n number of experiments. The 
vertical bars represent S.E.M.. *p < 0.05 represent significant differences from BK (30 μM) alone. 
Panel C shows representative traces of single-cell [Ca2+]i oscillations in rat subcutaneous fibroblasts 
loaded with Fluo-4 NW (Ci) obtained in parallel with the incorporation of the membrane-selective 
fluorescent dye, FM4-64 (Cii), used to evaluate vesicle endocytosis and exocytosis in cells. Changes 
in fluorescence were detected in the time-lapse mode using a laser-scanning confocal microscope. 
Vertical lines indicate the time of drugs application. Fluorescence confocal micrographs were 
obtained at the indicated time points (a, b and c). Image scale bars: 30 μm. 
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The plateau phase of bradykinin [Ca2+]i recruitment is partially 
dependent on the activation of ADP-sensitive P2Y12 purinoceptors  
Extracellular inactivation of ATP directly into AMP with apyrase (NTPDase1 
or CD39, 2 U/mL, n = 8) reduced significantly (p < 0.05) the plateau phase of 
bradykinin (30 μM, n = 17) response, while keeping fairly conserved the 
magnitude of the initial [Ca2+]i rise (Figure 2.2.5Ai). Surprisingly, inhibition of 
membrane-bound NTPDases with POM-1 (141) (20 μM, n = 11) also decreased the 
plateau phase of bradykinin-induced [Ca2+]i response in human subcutaneous 
fibroblasts (Figure 2.2.5Aii). The result obtained with POM-1 (20 μM) was 
confirmed when we tested the effect of bradykinin on [Ca2+]i oscillations in the 
absence of Mg2+, an ion that must be present in millimolar concentration in the 
extracellular fluid for maximum activity of ectonucleotidases (36) (Figure 
2.2.5Aiii). These findings provide the first evidence that the plateau phase of 
bradykinin-induced [Ca2+]i accumulation by human subcutaneous fibroblasts 
requires the release of ATP and its subsequent conversion into other biologically 
active metabolites, most probably ADP, by ectonucleotidases. 
The kinetics of the extracellular catabolism of adenine nucleotides (ATP, 
ADP and AMP) and formation of metabolites in fibroblasts cultured from the 
human subcutaneous tissue is shown in Figure 2.2.5B. Average half-life times of 
ATP, ADP and AMP were respectively 12.6 ± 4.2 min, 27.0 ± 1.6 min and 1.5 ± 0.2 
min (n = 4 observations from two individuals), when the substrates were used in a 
3 μM concentration. ATP (3 μM) was sequentially metabolized into ADP, adenosine 
(ADO), inosine (INO) and hypoxanthine (HX) (Figure 2.2.5B). AMP (3 μM) was 
rapidly and sequentially converted into ADO and INO respectively by ecto-5’-
nucleotidase (CD73) and adenosine deaminase (ADA), which might explain why 
AMP accumulation was almost negligible when ATP (3 μM) and ADP (3 μM) were 
used as substrates. 
The analysis of the corresponding half-life time values clearly indicates that 
the extracellular catabolism of ADP into AMP is the rate-limiting step to generate 
ADO from exogenously added adenine nucleotides in cultured human 
subcutaneous fibroblasts. Therefore, transient accumulation of ADP in the 
cultures is in favor of a preferential activation of ADP-sensitive P2Y purinoceptors. 
To investigate the contribution of ADP-sensitive P2Y purinoceptors activation to 
bradykinin (30 μM)-induced [Ca2+]i response in human subcutaneous fibroblasts, 
we tested its effect in the presence of selective P2Y1, P2Y12 and P2Y13 receptors 
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antagonists (Figure 2.2.5C). Selective blockade of the P2Y12 receptor with AR-C 
66096 (0.1 μM, n = 6) significantly (p < 0.05) attenuated the plateau phase of 
[Ca2+]i rise caused by bradykinin (30 μM, n = 20) without much affecting the 
magnitude of the initial [Ca2+]i rise (Figure 2.2.5Cii). No significant differences (p > 
0.05) were observed in the presence of MRS 2179 (0.3 μM, n = 10) and MRS 2211 
(10 μM, n = 10) which selectively antagonize P2Y1 and P2Y13 receptors, 
respectively (Figure 2.2.5Ci and 2.2.5Ciii). None of these antagonists modified 
per se [Ca2+]i in human subcutaneous fibroblasts. The expression of the P2Y12 
receptor in cultured human subcutaneous fibroblasts was confirmed by 
immunocytochemistry (Figure 2.2.5D). 
 
Adenine nucleotides, but not adenosine, increase the influx of Ca2+ in 
human subcutaneous fibroblasts  
Changes in [Ca2+]i in human subcutaneous fibroblasts treated with adenine 
nucleotides (1 mM) in the presence and in the absence of extracellular Ca2+ are 
shown in Figure 2.2.6A. Exogenous application of ATP and ADP (1 mM) transiently 
increased intracellular [Ca2+]i reaching, respectively, 43 ± 4% (n = 8) and 25 ± 8% 
(n = 3) of the maximal calcium load caused by ionomycin (5 μM, 100% response) 
within 20 s from drug application. In Ca2+-free medium (plus EGTA, 100 μM), ATP- 
and ADP-induced [Ca2+]i transients were partially but significantly (p < 0.05) 
attenuated (Figure 2.2.6A). 
Adenosine (ADO) is a recognized anti-nociceptive agent (see e.g. (142)) and 
plays prominent roles in fibroblasts proliferation and tissue remodeling in the 
skin, liver and lung (66), yet contradictory effects of the nucleoside have been 
described on cardiac fibroblasts (63,64). Given the high amounts of ADO 
accumulating in cultured fibroblasts of the human subcutaneous tissue as a result 
of the extracellular catabolism of released adenine nucleotides (see Figure 2.2.5), 
we sought to investigate the contribution of the nucleoside to bradykinin-induced 
Ca2+ signals in these cells. To this end, we used the enzymatically stable 
adenosine analogue, 5′-(N-ethylcarboxamide) adenosine (NECA), which non-
selectively activates all four adenosine receptor subtypes in the submicromolar 
range. NECA (10 μM, n = 6) had a negligible effect on [Ca2+]i in human 
subcutaneous fibroblasts when it was applied either alone (Figure 2.2.6Bii) or in 
the presence of bradykinin (30 μM, n = 5) (Figure 2.2.6Biii). No statistical 
significant (p > 0.05) difference was found in [Ca2+]i oscillations caused by 
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bradykinin (30 μM) in the presence of NECA (10 μM, n = 6) (Figure 2.2.6Bii) as 
compared to the control situation (Figure 6Bi). Moreover, pretreatment of the cells 
with the non-selective adenosine receptor antagonist, 8-phenyltheophylline (8-PT, 
2.5 μM, n = 5), was devoid of effect on bradykinin-induced [Ca2+]i rise (Figure 
2.2.6C), suggesting that adenosine has a minor effect on Ca2+ signaling operated 
by bradykinin in human subcutaneous fibroblasts. 
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Figure 2.2.5. Bradykinin-induced [Ca2+]i mobilization is partially dependent on the activation of 
P2Y12 purinoceptor. Panel A shows the effect of bradykinin (BK, 30 μM) after pretreating human 
subcutaneous fibroblasts with apyrase (2 U/mL, Ai), which catabolizes ATP/ADP into AMP, and after 
inhibition of ectonucleotidases, with POM-1 (20 μM, Aii) or after removing Mg2+ from the incubation 
fluid (Aiii). Panel C shows the effects of BK (30 μM) in the absence/presence of selective P2Y1, P2Y12 
and P2Y13 receptor antagonists, respectively MRS 2179 (0.3 μM, Ci), AR-C 66096 (0.1 μM, Cii) and 
MRS 2211 (10 μM, Ciii). Cells were pre-incubated with the cell-permeant fluorescent calcium 
indicator, Fluo-4 NW (2.5 μM, see Experimental procedures). [Ca2+]i transients were calibrated to the 
maximal calcium load produced by ionomycin (5 μM, 100% response). Black arrows indicate the time 
of drugs application. No changes in baseline fluorescence were observed after application of the 
modulators. Each point represents pooled data from an n number of experiments. The vertical bars 
represent S.E.M.. *p < 0.05 represent significant differences from BK (30 μM) alone. Panel B 
illustrates the time course of the extracellular catabolism of adenine nucleotides in human 
subcutaneous fibroblasts grown in culture for 11 days. ATP, ADP or AMP (3 μM) were added to the 
culture medium at time zero; samples (75 μL) were collected at indicated times. Each sample was 
analyzed by HPLC to separate and quantify ATP (white), ADP (black), AMP (grey), adenosine (ADO, 
red), inosine (INO, orange) and hypoxanthine (HX, green). Each point represents pooled data from 
two individuals; 2 replicas were performed for each individual. The calculated half-life time (t½) for 
each initial substrate is shown for comparison. Panel D shows immunoreactivity of human 
subcutaneous fibroblasts against the P2Y12 receptor; shown image is representative of three 
independent experiments. Image scale bar is 30 μm. 
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Figure 2.2.6. Adenine nucleotides, but not adenosine, increase Ca2+ influx from the extracellular space in 
human subcutaneous fibroblasts. In panel A, human subcutaneous fibroblasts were incubated with 1 mM ATP 
or ADP in control conditions and in Ca2+-free medium (plus EGTA, 100 μM). Each bar represents pooled from an n 
number of experiments. The vertical bars represent S.E.M.. *p < 0.05 represent significant differences compared 
with the effect of ATP or ADP alone. Panel B illustrates [Ca2+]i oscillations caused by NECA (10 μM), an 
enzymatically stable non-selective adenosine receptor agonist, compared with the effect of bradykinin (BK, 30 
μM) in fibroblasts of the human subcutaneous tissue. NECA (10 μM) and BK (30 μM) were applied cumulatively in 
sequence (Bii) and in the reverse mode (Biii). Panel C shows BK (30 μM)-induced [Ca2+]i oscillations in the absence 
and in the presence of a non-selective adenosine receptor antagonist, 8-PT (2.5 μM). Cells were pre-incubated 
with the cell-permeant fluorescent calcium indicator, Fluo-4 NW (2.5 μM, see Experimental procedures). Changes 
in fluorescence were detected using a microplate reader. [Ca2+]i transients were calibrated to the maximal 
calcium load produced by ionomycin (5 μM, 100% response). Black arrows indicate the time of drugs application. 
No changes in baseline fluorescence was observed after application of 8-PT (2.5 μM). Each point represents 
pooled data from an n number of experiments. The vertical bars represent S.E.M.. 
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DISCUSSION 
Bradykinin is produced within the interstitium of most tissues and plays an 
important role in normal and pathological conditions, being considered an 
important inflammatory pain mediator (143) that is associated with chronic 
musculoskeletal pain syndromes (144,145). Recent findings have shown that in 
the central nervous system bradykinin triggers astrocyte-neuron signaling via 
glutamate release followed by NMDA receptors activation (146). In peripheral 
tissues, bradykinin receptors have already been described in sensory neurons of 
dorsal root ganglia (DRG), where it exerts direct and indirect effects via neuronal 
excitation and threshold modulation by the release of excitatory signaling 
molecules, respectively (22). To the best of our knowledge, this is the first report 
demonstrating that fibroblasts isolated from the human subcutaneous connective 
tissue respond to bradykinin by releasing ATP into the extracellular medium 
through the activation of B2 receptors, which are constitutively expressed in most 
of the tissues exhibiting bradykinin sensitivity. Although our experiments were 
conducted in non-stressful conditions, the involvement of inducible B1 receptors 
mediating bradykinin effects in human subcutaneous fibroblasts cannot be ruled 
out (147). Bradykinin-induced ATP release from these cells was demonstrated by 
two distinct experimental approaches: the luciferin-luciferase bioluminescence 
assay and ATP-binding quinacrine dye destaining by time-lapse confocal 
microscopy. Our data also suggest that bradykinin-induced ATP release from 
human subcutaneous fibroblasts requires Ca2+ recruitment from thapsigargin-
sensitive internal stores and occurs independently of extracellular Ca2+ by 
electrodiffusional translocation of the nucleotide via hemichannels containing 
connexins (most probably Cx43) and Panx1. 
In several cell types (138,139), including human fibroblasts of the foreskin 
(140), bradykinin elicits an abrupt rise in [Ca2+]i to a peak that depends on Ca2+ 
recruitment from internal stores, which then declines to a plateau that is 
sustained by Ca2+ entry from the extracellular compartment. The long lasting 
elevation of [Ca2+]i seen after the initial [Ca2+]i peak probably results from a 
receptor- or second messenger-operated Ca2+ current activated by bradykinin, 
rather than via a capacitative pathway (140). Here, we demonstrate for the first 
time that ADP-sensitive P2Y12 purinoceptors may be, at least in part, responsible 
for the Ca2+ influx that is characteristic of the plateau phase of elevated [Ca2+]i 
caused by bradykinin in human subcutaneous fibroblasts. This conclusion is 
supported by results showing that: [1] human subcutaneous fibroblasts exhibit 
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P2Y12 receptor immunoreactivity, [2] bradykinin induces the release of ATP that is 
subsequently hydrolyzed into ADP by membrane-bound ectonucleotidases, [3] 
ADP has a tendency to accumulate transiently in the cultures, given that we found 
that the extracellular catabolism of ADP into AMP is the rate-limiting step of the 
ectonucleotidase cascade, and, finally, [4] adenine nucleotides-induced [Ca2+]i 
rises in human subcutaneous fibroblasts are depend on extracellular Ca2+. 
The pathways underlying bradykinin-induced long lasting Ca2+ influx 
resulting from the cooperation with ADP-sensitive P2Y12 purinoceptors need to be 
further investigated. Interestingly, bradykinin causes a rapid translocation of all 
protein kinase C isoforms from the cytosol to the plasma membrane within the 
time frame (30 s) of ATP appearance in the cultures (128), which may favor the 
synergism between B2 and P2Y12 receptors activation. The involvement of ADP-
sensitive P2Y12 receptors in neuropathic pain, has been already reported; authors 
suggested that this could be due to an unclear mechanism involving non-neuronal 
cells, such as spinal microglia (148,149) and trigeminal ganglion satellite cells 
(150). The close proximity between P2Y12 receptor-expressing fibroblasts of the 
subcutaneous tissue and sensory nerve fibers exhibiting numerous ligand-gated 
receptors (including ionotropic P2X and metabotropic P2Y purinoceptors) implies 
that adenine nucleotides released from stimulated fibroblasts may alter acute and 
chronic pain perception. During acute tissue injury, excessive ATP release from 
damaged fibroblasts, keratinocytes, blood vessels and inflammatory cells may 
cause pain by activating excitatory purinoceptors on nociceptive sensory nerve 
endings (149,151-153). Lower levels of ATP released from intact cells in response 
to mild mechanical and thermal stimulation may participate in normal tactile 
sensation and also contribute to the spontaneous pain and tactile hypersensitivity 
that occurs under chronic painful conditions involving the subcutaneous 
connective tissue when nerve endings become sensitized (151,154). We, now, 
postulated a new type of interaction involving an autocrine action of ATP, via 
P2Y12 receptors, triggered by the activation of bradykinin B2 receptors in human 
subcutaneous fibroblasts. Moreover, increased sensitivity to extracellular ATP has 
been described in fibroblasts from patients affected with systemic sclerosis (155). 
Little is known about the mechanisms upstream the nucleotide release 
from human fibroblasts despite the importance of connective tissue ATP signaling 
in the pathogenesis of acute and chronic inflammatory pain (44,77). Multiple 
nucleotide-releasing pathways have been identified in intact cells, which represent 
a critical component for the initiation of the purinergic signaling cascade (77). 
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Experiments designed to manipulate exocytosis of vesicles/organelles containing 
compartmentalized ATP suggest that it might not represent an important pathway 
for releasing ATP from human fibroblasts stimulated with bradykinin. Several non-
vesicular ATP release mechanisms have been proposed, yet many remain 
controversial and are complicated by the non-specificity of available inhibitors. 
Hemichannels possessing connexin and Panx1 subunits represent an important 
mechanism for the cellular release of ATP. The opening of hemichannels occurs in 
response to many physiological and pathological situations, including volume 
regulation, proliferation, calcium wave propagation by extracellular messengers 
and cell death during metabolic inhibition (156). Using immunofluorescence 
confocal microscopy and Western blot analysis, we demonstrated that fibroblasts 
of the human subcutaneous tissue exhibit strong anti-Panx1 immunoreactivity in 
addition to Cx43 that is characteristic from fibroblasts of other tissue origins 
(78,98). Moreover, functional data using non-selective connexin inhibitors 
targeting Cx43 hemichannels (e.g. 2-octanol, CBX) strongly depressed the plateau 
phase of bradykinin-induced [Ca2+]i response. Because connexin hemichannels are 
activated by moderate (< 500 nM) [Ca2+]i elevations, these channels may open in 
response to bradykinin during the initial [Ca2+]i rise (157) and contribute to ATP 
release and to the subsequent purinoceptor-mediated signaling. Closing of 
connexin containing hemichannels, which unlike Panx1 hemichannels seal when 
the spike amplitude rises above 500 nM, contributes to shape bradykinin-induced 
[Ca2+]i oscillations as demonstrated by the partial reduction of the initial [Ca2+]i rise 
of bradykinin in the presence of 2-octanol and CBX. 
Considering the relatively high potency of CBX (300 μM) and the fact that 
this compound also blocks Panx1 containing hemichannels (101), we tested the 
effect of the selective Panx1 mimetic inhibitory peptide, 10Panx, which also 
depressed the plateau phase of the bradykinin-induced [Ca2+]i response in parallel 
to the decline of ATP release from fibroblasts loaded with quinacrine. Like the 
effects obtained with apyrase and with the selective P2Y12 antagonist, AR-C 
66096, inhibition of hemichannels containing Cx43 and Panx1 were more 
effective in depressing the plateau phase rather than the peak of the bradykinin 
response. Taken together, data suggest that Cx43 and Panx1 containing 
hemichannels have a predominant role on ATP release from human subcutaneous 
fibroblasts stimulated with bradykinin, thereby instigating the regenerative 
propagation of intracellular Ca2+ signals. Our findings are in agreement with the 
observation that mechanically stimulated cardiac fibroblasts release ATP in a CBX-
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sensitive manner, an effect that the authors attributed to Cx43 hemichannels not 
excluding a possible involvement of Panx1 containing hemichannels (59). 
Regardless of whether channel-mediated efflux or vesicle exocytosis 
comprises the predominant ATP release mechanism, most studies (but not all, see 
e.g. (158)) have identified elevation of cytosolic Ca2+ as an important regulator of 
nucleotide export in different cell model systems. The molecular mechanism by 
which bradykinin releases ATP through the opening of Cx43 and Panx1 
hemichannels in human subcutaneous fibroblasts may be the generation of 
inositol trisphosphate (IP3) by phospholipase C and the downstream [Ca2+]i 
mobilization from internal stores (114,115). Our data, showing that intracellular 
Ca2+ depletion with thapsigargin impaired quinacrine dye destaining induced by 
bradykinin is in favor with the hypothesis that Ca2+ mobilization is necessary for 
ATP release in these cells. Further experiments are required to discard the ability 
of bradykinin, like certain Gq-coupled receptors, to additionally stimulate Rho-
GTPase acting to strongly potentiate a Ca2+-activated ATP release pathway 
(116,117). Seminario-Vidal and col. (2009) (117), demonstrated that Ca2+- and 
RhoA/Rho kinase-dependent ATP release from thrombin-stimulated A549 lung 
epithelial cells occurs via connexin or pannexin hemichannels, a pathway that 
seems to be not competent for ATP release in human astrocytoma cells (116). 
Given the actions exerted by Rho/Rho kinase on cytoskeleton components (e.g. 
regulating myosin-light chain phosphorylation and actin polymerization), those 
authors speculated that Rho-promoted membrane-cytoskeletal rearrangements 
facilitate the insertion of hemichannel subunits within the plasma membrane. 
Bradykinin can increase glutamate release from mouse astrocytes through 
volume-sensitive outwardly rectifying (VSOR) anion channels without cell swelling 
via a mechanism that is regulated by high intracellular Ca2+ in nanodomains (159). 
Although we did not test directly whether this pathway plays a role in bradykinin-
induced [Ca2+]i-dependent ATP release from human subcutaneous fibroblasts, it 
appears that VSOR currents exhibit a slow activation kinetics requiring 15-20 min 
after bradykinin application to reach a sustained plateau (159). This activation 
pattern is entirely different from the rapid (within 30 s) ATP releasing response to 
bradykinin observed in human fibroblasts (see Figure 2.2.3), thus indicating that 
slow activating but prolonged VSOR currents would play a minor, if some, role in 
the release of ATP in our experimental time frame. In our hands mefloquine (MFQ, 
3 μM, Figure 2.2.4Bi), which also blocks non-selectively anion channels, failed to 
modify bradykinin-induced [Ca2+]i signals. Moreover, modulation of VSOR channel 
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permeability through the activation of protein kinase C with the phorbol ester (12-
myristate 13-acetate, 1-10 μM, n = 3) did not mimic the effect of bradykinin. 
Involvement of soluble signaling mediators, such as ATP and/or its 
metabolites, may also explain heterogeneity of individual [Ca2+]i responses to 
bradykinin within a cell population; confocal microscopy studies showed that 
some cells displayed no plateau phase whereas others were not noticeably 
affected by bradykinin removal and continued to respond for a few minutes (see 
Figure 2.2.1C). This is consistent with the generation of concentration gradients 
by released ATP and metabolites formation (namely ADP) via ectonucleotidases, 
which enables differential targeting of subtype-specific P2 purinoceptors and, 
thus, cell-to-cell communication depending on proximity. Therefore, we may 
speculate that bradykinin-stimulated fibroblasts trigger a “purinergic wave” 
mediated by released ATP and metabolites formation that can affect sensory 
afferent nerve endings localized in the vicinity, representing the first insights of a 
fibroblast-neuron communication unproved so far. 
Recently, it has been reported that mechanical stimulation of human 
epidermal keratinocytes induces propagating Ca2+ waves depending on non-
vesicular release of ATP through connexin hemichannels (151). In view of the 
potential contribution of the cutaneous release of ATP to acute and chronic pain 
syndromes, this and other groups demonstrated that human epidermal 
keratinocytes co-cultured with neurons of the dorsal root ganglia interplay 
through the release of ATP following keratinocytes-born [Ca2+]i waves (160). 
Likewise, subcutaneous inflammation or injection of ATP causes pain sensation 
through the activation of P2X3 receptors expressed in sensory nerve endings, 
which may become sensitized in both animal models and human patients 
(161,162). Knocking down or selectively antagonizing P2X3 receptor activity 
results in reduced responses to ATP, as well as reduced thermal and mechanical 
hyperalgesia in inflammatory and neuropathic pain rat models (163,164). P2Y 
purinoceptors, especially P2Y1 and P2Y2, expressed in primary sensory endings 
have also been implicated in chronic pain states (160). Authors from the latter 
study agree that cutaneous ATP release does not appear to contribute to pain 
sensation in the absence of tissue injury. However, under chronic painful 
conditions, such as inflammation and nerve injury, nerve endings may become 
sensitized and a normally innocuous level of subcutaneous ATP may now be 
sufficient to reach the firing threshold of nociceptors (165). Despite direct 
modulation of nociceptors threshold by ATP released from different cell types 
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may play a key role to the association between subcutaneous connective tissue 
injury and musculoskeletal pain, there are alternative mechanisms that should 
also be considered in this context. These include interference with muscle tension 
due to fusimotor effects induced by group III and IV afferents activation, which by 
projecting to γ-motoneurons amplify muscle spindles activity and, thereby, 
increases muscle tone, generating metabolites (e.g. bradykinin) that enter in a 
positive feedback loop (reviewed by (144,145,166)). 
In addition, it has been proposed that mechanical deformation of the skin 
by needles and application of heat or electrical current leads to release of large 
amounts of ATP from keratinocytes, fibroblasts and other cells in skin (149). 
Impulses generated by P2 purinoceptors in sensory fibers in the skin connect with 
interneurons that may negatively modulate neural pathways to the pain centers in 
the cortex. This is the basis for the novel hypothesis for the involvement of 
purinergic signaling in acupuncture (149). Furthermore, purines are known to 
cause intracellular Ca2+-dependent transient changes in cultured human fibroblast 
cytoarchitecture, which share similarities with the increase in cross-sectional area 
of fibroblasts in response to acupuncture (71). Although evidence has been 
presented of the role of adenosine in acupuncture-mediated anti-nociception by 
demonstrating that the local concentrations of the nucleoside increase in human 
subjects (167) and that adenosine is implicated in the proliferation of fibroblasts 
and remodeling of the skin, liver and lung (reviewed in (66), we failed to 
demonstrate any contribution of the nucleoside to bradykinin-induced [Ca2+]i 
signals in cultured human subcutaneous fibroblasts. Controversy still exists 
regarding adenosine participation in wound healing and scarring. For instance, 
the adenosine A2A receptor promotes skin fibrosis and scarring (168) and 
increases collagen production in human dermal fibroblasts (169) probably by 
activating the Gs/cyclicAMP pathway (170), yet it remains controversial how A2A 
receptors increase collagen production since cyclicAMP has been found to 
decrease the synthesis of collagen and DNA by fibroblasts (171). Thus, further 
studies are required to test long-term effects of extracellular adenosine, which 
may originate from the hydrolysis of ATP released from fibroblasts stimulated 
either mechanically (e.g. acupuncture) or by inflammatory mediators, such as 
bradykinin. Our findings demonstrating that adenosine accumulates as an end 
product of the catabolism of released ATP in the vicinity of fibroblasts within the 
subcutaneous connective tissue may be of clinical relevance, given the role of the 
nucleoside on dermal fibrosis (via A2A receptors) and its anti-nociceptive 
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properties (via A1 receptors) on free nerve endings and sensory afferents 
(66,172). 
 
CONCLUSIONS 
Data indicate that stimulation of constitutively expressed B2 receptors with 
bradykinin elicits the opening of hemichannels containing Cx43 and Panx1 
subunits, followed by ATP diffusion out of human subcutaneous fibroblasts. ADP 
originating from the catabolism of released ATP by membrane-bound 
ectonucleotidases acting in an autocrine or paracrine way on plasma membrane 
P2Y12 purinoceptors may contribute to sustain elevated [Ca2+]i levels in 
neighboring cells. Thus, targeting the pathways leading to nucleotides release 
and the purinergic cascade in human fibroblasts of the subcutaneous tissue may 
be useful in designing novel therapeutic strategies for tuning the communication 
between inflammatory cells, fibroblasts and sensory nerve endings, which are key 
players in the pathogenesis of painful musculoskeletal diseases with widespread 
involvement of the subcutaneous connective tissue (e.g. fibromyalgia). 
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ABSTRACT  
Changes in connective tissue remodeling are involved in chronic musculoskeletal 
pain. Adenosine is a potent modulator of inflammation and tissue repair. 
However, controversy still exists regarding adenosine participation in wound 
healing and fibrosis (see e.g. (66)). Previously we showed that although adenosine 
accumulates in the extracellular milieu following the catabolism of released 
adenine nucleotides, the nucleoside failed to demonstrate any contribution to 
[Ca2+]i signals in cultured human subcutaneous fibroblasts challenged acutely with 
inflammatory mediators (e.g. bradykinin). Here, we analyzed the expression of all 
four adenosine P1 receptors in human subcutaneous fibroblasts and investigated 
their role in cell proliferation and type I collagen production during 28 days of cell 
cultures. Data showed that adenosine accumulation in the cultures may result 
from reduced adenosine deaminase activity in these cells (t½ of 3 µM ADO, 40.1 ± 
8.3 min) as compared with the activity of the adenosine forming enzyme, ecto-5’-
nucleotidase (t½ of 3 µM AMP, 1.5 ± 0.2 min). In addition, human subcutaneous 
fibroblasts express a significant immureactivity against the A2A receptor; these 
cells show weak labeling with A2B and A3 antibodies and did not stain with the A1 
receptor antibody. Prolonged exposure (during 28 days) of human subcutaneous 
fibroblasts to adenosine or its stable analogues, NECA and CGS 21680, 
significantly increased fibroblasts growth and type I collagen production. In 
conclusion, adenosine, via A2A receptors activation, promotes proliferation and 
type I collagen synthesis by human subcutaneous fibroblasts, which might 
suggest that these receptors play an active role in connective tissue remodeling 
and, thus, in chronic musculoskeletal pain. 
 
Keywords: human subcutaneous fibroblasts, adenosine, A2A receptor, 
proliferation, type I collagen 
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INTRODUCTION 
Subcutaneous connective tissue disorganization appears to occur in 
patients with chronic pain, possibly as a result of chronic inflammation and 
fibrosis (13,14,16). Recently, it has been suggested that purinergic signaling may 
potentially play a role in subcutaneous connective tissue remodeling, namely due 
to the activation of P2 receptors (70,71,173). There is, however, lack of evidence 
regarding the purinoceptor subtypes that are expressed in the human 
subcutaneous connective tissue.  
On the other hand, it seems that adenosine, a ubiquitous purine nucleoside 
and the final active metabolite of ATP, might rapidly appear in the extracellular 
fluid of human subcutaneous fibroblasts due to the action of membrane-bound 
ecto-NTPDases that catabolize adenine nucleotides. In fact, we previously 
demonstrated that AMP is rapidly catabolized into adenosine in cultured human 
subcutaneous fibroblasts (173), suggesting that adenosine might accumulate and 
play an important role in subcutaneous connective tissue physiology.  
Furthermore, there is increasing evidence that, depending on the tissue, 
adenosine might play a role in wound healing which, under certain circumstances, 
may lead to tissue fibrosis (66). In ischemic, hypoxic or inflamed conditions, 
adenosine levels in the extracellular fluid may be extremely elevated. 
Nevertheless, tissue adenosine accumulation in response to stressful stimuli 
might have a dual modulatory role in homeostasis. While adenosine first acts as 
an alarm molecule that reports injury to the surrounding tissue, it then generates 
a range of tissue responses that can be generally viewed as organ protective 
(174). Adenosine effects are mediated by differential activation of four G protein-
coupled P1 receptors, namely A1, A2A, A2B and A3, each one may undertake a 
specific role. However, depending on the tissue, evidences have been provided 
showing that activation of the same receptor may induce opposing effects. For 
instance, the adenosine A2B receptor inhibits fibrosis in the heart, but it promotes 
fibrosis in the lung. In the skin, liver, and lungs, both A2A and A2B receptors 
operate by increasing fibrosis (66).  
Given that, to our knowledge, evidence about the role of adenosine in 
human subcutaneous connective tissue remodeling is missing, we analyzed the 
expression of all four types of P1 purinoceptors, as well as  their role in 
fibroblasts proliferation and type I collagen production.   
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EXPERIMENTAL PROCEDURES 
Cell cultures  
Human fibroblasts were isolated from the subcutaneous tissue of organ 
donors (45 ± 6 years old (mean ± standard error of the mean), n = 12) with no 
clinical history of connective tissue disorders. The protocol was approved by the 
Ethics Committee of Hospital Geral de Santo António SA (University Hospital) and 
of Instituto de Ciências Biomédicas de Abel Salazar (Medical School) of University 
of Porto. The investigation conforms to the principles outlined in the Declaration 
of Helsinki. Subcutaneous tissues were maintained at 4-6ºC in M-400 
transplantation solution (4.190 g/100 mL mannitol, 0.205 g/100 mL KH2PO4, 
0.970 g/100 mL K2HPO4·3H2O, 0.112 g/100 mL KCl, and 0.084 g/100 mL 
NaHCO3, pH 7.4) until used, which was between 2 and 16 hours after being 
harvested (84). Cells were then obtained by the explant technique and cultured in 
DMEM medium supplemented with 10% fetal bovine serum (FBS), 2.5 µg/mL of 
amphotericin B and 100 U/mL of penicillin/streptomycin, at 37ºC in a humidified 
atmosphere of 95% air and 5% CO2. Medium was replaced twice a week. Primary 
cultures were maintained until near confluence (~3-4 weeks), then adherent cells 
were enzymatically released with 0.04% trypsin-EDTA solution plus 0.025% type I 
collagenase in phosphate-buffered saline (PBS). The resultant cell suspension was 
cultured and maintained in the same conditions mentioned above. All the 
experiments were performed in the first subculture.  
 
Antibody production  
Genetic immunization protocol was carried out with pcDNA3.1 plasmid 
encoding for human CD73 using Hartley guinea pigs, obtained from Charles River 
Laboratories (Quebec City, Canada). 
 
Immunocytochemistry  
Human fibroblasts were seeded in chamber slides at a density of 2.5x104 
cells/mL and allowed to grow for 5-15 days. Cultured cells were fixed in 4% 
paraformaldehyde (PFA) in PBS for 10 minutes, washed 3 times in PBS (10 minutes 
each) and, subsequently, incubated with blocking buffer I (10% FBS, 1% bovine 
serum albumin (BSA), 0.1% Triton X, 0.05% NaN3) for 1 h. Primary antibodies, 
diluted in blocking buffer II (5% FBS, 1% BSA, 0.1% Triton X, 0.05% NaN3), were 
applied [mouse anti-porcine vimentin 1:75 (DAKO); rabbit anti-human collagen I 
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1:50 (AbDSerotec); rabbit anti-rat A1 1:50, rabbit anti-human A2B 1:75 (Chemicon); 
rabbit anti-canine A2A 1:100 (Alpha Diagnostics); goat anti-human A3 1:50 (Santa 
Cruz);  and guinea-pig anti-human CD73 1:300 (University of Laval, Québec, 
Canada; see the Centre de Recherche du CHUL Web site for further details)], and 
the slides incubated overnight at 4ºC. After incubation, cells were washed 3 times 
in PBS 1X (10 minutes each). The donkey anti-rabbit IgG Alexa Fluor 488, donkey 
anti-mouse IgG Alexa Fluor 568, donkey anti-guinea pig IgG Alexa Fluor 568 and 
donkey anti-goat IgG Alexa Fluor 633 secondary antibodies (Invitrogen) were 
diluted in blocking buffer II (5% FBS, 1% BSA, 0.1% Triton X) and applied for 1h 
protected from light. A last wash was performed with PBS 1X and glass slides 
were mounted with VectaShield medium and stored at 4ºC. Observations were 
performed and analyzed with an Olympus FV1000 confocal microscope (49,93). 
 
Enzymatic kinetic experiments and HPLC analysis  
After a 30 minutes equilibration period at 37ºC, cells grown for 11 days 
were incubated with 3 or 30 μM of adenosine, which was added to the culture 
medium at zero time. Samples (75 μL) were collected from each well at different 
times up to 30 minutes for high-performance liquid chromatography (HPLC, 
LaChrome Elite, Merck, Germany) analysis of the variation of substrate 
disappearance and product formation (49,89). Adenosine catabolism analysis was 
performed at room temperature with a LiChrospher 100 RP-18 (5 µm) column 
(Merck) by isocratic reverse-phase HPLC-UV set at 254 nm (90). The eluent was 
composed of 91% of 100 mM KH2PO4, pH = 7 and 9% of methanol during 10 min 
with a constant rate flow of 1.25 mL/min. Under these conditions, the retention 
times of adenosine and its metabolites were as follows: adenosine (8.03 min), 
inosine (2.73 min) and hypoxantine (1.78 min). Concentrations of the substrate 
and products were plotted as a function of time (progress curves). The following 
parameters were analyzed for each progress curve: half-life time (t1/2) of the initial 
substrate, time of appearance of the different concentrations of the products, 
concentration of the substrate or any product remaining at the end of the 
experiment. The spontaneous degradation of adenosine at 37ºC in the absence of 
the cells was (0%) over 30 minutes. At the end of the experiments, the remaining 
incubation medium was collected and used to quantify the lactate dehydrogenase 
(LDH, EC 1.1.1.27) activity. The negligible activity of LDH in the samples collected 
at the end of the experiments is an indication of the integrity of the cells during 
the experimental period. 
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Cell viability/proliferation  
Viability /proliferation studies included the MTT assay as previously 
described (50). Human fibroblasts were seeded in flat bottom 96 well plates at a 
density of 3x104 cells/mL and cultured in supplemented DMEM as described 
before. Cell cultures were routinely monitored by phase contrast microscopy and 
characterized at days 1, 7, 14, 21 and 28. The MTT assay consists on the 
reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
to a purple formazan reaction product by viable cells. In the last 4 h of each test 
period, cells were incubated with 0.5 mg/mL of MTT for 4 h in the conditions 
referred above. The medium was carefully removed, decanted and the stained 
product dissolved with DMSO before absorbance (A) determination at 600 nm 
using a microplate reader spectrometer (Synergy HT, BioTek). Results were 
expressed as A/well. 
 
Total type I collagen determination  
Type I collagen determination was performed using the Sirius Red staining 
assay. Human fibroblasts were cultured as described for the viability/proliferation 
studies. The staining protocol was adapted from Tullberg-Reinert & Jundt (1999) 
(88). Cell layers were washed twice in PBS before fixation with Bouin’s fluid for 1 
h. The fixation fluid was removed by suction and the culture plates were washed 
by immersion in running tap water for 15 minutes. Culture dishes were allowed to 
air dry before adding the Sirius Red dye (Direct Red 80). Cells were stained for 1 h 
under mild shaking on a microplate shaker. To remove non-bound dye, stained 
cells were washed with 0.01 N hydrochloric acid and then dissolved in 0.1 N 
sodium hydroxide for 30 minutes at room temperature using a microplate shaker. 
Optical density was measured at 550 nm against 0.1 N sodium hydroxide as 
blank (88). Results were expressed as A/well. 
 
Materials and reagents  
Amphotericin B, bovine serum albumin (BSA), Dulbecco’s Modified Eagle’s 
Medium (DMEM), ethylene diaminetetraacetic acid (EDTA), fetal bovine serum 
(FBS), 5′-(N-ethylcarboxamide)adenosine (NECA), penicillin/streptomycin, 
phosphate buffered saline system (PBS), and type I collagenase were purchased 
from Sigma-Aldrich. 2-(2-Furanyl)-7-[3-(4-methoxyphenyl­)propyl]-7H-pyrazolo[4,3-
114 
 
e][1,2,4]triazolo[1,5-c]p­yrimidin-5-amine (SCH 442416), and 4-[2-[[6-Amino-9-(N-
ethyl-β-D-ribofu­ranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzene­propanoic 
acid hydrochloride (CGS 21680) were obtained from Tocris Cookson Inc.. 
Dimethylsulphoxide (DMSO) and glacial acetic acid were obtained from Merck and 
Bouin’s solution was acquired from Panreac. CGS 21680, NECA, and SCH 442416 
were prepared in dimethyl sulfoxide (DMSO). All other drugs were prepared in 
distilled water. All stock solutions were stored as frozen aliquots at -20ºC. 
Dilutions of these stock solutions were made daily and appropriate solvent 
controls were done. No statistically significant differences between control 
experiments, made in the absence or in the presence of DMSO at the maximal 
concentration used (0.05% v/v), were observed. The pH of the solutions did not 
change by the addition of the drugs in the maximum concentrations applied to 
the preparations.   
Tissue culture plates: 96-well plates were purchased from Corning; 
chamber slides were from Nunc. 
 
Presentation of data and statistical analysis  
Data are expressed as mean ± S.E.M. from an n number of 
experiments/cells/individuals. Data from different individuals were evaluated one-
way analysis of variance (ANOVA). Statistical differences found between control 
and drug-treated cultures were determined by the Bonferroni’s method. p values 
< 0.05 were considered to represent significant differences.  
 
RESULTS 
Extracellular catabolism of adenosine by human subcutaneous 
fibroblasts in culture  
Cell cultures obtained from subcutaneous connective tissue exhibited a 
positive immunoreactivity against the fibroblast-cell markers, vimentin and type I 
collagen (Fig. 2.3.1A). Human subcutaneous fibroblasts also exhibited strong 
immunoreactivity against the ecto-5’-nucleotidase (CD73) (Fig. 2.3.1B), the 
enzyme that is responsible for extracellular AMP dephosphorylation, thus 
enabling fast adenosine formation from released adenine nucleotides. Analyzing 
the kinetics of the extracellular catabolism of exogenously applied adenosine, 
one may conclude that adenosine deamination occurs slowly in cultured human 
subcutaneous fibroblasts, which allows adenosine to accumulate in the 
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extracellular milieu (Fig. 2.3.1C). When cells were incubated with 3 µM adenosine, 
inosine was the only metabolite detected whose concentration slowly increased 
with time, reaching the maximum value of 0.96 ± 0.58 µM after 30 min of 
adenosine application (Fig. 2.3.1Ci). Adenosine (3 µM) was metabolized with a 
half-life time (t1/2) of 40.1 ± 8.3 min (n = 4 observations from 2 individuals). 
Increasing the concentration of the substrate to 30 µM adenosine, formation of 
inosine increased to the maximum value of 4.05 ± 2.83 µM after 30 min of 
incubation; formation of hypoxanthine was negligible (less than 1 µM) (Fig. 
2.3.1Cii). Adenosine (30 µM) was metabolized even more slowly; a t1/2 of 157.6 ± 
16.6 µM was calculated (n = 4 observations from 2 individuals). The semi-
logarithmic representation of progress curves obtained by polynomial fitting of 
the nucleoside catabolism show a linear pattern (y = -0.0051x + 0.4578 and R2 = 
0.99 for 3 µM: y = -0.0015x + 1.4640 and R² = 0.99 for 30 µM). Given that the 
slope of the progress curves decreased upon increasing the concentration of the 
substrate from 3 to 30 µM, data indicate that the kinetics of the catabolism of 
adenosine is more slowly whenever the concentration of the nucleoside increases, 
thus favoring its extracellular accumulation.  
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Figure 2.3.1. Adenosine accumulation in human subcutaneous fibroblasts in culture. Panel A 
demonstrates the immunoreactivity against vimentin (red), which has been described as a reliable 
fibroblast marker, as well as the staining of type I collagen (green), which is produced by activated 
fibroblasts. Panel B shows immunoreactivity of human subcutaneous fibroblasts against ecto-5’-
nucleotidase (CD73). DAPI (blue) represents the staining of cell nucleus; images were obtained 
under confocal microscope and are representative of, at least, three individuals; scale bar is 60 µm 
(A and B). Panel C shows the time course of the extracellular catabolism of adenosine (3 µM, i; and 
30 µM, ii) in human subcutaneous fibroblast cultures grown during 11 days. Adenosine was added 
to the culture medium at time zero. Samples (75 µl) were collected from each well at indicated times 
in the abscissa. Each collected sample was analyzed by HPLC to separate and quantify AMP (filled 
squares), adenosine (open squares), inosine (filled triangles) and hypoxanthine (open triangles). 
Each point represents pooled data from two individuals; 2 replicas were performed in each 
individual experiment. Vertical bars represent S.E.M. and are shown when they exceed the symbols 
in size. The calculated half-life time (t1/2, min) for each initial substrate is shown for comparison.  
 
P1 receptor expression in human subcutaneous fibroblasts in culture  
The expression of P1 receptors in human subcutaneous fibroblasts in 
culture was assessed by immunofluorescence confocal microscopy using cells 
from, at least, 3 individuals. Results provided clear evidence for the expression of 
A2A receptors in these cells (Fig. 2.3.2). In contrast, human subcutaneous 
fibroblasts showed weak positive immunoreactivity against the A2B and A3 
receptors and no staining was detected for the A1 receptor (Fig. 2.3.2). Omission 
of primary antibodies from the incubation buffer completely prevented secondary 
antibody labeling (data not shown).   
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Figure 2.3.2. Immunocytochemical staining of adenosine P1 receptors in fibroblasts isolated from 
human subcutaneous tissue. Panel shows immunoreactivity of human subcutaneous fibroblasts 
against A1, A2A, A2B and A3 receptors; cells grown for 7 days. Images obtained under confocal 
microscope; representative of, at least, three individuals. Scale bar is 60 µm. 
 
Effect of adenosine on proliferation/viability and type I collagen 
production by human subcutaneous fibroblasts  
To investigate the involvement of adenosine P1 receptors on cell 
proliferation/viability (through the MTT method) and extracellular matrix 
production, namely type I collagen production (Sirius Red assay), fibroblasts were 
continuously incubated (during 28 days) with adenosine (100 µM) or its stable 
analogue 5′-(N-ethylcarboxamide)adenosine (NECA, 100 µM). Given that the 
immunocytochemical analysis showed a strong immunoreactivity of fibroblasts 
against the A2A receptor compared to A1, A2B and A3 receptors, we also tested the 
cells with the selective A2A receptor agonist, CGS 21680 (10 nM), with and without 
the selective antagonist of the A2A receptor, SCH 442416 (10 nM). For each 
individual, 4-8 replicas were performed. Results obtained showed that human 
subcutaneous fibroblasts in culture under control conditions (no added drugs) 
proliferate (Fig. 2.3.3A) and produce type I collagen (Fig. 2.3.3C) progressively 
with time in culture. Prolonged exposure to adenosine (100 µM, n = 4) and NECA 
(100 µM, n = 4) stimulated cell growth (Fig. 2.3.3Bi) and type I collagen 
production (Fig. 2.3.3Di) above the control condition from day 14 onwards. 
Human fibroblasts proliferation (Fig. 2.3.3Bi) and type I collagen production (Fig. 
2.3.3Di) were more significant (p < 0.05) upon the incubation of the cells with the 
selective A2A receptor agonist, CGS 21680 (10 nM, 4-8 replicas from two 
individuals). Similarly, the A2A receptor agonist progressively increased (p < 0.05) 
type I collagen production until culture day 28 (Fig. 2.3.3Di). Figures 2.3.3Bii and 
2.3.3Dii, show that the effects of CGS 21680 (10 nM) on fibroblast cells growth 
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and type I collagen production were both attenuated in the presence of the 
selective A2A receptor antagonist, SCH 442416 (10 nM).  
 
 
Figure 2.3.3. Proliferation/viability and type I collagen production by human subcutaneous 
fibroblasts grown for 28 days in culture: role of adenosine. Panels A and B represent 
proliferation/viability of cells, measured by the MTT assay; results are expressed as absorbance 
determination at 600 nm per well at certain time points. Panels C and D represent total type I 
collagen production assessed by Sirius Red staining; results are expressed as absorbance 
determination at 550 nm per well at certain time points. A and C, illustrate respectively curves of 
human subcutaneous fibroblasts proliferation/viability (MTT values) and type I collagen production 
(Sirius Red values). Adenosine (100 μM), the stable non-selective agonist of P1 receptors NECA (100 
μM) and the selective agonist of the A2A receptor CGS 21680 (10 nM) were all applied continuously to 
the culture media; CGS 21680 (10 nM) was applied in the absence and in the presence of the 
selective A2A receptor antagonist, SCH 442416 (10 nM). The ordinates represent changes in cell 
growth (MTT values, Bi and Bii) and type I collagen production (Sirius Red values, Di and Dii) 
compared to their respective internal controls (in the absence of test drugs) at the same time points 
(Panels B and D). Zero represents similarity between the two values (drug - control); positive and 
negative values represent facilitation or inhibition of either cell growth or type I collagen production 
relative to control data obtained at the same time points. Each column represents pooled data n 
individuals; 4-8 replicas were performed for each individual. The vertical bars represent S.E.M.. *p < 
0.05 represent significant differences from control values obtained in the absence of tested drugs.  
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Given the similarity between both proliferation/viability and type I collagen 
patterns, we normalized collagen production (Sirius Red values) to 
proliferation/viability (MTT values), at the same time points. Interestingly, after 
this normalization differences in collagen production were no longer observed for 
NECA (100 µM, n = 4; Fig. 2.3.4Ai). In the case of adenosine (100 µM, n = 4; Fig. 
2.3.4Ai) and CGS 21680 (10 nM, n = 2; Fig. 2.3.4Ai), normalization revealed that 
type I collagen production increased significantly (p < 0.05) beyond proliferation / 
viability of the human subcutaneous fibroblasts on culture day 28. Moreover, the 
effect of CGS 21680 (10 nM) was attenuated in the presence of the selective A2A 
receptor antagonist, SCH 442416 (10 nM). 
 
 
 
Figure 2.3.4. Type I collagen production normalized to proliferation/viability of human 
subcutaneous fibroblasts grown for 28 days in culture: role of adenosine. Panel A represents type I 
collagen production, assessed by Sirius Red staining, normalized to the proliferation/viability of 
cells, measured by the MTT assay; results are expressed as absorbance determination at 550 nm / 
absorbance determination at 600 nm, per well at certain time points. Adenosine (100 μM, Ai), the 
stable non-selective agonist of P1 receptors NECA (100 μM, Ai) and the selective agonist of the A2A 
receptor CGS 21680 (10 nM, Ai), were all applied continuously to the culture media; CGS 21680 (10 
nM) was also applied in the presence of the selective A2A receptor antagonist, SCH 442416 (10 nM, 
Aii). Each column represents pooled data n individuals; 4-8 replicas were performed for each 
individual. The vertical bars represent S.E.M.. *p < 0.05 represent significant differences from 
control values obtained in the absence of tested drugs. 
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DISCUSSION  
Adenosine is present in most biological fluids but its concentration 
increases during tissue or organ stress, when it acts as an endogenous modulator 
of inflammation and tissue repair. Under basal conditions, the extracellular 
adenosine concentration is relatively constant (30-300 nM) and above its 
intracellular concentration, mostly due to the high affinity of intracellular 
adenosine kinase for the nucleoside. The extracellular concentration of adenosine 
may increase dramatically to the micromolar range upon increasing the release of 
adenine nucleotides, namely ATP, from stressed and/or damaged cells (reviewed 
by (170)). However, the levels achieved by adenosine in close proximity of its 
receptors are strictly regulated by a variety of dynamic mechanisms, of which the 
catabolic enzyme adenosine deaminase (ADA) represents a critical regulator of 
receptor stimulation, thus playing a pivotal role in the modulation of the 
purinergic responses (73). Interestingly, it has been shown that ADA knockout 
mice, which have a systemic elevation of adenosine levels, exhibit signs of 
fibrosis in the lungs, liver and kidneys, suggesting a profibrotic trend in multiple 
tissues (74). Still, the role of adenosine in tissue remodeling seems controversial. 
Though evidence suggests that adenosine promotes fibrosis in several organs 
through different mechanisms, which might be associated to distinct patterns of 
adenosine receptors expression in different organs commanding the overall role 
of the nucleoside (175), it has been described that the same subtype of adenosine 
receptor (e.g. A2B) may inhibit or promote fibrosis depending on the target tissue 
(66). Given that subcutaneous connective tissue disorganization appears to be 
involved in the pathogenesis of chronic pain (13,14,16), we sought it was 
important to unveil the role of adenosine in human subcutaneous connective 
tissue remodeling. Despite adenosine receptors have been identified in human 
dermal fibroblasts, to our knowledge, no previous evidence exists describing the 
expression of adenosine receptors in the related human subcutaneous 
(hypodermal) fibroblasts. We have previously demonstrated that adenosine 
increases following the incubation of cultured human subcutaneous fibroblasts 
with adenine nucleotides, namely ATP, ADP and AMP (173,176). Now, we 
confirmed that non-stimulated human subcutaneous fibroblasts exhibit a minor 
activity of ADA, allowing for adenosine accumulation. Our data also show that the 
A2A receptor appears to be the most expressed P1 receptor subtype in human 
subcutaneous fibroblasts in culture. Interestingly, it has been previously shown 
that the A2A receptor is also the dominant adenosine receptor in the skin, as well 
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as in the peritoneum and the liver (66), which makes targeting this receptor 
subtype highly appealing to control tissue remodeling. 
To characterize further the contribution of adenosine and the role of A2A 
receptors in proliferation and collagen production by fibroblasts of the human 
subcutaneous connective tissue, we tested the effect of adenosine and of two 
stable analogues with affinity to A2 receptors, both A2A (CGS 21680C) and A2B 
(NECA). Results are in agreement with the hypothesis that prolonged exposure to 
adenosine stimulates human subcutaneous fibroblasts growth and type I collagen 
production through the activation of the A2A receptor. This was suggested 
because CGS 21680 was the more potent and effective agonist tested and by the 
fact that the selective A2A receptor antagonist, SCH 442416 (10 nM), attenuated 
the effects of CGS 21680. Data is in agreement with the idea that the A2A receptor 
might be a key player in subcutaneous connective tissue remodeling, and 
therefore might participate in wound healing disorders, such as fibrosis. In the 
skin, it has been previously reported that adenosine, acting via the A2A receptor, 
promotes wound healing and excisional wound closure, and that the 
enhancement in dermal wound healing is accompanied by an increase of the 
matrix (collagen) in the wounds. In addition, the A2A receptor plays an important 
role in the pathogenesis of fibrotic malignancies of the skin such as dermal 
fibrosis. The blockade of the A2A receptor prevents dermal fibrosis and scarring by 
reducing collagen content and misalignment (reviewed in (170,175)). 
Interestingly, we found that adenosine potentiates the ability of each fibroblast to 
synthetize collagen, similarly to that occurring in the skin where the A2A receptor 
activation directly stimulates collagen production by dermal fibroblasts (reviewed 
in (170)).  
Previously, it has been described that adenosine can regulate cells 
proliferation and differentiation possibly due to changes in mitogen-activated 
protein kinases (MAPK). Among the MAPK family, which is subdivided into 
extracellular regulated kinases (ERK), like ERK1/2, and stress-activated protein 
kinases (SAPK), like p38 and jun-N-terminal kinase (JNK), the ERK1/2 seems to 
represent the preferential pathway for cell division and proliferation responses. 
These kinases, commonly activated via receptor tyrosine kinases, have also been 
shown to be activated by G protein-coupled receptors, such as P1 receptors (177). 
As an example, adenosine analogues exerting mitogenic effects on human 
endothelial cells via the A2A receptor seem to activate ERK1/2 using the cAMP-ras-
MEK1 pathway (177). Therefore, one may speculate that human fibroblasts from 
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subcutaneous connective tissue might act similarly. However, the signaling 
cascades used by the A2A receptor seem to vary with the cellular background and 
the signaling machinery that the cell possesses. For instance, the A2A receptor-
mediated ERK1/2 activation in CHO cells is dependent on Gs-cAMP-PKA-rap1-p68 
B-raf-MEK1. On the other hand, the A2A receptor-mediated activation in HEK 293 
cells involves PKC, ras, and sos, but not Gs, cAMP, or PKA, even though cAMP 
levels do rise in a Gs-dependent manner (177). Thus, further studies are required 
to ascertain the transduction pathways involved in the observed A2A receptor-
mediated increase of proliferation and type I collagen synthesis by human 
subcutaneous fibroblasts. 
Overall, these data enlighten the idea that the A2A receptor might be a key 
player in subcutaneous connective tissue remodeling by modulating its elastic 
properties. Therefore, we hypothesize that a disturbed adenosine homeostasis 
promotes a deficient remodeling of connective tissue and, given that 
subcutaneous connective tissue forms an interconnected net throughout all body 
(7,78), any local increased tension can elicit prolonged release of adenine 
nucleotides which might induce and sustain changes of all the connective tissue 
net, further restraining its compliance globally. This occurrence could, eventually, 
be the basis of a peripheral modulation of the inputs, namely of nociception 
transmission from peripheral soft tissues, and be involved in the pathogenesis of 
chronic pain conditions. In fibromyalgia, though a central modulation of the pain 
circuits has been described, its etiology and pathophysiology has not been clearly 
understood and it is still unknown if there is a peripheral modulation leading to a 
central sensitization. Interestingly, recent data indicates that adenosine and 
inosine may be involved in pain transmission in fibromyalgia patients, who 
showed an increased activity of serum-ADA (178). This finding suggests that 
these patients have reduced adenosine levels, which, given that adenosine is 
known as an important anti-nociceptive mediator, would explain a reduced 
threshold for pain eliciting. In addition to this, given that under normal 
physiologic conditions adenosine appears to accumulate in the subcutaneous 
connective tissue and potentiate fibroblasts growth, which are the major key 
players in the extracellular matrix remodeling, both by synthetizing new proteins 
as well as by degrading them, reduced levels of adenosine may restrain the ability 
of fibroblasts for connective tissue remodeling by limiting their growth. In other 
words, we postulate that lower levels of adenosine may reduce the regenerative 
ability of subcutaneous connective tissue due to a decrease of new fibroblasts 
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growth, leading to viscoelastic changes that might compromise the global 
compliance of this tissue and, subsequently, reduce the pain thresholds. Thus, we 
believe that the role of connective tissue in nociception might be complex and 
purines should be taken into consideration. 
In conclusion, adenosine, via the A2A receptor activation, promotes the 
proliferation and type I collagen production from human subcutaneous 
fibroblasts, which might suggest that these receptors play an active role in 
connective tissue remodeling and, thus, in chronic musculoskeletal pain.  
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Purines and pyrimidines are involved in the fine-tuning modulation of 
inflammatory events and painful conditions, such as musculoskeletal pain-related 
disorders (109,179). There is, however, considerable speculation about the 
mechanism(s) by which purinergic signals operate musculoskeletal pain. In 
patients with chronic low back pain, signs of peripheral soft tissue changes have 
been found, namely subcutaneous connective tissue disarrangement (e.g. 
increased stiffness, thickness or disorganization) (14,16) suggesting that 
connective tissue might be an important player in the pathogenesis of chronic 
musculoskeletal pain. Interestingly, the analgesic effects induced by acupuncture 
seem to involve the release of ATP and/or its metabolites, including adenosine 
(142,167). Given that acupuncture is typically applied to deep tissue (142,167), it 
is more likely that deeper structures than the skin, such as the subcutaneous 
connective tissue, will play a pivotal role in mediating the effects of acupuncture. 
Altogether, these evidences point out that subcutaneous connective tissue might 
represent an active structure that influences afferent nociceptive circuitries from 
the periphery, modulating pain. 
In order to understand the underlying purinergic mechanisms that could be 
involved in connective tissue remodeling under stressful and non-stressful 
conditions, we decided to isolate its major cell constituent, fibroblast. Given that: 
1) histamine and bradykinin are released or synthesized, respectively, following 
tissue injury which can occur for example upon sustained muscle contraction; and 
that 2) these inflammatory mediators have been shown to induce the release of 
ATP in several cell types, such as smooth muscle fibers, epithelial, endothelial and 
urothelial cells, as well as various immortalized cell lines, we investigated the 
involvement of ATP in histamine- and bradykinin-induced response in human 
subcutaneous fibroblasts in culture. 
First of all, our results provided evidence that human subcutaneous 
fibroblasts are sensitive to both histamine (100 µM) and bradykinin (> 1 µM), 
showing an increase of the cytosolic intracellular Ca2+ ([Ca2+]i) via the activation of 
H1 and B2 receptors, respectively. The histamine- and bradykinin-induced [Ca2+]i 
rises depended on PLC activation and recruitment of Ca2+ from intracellular stores, 
which is compatible with the involvement of the Gq → PLC → IP3 signaling pathway 
that is characteristic of H1 and B2 receptors activation. Interestingly, for both 
inflammatory mediators the [Ca2+]i responses produced by the cells were biphasic, 
showing a fast Ca2+ rise component which declined within 1 min to a sustained 
plateau above baseline, which was maintained via Ca2+ entry from the extracellular 
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milieu. Confirming our initial hypothesis, we found that the observed sustained 
[Ca2+]i elevation was partially due to P2 purinoceptors activation. In parallel to the 
observed [Ca2+]i oscillations, ATP release in response to histamine and bradykinin 
was also detected, further corroborating purines involvement in the inflammatory 
response of these mediators.  
Notably, both the nucleotide-releasing pathways triggered by each 
inflammatory mediator and the subsequent activated P2 purinoceptor subtypes 
seem to be different. While both histamine and bradykinin caused the opening of 
pannexin-1 hemichannels, involvement of connexin hemichannels (possibly Cx43 
and others) seems to be involved only in bradykinin-induced responses. This 
finding suggests that, although both H1 and B2 receptors couple to a Gq protein, 
distinct downstream pathways might be stimulated. Response variability may 
arise from the fact that receptors engage different transducing elements and PLC 
isoforms in a microdomain-specific manner, like lipid rafts or caveolae, which are 
characterized by bringing together receptors, G proteins and effector systems. 
For instance, it has been described that Cx43 interacts with caveolins (caveolin-1, 
Cav-1) and targets to lipid rafts domains (180). Moreover, it has been proposed 
that the association between Cav-1 and Cx43 may work like a molecular 
chaperone or scaffold (181). There is broad evidence that association of 
transmembrane receptors and signaling molecules within lipid rafts/caveolae 
provides an enriched environment for protein-protein interactions necessary for 
signal transduction. Several receptors translocate into submembrane 
compartments after ligand binding, while others move in the opposite direction 
(182). The role of such a dynamic localization and functional relevance in 
signaling modulation and receptor desensitization or internalization requires 
further investigation in the target cells used in this study, the fibroblasts of the 
human subcutaneous tissue. Moreover, disruption of submembrane 
compartments can shift the purinergic receptors from raft/caveolar to non-
raft/non-caveolar fractions, and then abolish their ability to activate lipid 
signaling pathways and to integrate with additional lipid-controlled signaling 
events. This might modulate the biological response to purinergic ligands and, 
above all, indicates that the topology of the various purinergic components at the 
cell surface not only organizes the signal transduction machinery, but also 
controls the final cellular response (182). This ability of rapid rearrangement of 
the cell machinery might also explain the fact that histamine-evoked response 
involved P2Y1 receptor, whereas bradykinin elicited P2Y12 receptor activation. 
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Interestingly, lipid rafts are required in Gαi signaling downstream of the P2Y12 
receptor during ADP-mediated platelet activation (183). Together, these facts may 
help to understand that, in the same cell, histamine- and bradykinin-induced 
purinergic potentiation loops might involve distinct, complex and dynamic 
microdomains, whose organization deserves further research.  
Interestingly, in both histamine- and bradykinin-induced purinergic 
signaling, ATP catabolism into ADP was required. Although E-NTPDase1 was 
found to be the most representative E-NTPDase expressed by human 
subcutaneous fibroblasts, transient ADP accumulation might be possible given 
that expressed E-NTPDase2 is a preferential nucleoside triphosphatase that 
hydrolyses ATP 10 to 15 times more efficiently than ADP (39,184). Remarkably, 
we also found that AMP was rapidly dephosphorylated into adenosine 
independently of the nucleotide substrate used (half-life time of 1.5-3 min, 3-30 
µM, respectively). A strong immunoreactivity against ecto-5’nucleotidase/CD73 
corroborated the functional HPLC analysis, suggesting that adenosine might play 
an important role in the physiology of fibroblasts and, ultimately, connective 
tissue remodeling. Although we failed to demonstrate any contribution of the 
nucleoside to bradykinin-induced [Ca2+]i signals, our results suggest that 
adenosine, possibly via A2A receptor activation, potentiates human subcutaneous 
fibroblasts growth and type I collagen production. Interestingly, adenosine 
receptors have been associated with controversial roles, like wound healing and 
tissue fibrosis. For instance, in the heart, the A2B receptor seems to inhibit 
fibrosis, whereas in the lung promotes it. On the other hand, in the skin, liver, 
and lungs, both A2A and A2B receptors mediate and increase fibrosis (66). In fact, it 
was demonstrated that adenosine A2A receptors promote skin fibrosis and 
scarring (66,168) by increasing collagen production in human dermal fibroblasts 
(169) probably via the Gs/cAMP pathway (170), though cAMP also may decrease 
collagen production (171). These findings demonstrate that the role of adenosine 
in these processes is still unclear. Therefore, and despite the generation of 
adenosine from the catabolism of the released nucleotides does not seem to 
contribute to the acute bradykinin exposure-induced response in human 
subcutaneous fibroblasts, further studies are required to better understand which 
situations might trigger adenosine signaling. Moreover, given that adenosine 
accumulates as an end product of the catabolism of released ATP in the vicinity of 
fibroblasts within subcutaneous connective tissue, neighboring structures, such 
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as free nerve endings, may become a potential target to the well-known anti-
nociceptive nucleoside via A1 receptor activation (172).   
Besides adenosine, ATP and ADP may also evoke a paracrine response to 
the neighboring cells. In the intestine, it has been demonstrated that the ATP 
released by mechanically stimulated fibroblasts elicits a Ca2+-wave propagation 
through the fibroblasts’ network via P2Y1 receptor activation. The released ATP, 
acting on P2X receptors localized in the terminals of mucosal sensory neurons, 
also seems to regulate the intestinal peristaltic motility (57). Likewise, it has been 
reported that human epidermal keratinocytes co-cultured with neurons from DRG 
interplay through the release of ATP following keratinocytes-born [Ca2+]i waves, 
strongly indicating a dynamic cross-talk between both cell types via extracellular 
ATP (151,160). 
Therefore, we may speculate that histamine- and bradykinin-stimulated 
fibroblasts trigger a “purinergic wave” operated by ATP release and formation of 
its metabolites in the extracellular milieu, which can affect sensory nerve 
afferents localized in the vicinity, representing the first insights of a 
subcutaneous fibroblast-neuron communication unproved so far. In fact, 
subcutaneous inflammation or injection of ATP causes pain sensation through the 
activation of P2X3 receptors expressed in sensory nerve endings, which may 
become sensitized in both animal models and human patients (161,162). 
Knocking down or selectively antagonizing P2X3 receptor activity results in 
reduced responses to ATP, as well as reduced thermal and mechanical 
hyperalgesia in inflammatory and neuropathic pain models in the rat (163,164). 
P2Y purinoceptors, especially P2Y1 and P2Y2, expressed in primary sensory 
endings have also been implicated in chronic pain situations (160). Several 
authors agree that cutaneous ATP release does not appear to contribute to pain 
sensation in the absence of tissue injury. However, under chronic painful 
conditions, such as inflammation and nerve injury, nerve endings may become 
sensitized and a normally innocuous level of subcutaneous ATP may then be 
sufficient to reach the firing threshold of nociceptors (165). Despite the fact that 
direct modulation of nociceptors threshold by ATP released from different cell 
types may play a key role to the association between subcutaneous connective 
tissue injury and musculoskeletal pain, there are alternative mechanisms that 
should also be considered in this context. These include interference with muscle 
tension due to fusimotor effects induced by group III and IV afferents activation, 
which, by projecting to γ-motoneurons, amplify muscle spindles activity and, 
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thereby, increase muscle tone, generating metabolites (e.g. bradykinin) that enter 
in a positive feedback loop (reviewed by (144,145,166)). Moreover, such a motor 
control dysfunction, which represents a sub-optimal neuromuscular control, also 
leads to a decreased ability to provide the needed articular stability of the 
mobilizing segments, therefore contributing to a mechanical instability, thus 
promoting more inflammation and pain.  
It has been proposed that mechanical deformation of the skin by 
acupuncture needles and application of heat or electrical current leads to the 
release of large amounts of ATP (and adenosine) from keratinocytes, fibroblasts 
and other cells in the skin (149). According to this hypothesis, the released ATP 
generates P2 purinoceptors-dependent impulses in sensory fibers of the skin, 
which connect with interneurons that may negatively modulate neural pathways 
to the pain centers in the cortex. This is the basis of the novel hypothesis for the 
involvement of purinergic signaling in acupuncture (149). However, and though 
the skin is penetrated during such procedures, acupuncture is typically applied to 
deeper tissues, like muscles and connective tissue (142,167). Therefore, as 
mentioned above, it is more likely that deeper structures, such as the 
subcutaneous connective tissue, deep fascia and muscles, are the key players 
mediating the anti-nociceptive effects of acupuncture.  
Recent studies provided important findings about purines mediating the 
analgesic effects of acupuncture (142,167). In mice, acupuncture locally increased 
the extracellular concentrations of ATP, ADP, AMP and adenosine. The authors 
also observed that the extracellular concentration of ATP returned to baseline 
after acupuncture, whereas adenosine, AMP and ADP remained significantly 
elevated for at least more 60 min. Further experiments pointed out that 
adenosine, via A1 receptor activation, might be mediating the acute analgesic 
effects of acupuncture. Using sections of tissue (skeletal muscles with the 
overlying subcutaneous tissue), the authors found out that AMP 
dephosphorylation seems to be the rate limiting step in adenosine production 
(142). Consistently with other reports (89,185), Goldman and coworkers (142) 
found that IMP was generated in much larger quantities than adenosine due to 
AMP deaminase, which functions as an enzymatic shuttle for AMP catabolism that 
bypasses adenosine production (89). Moreover, the authors found that 
deoxycoformycin, which inhibits AMP deaminase and adenosine deaminase, 
thereby suppressing the two major pathways involved in the elimination of 
extracellular adenosine, significantly increased the accumulation of adenosine 
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and suppressed IMP and inosine production in the isolated preparations (142). 
Interestingly, our results show that in subcutaneous fibroblasts maintained in 
culture, AMP is rapidly dephosphorylated into adenosine, yet no formation of IMP 
was detected, thus promoting the accumulation of the nucleoside. Therefore, we 
speculate that the major evidence seen by Goldman and coworkers (142) might 
be attributable to the muscular component of their preparation, where IMP and 
inosine formation is much more representative than in the connective tissue (89). 
These findings clearly indicate that purinergic signaling is different between 
muscle fibers and fibroblasts, and suggest that connective tissue might be the 
major key player in mediating the rapid adenosine formation seen after 
acupuncture. Similarly to acupuncture, ultrasound and other manipulative 
treatments that involve the mechanical challenge of the connective tissue, might 
also be associated with an efflux of cytosolic ATP that is sufficient to elevate 
extracellular adenosine and dampen pain in part through the activation of A1 
receptor in the sensory afferents of ascending nerve fibers.  
Besides the referred direct and indirect influence on nociception circuitries, 
the tension of the connective tissue might also influence the sensibility of the 
surrounding cells to trigger the release of nucleotides release to the extracellular 
space. Given that mechanical stimulation is known to evoke ATP release in several 
cells, in cases of increased mechanical tension due to changes in the viscoelastic 
properties of the connective tissue, for example due to fibrosis, a minor stimulus 
might be sufficient to induce ATP release by the neighboring cells of free nerve 
endings, thus modulating their activity. In addition, an efficient muscle 
contraction requires an optimal muscle fiber length, which is also influenced by 
the tension of the surrounding connective tissue, within which muscle fibers are 
inserted into. Thus, the role of connective tissue in nociception might be much 
more complex that it might look like.  
Concluding, human subcutaneous fibroblasts express several purinergic 
receptors, both P2 and P1 receptors. Under stressful situations, such as via the 
exposure to inflammatory mediators like histamine and bradykinin, human 
subcutaneous fibroblasts release ATP to the extracellular milieu, which concur to 
amplify the response induced by the primary ligand. For each mediator, the 
underlying signaling pathways might depend on specific microdomains within the 
cells, triggering a stimulus-specific rather than a cell-specific response. This 
signature involves different nucleotide-releasing pathways (Panx1 and Cx43 
hemichannels, among other connexins) and the activation of distinct purinoceptor 
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subtypes (P2Y1 and P2Y12), which might be determined by a dynamic mobilization 
of ectonucleotidases (probably E-NTPDase2) to specific regions of the cell 
membrane. Although we speculate that other stimuli, like mechanical, might 
trigger a purinergic signaling using the cellular machinery described above, we 
cannot rule out the involvement of other purinergic elements. Moreover, the fact 
that, in these cells, adenosine tends to accumulate in the extracellular fluid and 
that, via A2A receptor activation, adenosine seems to increase proliferation and 
type I collagen production, suggest that conditions that trigger huge amounts of 
ATP release, like cell damage, may involve other purinergic signaling units. 
Thus, targeting the pathways leading to nucleotides release and 
subsequent purinergic signaling in human fibroblasts of subcutaneous connective 
tissue may be useful in: 1) understanding the role of this tissue in the 
pathogenesis of chronic painful musculoskeletal disorders; 2) clarifying the 
mechanisms that may be involved in the analgesic effects induced by peripheral 
soft tissue manipulations, such as physical therapy techniques; and 3) 
enlightening for novel pharmacological therapeutic strategies towards the 
modulation of the communication between inflammatory cells, fibroblasts and 
sensory nerve endings. 
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